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Abstract
Cancer cachexia is defined as the unintentional loss of skeletal muscle mass with or without fat loss that
cannot be reversed by conventional nutritional support. Cachexia occurs in ~20% of cancer patients.
More specifically, 50% of lung cancer patients, the most common cancer worldwide, develop cachexia.
Cachexia occurs most often in lung and gastrointestinal cancers, whereas breast and prostate have the
lowest rate of cachexia. Cancer-induced cachexia disrupts skeletal muscle protein turnover (decreasing
protein synthesis and increasing protein degradation). Skeletal muscle’s capacity for protein synthesis is
highly sensitive to local and systemic stimuli that are controlled by mTORC1 and AMPK signaling. During
cachexia, altered protein turnover is thought to occur through suppressed anabolic signaling via mTORC1,
coinciding with the chronic activation of AMPK. While progress has been made in understanding some of
the mechanisms underlying the suppressed anabolic signaling in cachectic muscle, gaps still remain in
our understanding of muscle’s ability to respond to anabolic stimulus prior to cachexia development. The
purpose of this study was to determine if cachexia progression disrupts the feeding regulation of AMPK
signaling and if gp130 signaling and muscle contraction could regulate this process.
Specific aim 1 examined the feeding regulation of skeletal muscle protein synthesis in pre-cachectic
tumor bearing mice. Feeding increased muscle protein synthesis, while lowering AMPK signaling in precachectic tumor bearing mice. Importantly, pre-cachectic tumor bearing mice have overall suppressed
muscle protein synthesis independent of the fast or fed condition. Muscle specific AMPK loss was
sufficient to improve the fasting suppression of muscle mTORC1 and protein synthesis in pre-cachectic
tumor bearing mice. Specific aim 2 examined if muscle gp130 signaling regulates the feeding regulation
of AMPK during cancer cachexia progression. Muscle gp130 loss lowered the fasting induction of AMPK
in pre-cachectic tumor bearing mice without improving protein synthesis. Muscle gp130 loss did not alter
the feeding regulation of muscle Akt/mTORC1 signaling and protein synthesis. Specific Aim 3 examined if
an acute bout of muscle contractions could improve the muscle protein synthesis response to feeding
during the progression of cachexia. Pre-cachectic tumor bearing mice exhibit suppressed protein
synthesis in response low frequency electrical stimulation, and the inability to synergistically induce
protein synthesis in response to feeding and contraction.
In summary, pre-cachectic tumor bearing mice have lowered Akt/mTORC1 signaling and protein
synthesis. Feeding can induce Akt/mTORC1 and protein synthesis and AMPK regulates the fasting
suppression of protein synthesis in pre-cachectic tumor bearing mice. While gp130 loss reduces AMPK it
is not sufficient to improve protein synthesis in pre-cachectic tumor bearing mice. The added protein
synthesis response to feeding and contraction is blunted in pre-cachectic tumor bearing mice. These
findings provide novel insight into the regulation of Akt/mTORC1 signaling and protein synthesis in
response to feeding. Additionally, these studies highlight gp130’s regulation of AMPK prior to cachexia
development, and the blunted anabolic muscle response to feeding and contraction in pre-cachectic
tumor bearing mice. By understanding these intracellular signaling processes and perturbations prior to
cachexia development, we will be able to elucidate potential therapeutic targets and treatment options to
manipulate and prevent cancer cachexia.
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ABSTRACT
Cancer cachexia is defined as the unintentional loss of skeletal muscle mass with
or without fat loss that cannot be reversed by conventional nutritional support. Cachexia
occurs in ~20% of cancer patients. More specifically, 50% of lung cancer patients, the
most common cancer worldwide, develop cachexia. Cachexia occurs most often in lung
and gastrointestinal cancers, whereas breast and prostate have the lowest rate of cachexia.
Cancer-induced cachexia disrupts skeletal muscle protein turnover (decreasing protein
synthesis and increasing protein degradation). Skeletal muscle’s capacity for protein
synthesis is highly sensitive to local and systemic stimuli that are controlled by mTORC1
and AMPK signaling. During cachexia, altered protein turnover is thought to occur
through suppressed anabolic signaling via mTORC1, coinciding with the chronic
activation of AMPK. While progress has been made in understanding some of the
mechanisms underlying the suppressed anabolic signaling in cachectic muscle, gaps still
remain in our understanding of muscle’s ability to respond to anabolic stimulus prior to
cachexia development. The purpose of this study was to determine if cachexia
progression disrupts the feeding regulation of AMPK signaling and if gp130 signaling
and muscle contraction could regulate this process.
Specific aim 1 examined the feeding regulation of skeletal muscle protein
synthesis in pre-cachectic tumor-bearing mice. Feeding increased muscle protein
synthesis, while lowering AMPK signaling in pre-cachectic tumor-bearing mice.
Importantly, pre-cachectic tumor-9bearing mice have overall suppressed muscle protein
synthesis independent of the fast or fed condition. Muscle-specific AMPK loss was
sufficient to improve the fasting suppression of muscle mTORC1 and protein synthesis in
pre-cachectic tumor-bearing mice. Specific aim 2 examined if muscle gp130 signaling
regulates the feeding regulation of AMPK during cancer cachexia progression. Muscle
gp130 loss lowered the fasting induction of AMPK in pre-cachectic tumor-bearing mice
without improving protein synthesis. Muscle gp130 loss did not alter the feeding
regulation of muscle Akt/mTORC1 signaling and protein synthesis. Specific Aim 3
examined if an acute bout of muscle contractions could improve the muscle protein
synthesis response to feeding during the progression of cachexia. Pre-cachectic tumorbearing mice exhibit suppressed protein synthesis in response low frequency electrical
stimulation, and the inability to synergistically induce protein synthesis in response to
feeding and contraction.
In summary, pre-cachectic tumor-bearing mice have lowered Akt/mTORC1
signaling and protein synthesis. Feeding can induce Akt/mTORC1 and protein synthesis
and AMPK regulates the fasting suppression of protein synthesis in pre-cachectic tumorbearing mice. While gp130 loss reduces AMPK it is not sufficient to improve protein
synthesis in pre-cachectic tumor-bearing mice. The added protein synthesis response to
feeding and contraction is blunted in pre-cachectic tumor-bearing mice. These findings
provide novel insight into the regulation of Akt/mTORC1 signaling and protein synthesis
in response to feeding. Additionally, these studies highlight gp130’s regulation of AMPK
prior to cachexia development, and the blunted anabolic muscle response to feeding and
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contraction in pre-cachectic tumor-bearing mice. By understanding these intracellular
signaling processes and perturbations prior to cachexia development, we will be able to
elucidate potential therapeutic targets and treatment options to manipulate and prevent
cancer cachexia.
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CHAPTER 1.

INTRODUCTION

Cancer cachexia is defined as the unintentional loss of muscle mass with or
without fat loss, and is irreversible with nutritional support (Evans et al., 2008). Cancerassociated cachexia occurs in ~20% of cancer patients and is the cause of 40% of all
cancer related deaths (Evans et al., 2008). Lung cancer is the most common cancer
worldwide, with 50% of lung cancer patients developing cachexia (Jafri et al., 2015). The
overall 5-year survival rate for lung cancer patients is 19%, however this is greatly
impacted by cancer stage (Siegel et al., 2020). However, the survival rate falls to only 5%
for patients diagnosed at distant stages (Siegel et al., 2020). Therefore, therapeutic
strategies to prevent or minimize cancer induced cachexia are needed to improve patient
survival and life quality.
Skeletal muscle’s capacity for protein synthesis and degradation is highly
sensitive to local and systemic stimuli that are integrated intracellularly through
mTORC1 and AMPK signaling (Frost & Lang, 2007). Oscillations in protein synthesis
and breakdown occur throughout the day in response to feeding and fasting (Breen &
Phillips, 2011). Briefly, feeding elicits an increase in circulating glucose to promote
insulin release by the pancreas thereby translocating GLUT4 to the muscle’s membrane
to remove circulating glucose (Richter & Hargreaves, 2013) and circulating insulin can
also directly bind to IGF-1 resulting in a confirmational change to induce downstream
phosphorylation of IRS/AKT/mTORC1 (Boucher et al., 2014). Feeding can directly
target mTORC1 by increasing amino acid pool to promote protein synthesis (Liu &
Sabatini, 2020). Alternatively, fasting in pre-clinical models (24-48hrs) elicits an energy
stress demand resulting in increased muscle AMPK signaling (Bujak et al., 2015). AMPK
is a regulatory point of interaction due to its numerous effects on muscle protein turnover
by lowering ATP consumption of anabolic pathways and increasing catabolic pathways
to produce ATP. AMPK is activated by energy stress when ATP bound to AMPK subunit
is displaced with AMP, which occurs by reduced ratios of ATP:ADP and increased ratio
of AMP:ATP. Throughout the day in healthy tissue, ATP:ADP ratios are in constant flux
and exhibit a circadian rhythm with AMPK lowered after the dark cycle (Um et al.,
2011). To disrupt these ratios, either there is an interference of ATP production or
increased ATP consumption (Hardie, 2003). During periods of fasting, blood glucose
levels begin to fall which interferes with ATP production, therefore, glucose availability
is increased by stimulating liver glucose production. Furthermore, during longer periods
of fasting after glycogen stores have been depleted, metabolism of triglycerides are used
through beta oxidation and ketogenesis to produce ATP (Herzig & Shaw, 2018). While
these physiological changes to feeding and fasting occur throughout the day in healthy
populations, significant barriers still exist in our understanding of how cachexia
progression disrupts mTORC1 and AMPK signaling by feeding.
Cancer-induced cachexia disrupts skeletal muscle protein turnover in the basal
condition (decreasing protein synthesis and increasing protein degradation) (Aversa et al.,
2016; Baracos, 2000). In pre-clinical models, our laboratory has demonstrated altered
protein turnover through the suppression of anabolic signaling via mTORC1 which
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coincided with chronic activation of AMPK (White, Baynes, et al., 2011). Recent work
from our lab has shown that mTORC1 signaling exhibits diurnal fluctuations in response
to changes throughout the day in feeding and activity (Counts et al., 2020). Interestingly,
the cachectic environment disrupts these diurnal fluctuations, and suggest a link between
disruptions in feeding and activity behaviors to the progression of cachexia and altered
mTORC1 signaling (Counts et al., 2020). While our lab and others have shown that the
cachectic environment’s chronic activation of aberrant AMPK induces a higher basal
state of autophagy signaling (Penna, Ballaro, Martinez-Cristobal, et al., 2019; White,
Baynes, et al., 2011), recent unpublished data has highlighted that a short-term fast
accelerates protein degradation through AMPK in cachectic muscle. These findings have
significant implications because more evidence is identifying a potential therapeutic
window based on the time of day (Zhao et al., 2020) and nutritional state of the patient
(Lammers et al., 2020). However, significant barriers still exist in our understanding of
cachectic skeletal muscle’s protein synthesis response by fasting and feeding.
Inflammation has been implicated as a key mediator of cancer-induced cachexia
leading to chronic elevation of skeletal muscle STAT3 and MAPK activity (Deans &
Wigmore, 2005). Glycoprotein-130 (gp130) is a regulatory point of interaction between
systemic inflammation and JAK/STAT and MAPK muscle signaling (White & Stephens,
2011). We have previously reported muscle gp130 loss prevented Lewis lung Carcinoma
(LLC) induced muscle wasting and restored STAT3 and MAPK signaling (Puppa, Gao,
et al., 2014). Interestingly, the LLC model has known disruptions in mitochondrial
function prior to muscle wasting (Brown et al., 2017). Additionally, disruptions to the
muscle mitochondria are known to induce AMPK, thereby accelerating muscle wasting
(VanderVeen et al., 2017). Given that muscle gp130 can regulate mitochondrial quality
control (Hardee, Counts, et al., 2018), identifying if these are linked to cachexia
disruption of protein turnover by feeding is warranted.
Exercise training is a known inducer of anabolic signaling through mTORC1
(Burd et al., 2009) and reduces chronic systemic inflammation (Beavers et al., 2010). An
acute bout of skeletal muscle contraction is sufficient to induce glucose uptake, fatty acid
oxidation, mitochondrial biogenesis, and protein synthesis (Egan & Zierath, 2013).
Whereas repeated exercise bouts can induce functional adaptations in contractile proteins,
mitochondrial function, and metabolic regulation (Egan & Zierath, 2013). Exercise has
been hypothesized to be a potential therapeutic option for cancer induced cachexia
(Hardee et al., 2019). We have recently shown that repeated eccentric contractions are
sufficient to induce anabolic signaling in the cachectic environment, coinciding with
suppressed inflammatory signaling in glycolytic muscle (Hardee et al., 2020).
Additionally, we highlight repeated contractions improved muscle oxidative capacity
further supporting that cachectic muscle has the plasticity to respond to contraction
stimulus. While high frequency eccentric contractions show promising results in
preclinical models, clinical populations hesitate to employ such a potent stimulus
therefore rehabilitation settings utilize a low-to-moderate frequency of contraction/load
(Hody et al., 2019). We have previously shown that an acute bout of low-frequency
electrical stimulation (LFES) induced downstream mTORC1 signaling and oxidative
capacity, however this response was suppressed in cachectic muscle (Puppa, Murphy, et
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al., 2014). While we have made advances in our understanding of cachectic muscle’s
response to acute contraction, significant barriers still exist in understanding if the
suppressed contraction response is greater in more severe cachexia.
The anabolic response of resistance exercise in combination with nutritional
stimulus have been highly sought after in all populations (Barclay et al., 2019; Breen &
Phillips, 2013; Moore, 2019; Symons et al., 2011; Trommelen et al., 2019); specifically,
in the elderly or during disease in hopes to offset anabolic resistance. Several studies
have investigated skeletal muscle’s response to contraction and/or mechanical signaling
(Hornberger, 2011), however very little work has been done to examine the combined
effects of contraction and feeding on skeletal anabolic signaling (Gordon et al., 2014;
Nakayama et al., 2019) specifically during disease (Hardee, Counts, et al., 2018; Puppa,
Murphy, et al., 2014; Sato et al., 2019) and disuse (Roberson et al., 2020; Shimkus et al.,
2018). Interestingly, there is promising work that the combined effects of exercise and
nutrient supplementation can increase muscle protein synthesis to a greater extent than
feeding alone in prostate cancer patients (Hanson et al., 2017). There are gaps in our
understanding of how cancer cachexia disrupts the muscle metabolic response to feeding
and whether contraction can alter these responses. The purpose of the current project was
to determine if cachexia progression disrupts the feeding regulation of AMPK signaling
and if gp130 signaling and muscle contraction could regulate this process; see working
model (Figure 1-1). Our central hypothesis was that the feeding regulation of muscle
AMPK was disrupted at cancer cachexia initiation. Furthermore, the dysregulation of
AMPK signaling was caused by muscle gp130 signaling, and an acute bout of muscle
contractions could improve the feeding regulation during cancer cachexia progression.
SPECIFIC AIM 1: To determine if skeletal muscle AMPK regulation by feeding was
disrupted early in cancer cachexia progression and if this was related to early disruptions
in systemic metabolism.
SPECIFIC AIM 2: To examine if muscle gp130 signaling regulates the feeding
regulation of AMPK during cancer cachexia.
SPECIFIC AIM 3: To examine if an acute bout of muscle contraction could improve the
muscle protein synthesis response to feeding during the progression of cachexia.
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Figure 1-1.

Working model
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CHAPTER 2.

LITERATURE REVIEW
Cachexia

Cachexia is a severely debilitating condition that accompanies many chronic
diseases such as AIDs, renal failure, heart disease, and cancer. Cachexia is defined as the
unintentional loss of muscle mass with or without fat loss and is irreversible with
nutritional support (Evans et al., 2008; Muscaritoli et al., 2010). Cancer-associated
cachexia occurs in ~20% of cancer patients(Evans et al., 2008). Cachexia progression is
predominantly characterized by body weight loss over time and has been positively
associated to reduced survival (Evans et al., 2008; von Haehling et al., 2009).
Furthermore, the most recent consensus on cancer associated cachexia is defined as three
phases, and each phase’s progression is determined by the cancer type, stage, systemic
inflammation, inactivity, treatment, and food intake (Fearon et al., 2012; Roeland et al.,
2020). Additionally, pre-clinical studies and clinical trials have greatly improved our
understanding of the condition, however we still lack sufficient evidence to provide
therapeutic treatments to reverse to prevent cancer-induced cachexia.
Lung cancer is the most common cancer worldwide, with 50% of lung cancer
patients developing cachexia (Jafri et al., 2015). The overall 5-year survival rate for lung
cancer patients is 19%, however this is greatly impacted by the stage of diagnosis, for
example local or regional non-small cell lung cancer (NSCLC) is relativity high (3157%) (Siegel et al., 2020). However, the survival rate falls to only 5% for patients
diagnosed at distant stages (Siegel et al., 2020). The significant reduction in survival rate
is associated with a late-stage diagnosis compounded by toxic therapeutics. For example,
~60% of lung cancer patients reported weight loss prior receiving treatment, which was
associated with reduced survival and increased chemotherapy toxicity (Ross et al., 2004).
Due to the complexity of the condition, understanding the mechanisms involving lung
cancer development and cancer-induced systemic dysfunction that promote cachexia are
needed to improve patient survival.
Cachexia is not present in all cancer types, however those patients that develop
cachexia are more susceptible to chemotherapy toxicity, reduced recovery time after
surgery, increased infection rate, and decreased survival (Baracos et al., 2018; Esper &
Harb, 2005; von Haehling et al., 2009). The cachectic condition exhibits increased
systemic inflammation, altered metabolism, hypogonadism, and overall weakness
(Baracos et al., 2018; Tisdale, 2010), likely contributing to the abovementioned adverse
outcomes. Recent advances in understanding cachexia development have highlighted the
importance of muscle mass maintenance (Baracos et al., 2019). Importantly, skeletal
muscle is a strong predictor of survival in cachectic patients (Cho et al., 2017). For
example, in cachectic patients and pre-clinical models, diaphragm muscle mass loss
during cachexia lead to decreased work capacity, reduced respiration function, and
increased morbidity (Greising et al., 2018; Roberts, Ahn, et al., 2013). In addition,
cachectic patients exhibit decreased physical function (Fearon et al., 2006), which was
associated to greater body weight loss (Fouladiun et al., 2007). Lastly, pre-clinical
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models have highlighted that physical function decrements precede severe wasting
suggesting there might be a point of intervention to stave off cachexia (Counts et al.,
2020; VanderVeen et al., 2018). Taken together, these studies highlight the importance of
muscle mass health during cancer cachexia progression, however the complexity of the
condition has provided difficulty in understanding the molecular mechanisms that
promote cancer associated cachexia are poorly understood.
Cancer Cachexia
Understanding and determining the underlying mechanisms of cancer induced
cachexia have been long sought after. Approximately 40% of cancer patients will
experience progressive wasting of adipose or skeletal muscle tissue (Evans et al., 2008).
Human studies have been used to explore the mechanisms of cachexia progression,
however, there are currently limited studies that have defined the cachectic response in
cancer patients. This is in part due to the difficulty related to obtaining patient samples,
inability to control for cancer stage, tumor type, and therapeutics, thus pre-clinical
models are commonly used to eliminate confounders (Baracos, 2018). Interestingly,
recent work has sought to determine the most translatable pre-clinical model that exhibit
similar systemic features of human patients (Talbert et al., 2019), however this is only in
the beginning stages and is limited to pancreatic cancer. Our techniques of modeling
human cancer cachexia will advance, to date there are several established murine models
to examine the initiation and progression of cancer cachexia that us to elucidate the
underlying mechanisms of wasting (Ballaro et al., 2016). While it is acknowledged that
many different pre-clinical models are available, the following section will highlight
mouse and rat models that have been commonly used by our laboratory and others and
promising models for the examination of cancer induced muscle wasting.
There are many types of pre-clinical models in mice and rats used to examine
cancer induced cachexia, however there are several more mouse models. First, one
widely used mouse model of cancer induced cachexia is the Apc Min/+ which
spontaneously develops intestinal polyps. The mouse has a mutation in the Adenomatous
polyposis coli gene (Apc) which predispositions the mouse for multiple intestinal
adenomas (Min) (Moser et al., 1990). The Apc Min/+ model is commonly used because of
the slower development of cachexia compared to tumor implantation models.
Additionally, this model’s cachexia progression is closely related to tumor burden and
circulating IL-6 levels (Baltgalvis et al., 2010; White et al., 2012). The C26
adenocarcinoma model of cancer cachexia is an implantable tumor model in Babl/c mice.
The C26 model will develop one large non-metastatic tumor, and cachexia progression is
associated to tumor mass and plasma IL-6 (Bonetto et al., 2012). Cachexia progression in
the C26 model occurs rapidly, often within 2-3 weeks thus limiting the therapeutic
window. Most studies utilizing the C26 model investigate interventions to prevent
cachexia. The murine adenocarcinoma 16 (Mac 16) model of cancer induced cachexia is
used in nude Balb/c mice and suggest being independent of circulating cytokines
(Monitto et al., 2001). The Mac 16 model of cancer induced cachexia is known to elicit
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anorexia, however late-stage glucose and insulin signaling were independent of food
consumption.
Similar to C26, the implantable Lewis lung carcinoma (LLC) is another common
model of cancer induced cachexia. There are several murine models used to evaluate lung
cancer progression and treatment options to improve survival, however very few develop
cachexia (Kellar et al., 2015). The LLC model is a syngeneic xenograph model used to
study lung cancer in the C57Bl/6 mouse. The LLC model is commonly used due to its
tumorigenic properties, responsiveness to chemotherapy, and ability to metastasize to the
lungs and liver (Kellar et al., 2015). While there are a few other preclinical models to
examine lung cancer, these models are implemented in either Balb/c or nude mice, and
not all of them have been shown to exhibit cachexia (Kellar et al., 2015). Furthermore,
utilizing the LLC model in C57Bl/6J allows for the use of transgenic animal models.
Lastly, the LLC model is commonly used to examine early and late-stage cancer cachexia
phenotype by evaluating the animal at least at two different timepoint post tumor
inoculation (Chiappalupi et al., 2020; Han et al., 2020; Sun et al., 2016). Additionally,
recent studies have identified metabolic dysfunction in LLC mice and was more
pronounced in mice with larger tumors (Han et al., 2020), thus, highlighting the
heterogeneity within the LLC model (Counts et al., 2021).
Less investigated animal models of cancer cachexia, either by recent advances in
technology, translational difficulty or feasibility are the KPC, TOV21G, ES-2, and HT-29
models of cancer induced cachexia. KPC model of cancer cachexia (KRAS and mutant
P53 allele under pancreas specific Pdx-1 cre) is a recent model used to investigate
pancreatic ductal adenocarcinoma (PDAC) and development of cachexia can occur as
early as 5 days post tumor implantation (Michaelis et al., 2017). The TOV21G cells
(homo sapiens ovary cell carcinoma grade 3) induced muscle wasting and exhibited
elevated IL-6, and increased autophagy flux suggesting an IL-6/autophagy driven muscle
wasting model (Pettersen et al., 2017). Additionally, another very recent model of cancer
induced cachexia utilized ES-2 cells (Homo sapiens ovary clear cell carcinoma) in
immunodeficient mice and has only been minimally investigated (Pin et al., 2018).
Lastly, the HT-29 model of cancer induced cachexia is a human colorectal
adenocarcinoma cell line utilized in nude mice (Bonetto, Kays, et al., 2016). While we
have made advances in developing new models of cancer induced cachexia and aid in
targeting the heterogeneity of the condition, nevertheless, is remains ever important to
consider the mechanism of interest and efficacy of the model prior to study development.
Skeletal Muscle Protein Turnover
Skeletal muscle comprises 40% of the bodies total weight and has regulation of
whole-body metabolism (Zurlo et al., 1990). Skeletal muscle is necessary for body
posture and daily movement. Loss of skeletal muscle is a hallmark of cancer cachexia,
and muscle mass loss is directly related to increased morbidity and mortality. Given that
the maintenance of skeletal muscle mass and metabolic function are critical for health
(Wolfe, 2006), understanding the regulation of muscle wasting is critical for the
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development of therapeutic strategies for the proper treatment of cancer cachexia.
Skeletal muscle is a highly plastic tissue in which its homeostasis can be influenced by
the balance between the rates of protein synthesis and degradation, termed protein
turnover (Maddocks et al., 2011; Marimuthu et al., 2011). Given the importance of
skeletal muscle to overall health, understanding the mechanisms regulating protein
synthesis and breakdown are critically important for improving cancer cachexia
treatments. The next few sections will provide understanding into the regulation of
skeletal muscle protein turnover and how these processes are altered by cachexia.
Protein synthesis
Skeletal muscle protein turnover oscillates throughout the day in response to
exercise and feeding (Burd et al., 2009; Phillips, 2014). Skeletal muscle protein synthesis
is regulated by several factors such as nutrient status, activity level, and inflammation.
Protein kinase B (PKB or Akt) and the mechanistic / mammalian target of rapamycin
complex 1 (mTORC1) have established roles for the integration of anabolic signaling
initiated by growth factors, nutrients, and mechanical loading to regulate protein
synthesis (Laplante & Sabatini, 2009). Insulin and insulin-like growth factor 1 (IGF1) are
growth factors that stimulate mTORC1 signaling through the activation of Akt. Binding
of insulin/IGF1 to its cell surface receptor initiates phosphoinositide 3-kinase (PI3K)dependent activation of Akt T308 through phosphoinositide-dependent kinase 1 (PDK1).
Additionally, rapamycin-insensitive mTOR complex 2 (mTORC2) has also been shown
to be regulated by growth factors through the phosphorylation of Akt S473 (Fayard et al.,
2005). Furthermore, downstream target of Akt to control protein synthesis are glycogen
synthase kinase-3B (GSK3B), proline-rich Akt substrate 40 kDa (PRAS40), and tuberous
sclerosis 2 (TSC2) (Fayard et al., 2005). Briefly, GSK3B is inhibited by Akt
phosphorylation, which leads to the activation of eukaryotic translation initiation factor
2B (eIF2B) (Frame et al., 2001), while the inactivation of eIF2B inhibits protein
synthesis. Additionally, Akt phosphorylates TSC2 which removes the inhibition of
TSC1/2 complex on the Ras homologue enriched in brain (Rheb) activity on mTORC1
(Zoncu et al., 2011).
While the exact mechanisms of how amino acids stimulate protein synthesis are
unknown, recent work has shown that localization of mTORC1 to the lysosome has
emerged as a critical regulatory point in the activation of mTORC1 by amino acids and
exercise (Abou Sawan et al., 2018; Bar-Peled & Sabatini, 2014; Hodson et al., 2017).
Additionally, mTORC1 is found throughout the cytoplasm when amino acids are low,
when stimulated the regulator-rag complex targets mTORC1 to the lysosomal surface to
interact with GTPase Rheb (Abraham, 2010; Sancak et al., 2010). Furthermore, recent
work has highlighted the implications of GATOR 1 and 2 on the recruitment of mTORC1
to the lysosome via recruitment by RAG A/B and C/D (Graber et al., 2019). Gap Activity
towards RAG 1 (GATOR 1) is comprised of three subunits; Nitrogen permease regulatorlike 2 (NPRL2), Nitrogen permease regulator-like 3 (NPRL 3), and DEP domain
containing 5 (DEPDC5) while GATOR 2 is a made of 5 subunits. When amino acids are
high GATOR 1 and 2 form a super complex which allows for the RAG A/B and C/D
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activation therefore allowing full mTORC1 activation (Ho et al., 2016; Moro et al.,
2016). If the GATOR 1 and 2 are not forming a complex, then GATOR can inhibit RAG
activity thus preventing mTORC1 to reach the lysosome. Lastly, the most examined
output of mTORC1 is the phosphorylation of the eukaryotic initiation factor 4E (4E-BP1)
and the p70 ribosomal S6 kinase (S6K1) to promote protein synthesis. The
hyperphosphorylation of 4E-BP1 prevents binding to eukaryotic initiation factor 4E
(eIF4E) and the formation of 4E-BP1-eIF4E complex, resulting in the assembly of the
eIF4F complex and translation initiation (Kimball & Jefferson, 2010). Lastly, S6K1
activation by mTORC1 has been implicated in cap-dependent translation, translation
elongation, and ribosomal biogenesis (Bentzinger et al., 2008; Kimball et al., 1999).
While it is well established that muscle protein breakdown is activated during
wasting, whether suppressed protein synthesis regulation contributes to muscle mass loss
during cachexia is less known. To date, only a few studies have examined muscle protein
synthesis and breakdown rates in cancer patients (Dworzak et al., 1998; Emery et al.,
1984; van Dijk et al., 2015; van Dijk et al., 2019). While there are only a few human
studies, it has been concluded that changes in both basal and postprandial muscle protein
synthesis and breakdown rates contribute to the muscle wasting observed in cachectic
cancer patients, suggesting that the regulation of both are different (Brook et al., 2017;
Horstman et al., 2016).
While a majority of our understanding of protein synthesis during cachexia is
examined in murine models, protein synthesis rates are reduced in cachectic patients
(Dworzak et al., 1998). We have routinely shown suppressed protein synthesis during the
progression of cachexia in the Apc Min/+ mouse, and this suppression corresponded to a
reduction in muscle protein mTORC1 and IGF1 but were independent of Akt S473
(White, Baynes, et al., 2011). This early suppression of protein synthesis during cachexia
did not correspond to an initial change in AMPK, since AMPK activity does not increase
till late-stage cachexia (White, Baynes, et al., 2011). Interestingly, IL-6 receptor antibody
was sufficient to attenuate muscle mass loss and AMPK signaling, however IL-6 was not
sufficient to restore protein synthesis or mTORC1 (White, Baynes, et al., 2011).
However, pyrrolidine dithiocarbonate (PDTC; STAT3 and P65 inhibitor) was sufficient
in activating protein synthesis and reducing protein breakdown (Narsale et al., 2016).
Additionally, we have examined a role for systemic IL-6 in suppressing protein
synthesis during cachexia (White et al., 2013). Furthermore, cytokine dosing is
commonly used in cell culture to provide a high inflammatory environment. We have
previously shown that IL-6 exposure has the capacity to decrease C2C12 myotube
diameter and suppress mTORC1 signaling, and when AMPK is blocked the IL-6
suppression of protein synthesis is relieved (White et al., 2013). In the LLC tumor model,
downstream targets of mTORC1; 4EBP-1 and rpS6, are suppressed during cachexia
(Puppa, Gao, et al., 2014). Interestingly, gp130 loss did not improve the suppressed
mTORC1 signaling, but did prevent muscle wasting (Puppa, Gao, et al., 2014).
Furthermore, LLC tumor derived media on C2C12 myotubes suppressed protein
synthesis which coincided with STAT3 and AMPK phosphorylation (Gao & Carson,
2016). AMPK, but not gp130 inhibition rescued protein synthesis suppression.
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Collectively, these studies highlight that suppressed muscle protein synthesis and
mTORC1 signaling is linked to IL-6/STAT3, but alone is not sufficient to restore protein
synthesis during cachexia progression.
Protein breakdown
Muscle atrophy involves the upregulation of proteolytic systems to remove
contractile proteins and organelles (Bonaldo & Sandri, 2013). There are two main
proteolytic systems involved in muscle atrophy: ubiquitin-proteasome and autophagylysosome. Additionally, calpain proteolysis has also been implicated in muscle atrophy
(Huang & Zhu, 2016). Calpains are Ca2+-dependent cysteine proteases which can cleave
cytoskeletal protein for further breakdown at the proteasome. Lastly caspases are a family
of proteolytic enzymes that are most known for their role in initiating apoptosis (Bell et
al., 2016).
Ubiquitin-proteasome system (UPS) is the main mechanism for protein
degradation (Lecker et al., 1999). The UPS is comprised of 3 enzymes that conjugate
ubiquitin which are recognized for degradation. The first enzyme component is E1 (Ubactivating enzyme) which activates proteins after ATP cleavage. The ubiquitin is moved
from E1 to E2 (Ub-carrier or conjugating proteins). E1 and E2 are enzymatic components
that link the ubiquitin chain. The third enzyme E3 (Ub-protein ligase) is highly important
as it recognizes a specific protein substrate and catalyzes the transfer of activated
ubiquitin to a substrate chain. The degradation of proteins through the ubiquitin
proteasome is a highly coordinated process and in skeletal muscle utilizes the musclespecific E3 ligases Atrogin-1/MAFbx and MuRF-1 which are controlled upstream by
FOXO3a and were discovered initially through the studies examining starvation and
fasting conditions. The binding of E3 to E2 elicits the transfer of ubiquitin from E2 to the
substrate. These E3 ligases allow for targeted proteins to be recognized by the 26S
proteasome and ensure specificity of the UPS and additional adaptor proteins (Murton et
al., 2008). In addition to inducing protein synthesis, Akt has the capacity to inhibit
catabolic processes through the phosphorylation and inhibition of the FoxO. Akt can
phosphorylate FoxO at Thr24, Ser 256, and Ser319, which prevents nuclear entry and
activation of gene expression (Tzivion et al., 2011).
Cancer cachexia is commonly characterized by activated UPS in murine and
human studies (Bossola et al., 2003; Lorite et al., 1998; Tisdale, 2009; Williams et al.,
1999). Atrogin-1 and MuRF-1 are E3 ligases commonly investigated in cachectic skeletal
muscle. During the progression of cancer cachexia, ATP-dependent protein degradation
activity (Lorite et al., 1998), muscle E3 ligase expression, and ubiquitin conjugates are
increased with the initiation of cachexia (<5% body weight loss) and are further increased
with cachexia severity (White, Baynes, et al., 2011). Furthermore, we have shown that
systemic IL-6 is associated to muscle Atrogin-1 mRNA during cachexia suggesting a link
between inflammation and protein breakdown during cachexia (Baltgalvis et al., 2009).
Forkhead transcription factors (FoxO) and the inflammatory transcription factor, NFκB,
act on the promoters for Atrogin-1 and MuRF-1 respectively to stimulate their
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expression. FoxO and NFkB can accelerate muscle wasting by E3 ligase conjugation with
atrogenes (Cai et al., 2004; Sandri et al., 2004). Interestingly, it has been hypothesized
that E3 mRNA’s might be a biomarker for excessive muscle proteolysis, however it is
also important to understand that the induction of UPS is occurring under basal
conditions and therefore is interesting to hypothesize how the system will respond to a
stress.
Autophagy is a non-specific dynamic process used to remove damaged
organelles, abnormal protein aggregates, or bulk contents (Ravanan et al., 2017).
Autophagy can be initiated selectively and non-selectively by sequestering cytosolic
substrates within a phagophore which is then conjugated with ubiquitination-linked
proteins and degraded by a lysosome (Sanchez et al., 2012; Vainshtein & Hood, 2015).
Under basal conditions, autophagy is relatively low, however nutrient deprivation, cell
stress, and chemical reagents are known to induce autophagy (Ravanan et al., 2017).
While autophagy is constantly in flux; prolonged and excessive autophagy can lead to
cell death. The process of autophagy (self-eating) is comprised of 3 types;
macroautophagy, microautophagy, and chaperone-mediated autophagy (Klionsky, 2005).
Macroautophagy consist of an autophagosome (double membrane vesicle) formed by
portions of the cytoplasm. The autophagosome fuses with the lysosome to release the
inner single membrane into the lumen. Microautophagy consist of the direct engulfment
of cytoplasm at the lysosome. Lastly, the chaperone-mediate autophagy translocate
unfolded proteins directly across the lysosome. Despite all of this, most autophagy
conducted is considered macroautophagy. Autophagy is induced through the AMPK
activation of ULK-1 and has been extensively investigated with numerous catabolic
conditions including fasting (Sandri, 2010; Yan et al., 2012). AMPK has long been
established as a critical regulator of both protein synthesis and protein degradation and
induces both the ATP-independent autophagy lysosomal proteasome and the ATPdependent ubiquitin proteasome, respectively. Within the cell, AMPK phosphorylates
ULKS555 to form a complex with ATGs and Beclin. The formation of this complex
functions to cleave the C-terminus of ATG4 to produce LC3-1, which can then form
LC3-II thus allowing for the formation of the autophagosome membrane. Furthermore,
when activated, AMPK will phosphorylate tuberous sclerosis protein 2 (TSC2) and
Raptor, which inhibits mTORC1 activity (Gwinn et al., 2008). AMPK activation is also a
regulator of skeletal muscle degradation through the induction of proteasomal and
autophagic-lysosomal proteolysis by inhibiting mTORC1 (Bolster et al., 2002),
upregulation of E3 ligase expression via FOXO3a (Greer et al., 2007) and activation of
ULK-1 (Lira et al., 2013). Activation of mTORC1 inhibits autophagy through the
phosphorylation of multiple autophagy-related proteins that promote autophagy initiation
and autophagosome nucleation. Additionally, ULK1 phosphorylation S757 suppresses
the phosphorylation of ULK1 S555 thereby inhibiting AMPK. Lastly, transcription factor
EB (TFEB) is a member of the leucine-zipper family of transcript factors that control
lysosomal biogenesis (Martina et al., 2012). Recent evidence has shown TFEB
overexpression induces autophagy, which has known effects to regulate mTORC1which
will sequester in the cytoplasm and inhibit transcriptional activity (Bajaj et al., 2019).

11

The role of autophagy in muscle wasting, not only in cancer cachexia, but in any
disease has progression has gained great interest (Levine & Kroemer, 2008). Recent work
has shown increased autophagy in cachectic skeletal muscle from murine and humans’
models (Pigna et al., 2016; Tardif et al., 2013). Furthermore, autophagy associated
signaling was only induced in cachectic cancer patients, compared to cancer and noncancer patients, highlighting the potential specificity of autophagy occurring later in
cachexia progression (Aversa et al., 2016). To further support this rational, during severe
cancer cachexia, skeletal muscle AMPK is dysregulated and chronically activated which
could have dire consequences regarding muscle proteostasis. We have known for years
that during cancer cachexia progression autophagy associated proteins are increased
which coincided with increased AMPK signaling (White, Baynes, et al., 2011).
Furthermore, increasing autophagy activity exacerbates muscle wasting (Penna, Ballaro,
Martinez-Cristobal, et al., 2019). Taken together, these studies highlight autophagy’s role
in muscle wasting with cancer cachexia.
Skeletal muscle phenotype
Skeletal muscle is comprised of contractile and metabolic properties that elicit
responses to numerous physiological conditions (Schiaffino & Reggiani, 2011). Skeletal
muscle is comprised of heterogenous populations of muscle fibers that are characterized
by type: type I (slow-twitch) and type IIA/B (fast-twitch) (Szent-Gyorgyi, 2004). Slow
oxidative fibers; type I, are muscle fibers that have a high mitochondrial density, small
myonuclear domain, fatigue resistant, weak force production, and red in appearance
(Egan & Zierath, 2013). Fast oxidative-glycolytic fibers; type IIa, are fatigue resistance,
moderate mitochondrial density, moderate myonuclear domain, fatigue resistant,
moderate force production, and red in appearance. Fast glycolytic; type IIb, have low
mitochondrial density, large myonuclear domain, reaches fatigue prior to oxidative
muscle, strong force production, and white in appearance. There are slight differences
between the characterization of mice and human myosin isoforms, briefly mice have 1
slow myosin isoform (MHC I) and three fast myosin isoforms (MHC IIa, IIb, and IId)
(Schiaffino & Reggiani, 1994; Talbot & Maves, 2016). In addition, muscle fiber typing is
commonly used to understand the treatment's response on skeletal muscle phenotype. At
baseline though, muscle types in mice are characterized as the following: soleus fibers are
mostly type I and IIa, extensor digitorum longus (EDL) and tibialis anterior (TA) muscle
are comprised mostly of IIb, and the gastrocnemius is comprised of mostly IIb, but more
I than EDL and TA. Furthermore, the gastrocnemius has a red and white portion further
allowing for the comparison of muscle phenotype within the same muscle.
Skeletal muscle phenotype aids in the response to nutrients, chronic disease, and
activity (Egan & Zierath, 2013). Unfortunately, most studies that compare the effect of
muscle phenotype compare the treatment or study manipulation response in different
muscle’s without comparing the basal response between muscle (Deval et al., 2020;
Sebastian et al., 2016). To account for the differential regulation, several studies compare
a similar response in different muscle phenotypes. While this was not the purpose of
these studies, it does leave open to interpretation if the response or lack of response can
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be attributed to the basal phenotype. When comparing oxidative vs glycolytic muscles,
oxidative muscles exhibit elevated autophagy-lysosome proteins, without changes in the
E3 ligase mRNA (de Theije et al., 2015). Additionally, red gastrocnemius muscle has
increased nicotinamide phosphoribosyl transferase which is the rate-limiting enzyme in
the NAD salvage pathway compared to white gastrocnemius, supporting the higher
metabolism in oxidative compared to glycolytic (Brandauer et al., 2013). Increased
oxidative capacity in red muscle compared to white muscle is supported by increased
pgc1alpha and Sirt mRNA expression (White, Baltgalvis, et al., 2011). Interestingly,
mitochondrial fusion proteins were induced in glycolytic muscle, but mitochondrial
fission was similar between groups further elucidating to the basal differences between
muscle can differentially regulate their response to a stimulus.
Chronic disease, disuse, and inflammation are known to disrupt skeletal muscle
fiber types size and composition (Ciciliot et al., 2013; Dumitru et al., 2018; Gosker et al.,
2002; Hua et al., 2017). A myofiber's response to catabolic stimuli has been shown to be
regulated by phenotype; slow-oxidative fibers are more susceptible to disuse atrophy,
whereas fast-glycolytic muscles are more sensitive to cachectic stimuli. In cachectic
cancer patients, MHC I and II are decreased, only in late-stage cancer (Johns et al., 2014).
In the C26 model of cachexia, fiber types shifts to an increase in smaller fibers (Bonetto,
Rupert, et al., 2016), and exhibits a reduction in the total number of all fiber types
(Murphy et al., 2019; Roberts, Ahn, et al., 2013). Furthermore, in a genetic model of
cancer, fiber type IIa/b were decreased (Hardee et al., 2016), and highlights that the
changes in type II fibers occurs in the later stages of cachexia (Baltgalvis et al., 2010).
Interestingly, in a pancreatic model of cancer cachexia, only type IIx/IIb were decreased
(Talbert et al., 2019). Taken together, these studies highlight that cachexia progression
disrupts skeletal muscle fiber types, with a decrease in all fibers at end stage cachexia.
We have only just started to scratch the surface in investigating cachexia’s effect on
altering homeostasis in oxidative and glycolytic muscles. To date, we know that COXIV
protein expression was decreased in severe white gastrocnemius compared to weight
stable and red gastrocnemius (White, Baynes, et al., 2011). Reduced mitochondrial
content has been shown in both oxidative and glycolytic hindlimb muscles (White,
Baltgalvis, et al., 2011; White et al., 2012). Furthermore, mitochondrial fission mRNA
was induced with cachexia and fusion mRNA was lowered, without differences between
fiber type. Additionally, we have shown that BAX; a nuclear-encoded protein aids in
piercing the mitochondrial membrane to elicit apoptosis, is elevated in cachectic soleus
muscle without changes in red and white gastrocnemius muscle in tumor-bearing mice
(Baltgalvis et al., 2010). Taken together, there is sufficient data supporting that cachexia
differentially regulates oxidative and glycolytic fibers, however this has yet to be fully
understood.
Inflammation
Chronic inflammation is an adverse sequalae of many chronic diseases. While the
acute induction of inflammation in response to injury is necessary for recovery, long term
exposure can result in metabolic dysfunction and disrupted protein turnover. Pro-
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inflammatory cytokines; interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor
alpha (TNF- α), and leukemia inhibitory factor (LIF) that are chronically elevated during
cachexia are one of the initial triggers in inducing hypothalamus/pituitary and
mitochondrial dysfunction (Cole et al., 2018). Furthermore, inflammation has been
implicated as a key mediator of cancer-induced cachexia leading to the chronic elevation
of skeletal muscle STAT3 and MAPK activity (Deans & Wigmore, 2005), thereby
disrupting mitochondria. The next few sections will discuss the importance of
inflammatory signaling during cachexia progression and how gp130 is a regulatory point
of interaction between the systemic environment and muscle wasting.
Glycoprotein-130 (gp130) is transmembrane protein ubiquitously expressed in
most tissues. There are several circulating cytokines that react with gp130; IL-6, LIF,
oncostatin M (OSM), ciliary neutrophilic factor (CNTF), and cardiotrophin-1 (CT-1), to
elicit effects on most tissues (Ma et al., 2019). Gp130 resides in the membrane, therefore
interactions must occur through ligand-receptor responses. Signaling activity occurs
commonly by 1 of 3 mechanisms. Most commonly, the α-subunit binding by either IL-6,
IL-11, or CNTF triggers oligomerization with type 1 cytokine receptor β-subunit of
gp130 (Ernst & Jenkins, 2004). This reaction causes gp130-gp130 homodimerization to
elicit intrinsic signaling. Another mechanism of action is the heterodimerization of gp130
to a β-subunit; for example, LIFRβ and OsMRβ. Lastly, facilitation of the β-subunit can
be dimerized upon ligand blocking by a soluble component. This process is called
receptor conversion or trans-signaling meaning that a soluble receptor will bind to gp130.
Our understanding of these biological responses is that they are often overlapping,
however recent work has tried to highlight specificity of gp130 binding.
Our initial understanding of the effects of gp130 were examined to determine the
interplay between immune and hematopoietic cells (Kishimoto et al., 1994). Interestingly,
the majority of our understanding of the role of gp130 is by examining the loss of
associated cytokines (IL-6, LIF, IL-11), with the majority of gp130 understanding
derived from blocking/activating IL-6 signaling, thus limiting our understanding of the
implications of gp130 signaling (Hirota et al., 1999). Over 20 years ago, the loss of
gp130 highlighted the necessary function of gp130 on embryonic development since
gp130 loss is embryonic lethal (Yoshida et al., 1996). Even the post-natal loss of gp130
using cre-recombinase resulted in neurological, cardiac, hematopoietic, and
immunological defects (Betz et al., 1998; Ernst & Jenkins, 2004). However, in a
physiological state that induces gp130 associated signaling, the loss of gp130 in the liver
inhibited the progression of liver cancer (Hatting et al., 2015), and has been implicated as
a way to combat chronic disease (Drogemuller et al., 2008; Molyneaux et al., 2003;
Streetz et al., 2003). Alternatively, constitutive expression of gp130 induced cardiac
hypertrophy (Hirota et al., 1999). Taken together, these studies highlight that the
regulation of gp130 is a dynamic process and the activation or suppression of gp130
associated signaling is tissue and condition specific.
Gp130 is a regulatory point of interaction between systemic inflammation to
JAK/STAT and MAPK signaling in skeletal muscle (White & Stephens, 2011). The
phosphorylation of associated Janus kinase (JAK) is sufficient to recruit domain
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containing cytoplasmic protein tyrosine phosphatase (SHP-2) thereby initiating the
phosphorylation cascade of Ras-Raf-MEK-ERK. Additionally, the phosphorylation of
JAK can result in the phosphorylation of STAT1/3. STAT-dependent transcriptional
regulation of suppressor of cytokine signaling (SOCS) is a negative regulator of STAT
signaling by binding to JAK thus inhibiting the phosphorylation of STAT. In skeletal
muscle, we have previously induced gp130 loss by generating gp130-floxed on the
myosin light chain cre-promoter (Fix et al., 2018). Gp130 loss decreased STAT3 protein
expression by 75%. Gp130 loss did not affect muscle fatigue, run to fatigue time, and
COX activity in the gastrocnemius muscle (Fix et al., 2018). Interestingly, gp130
knockout mice had greater lean mass and body mass (Puppa, Gao, et al., 2014).
Furthermore, gp130 loss induced mitochondrial fission 1 protein (FIS-1) and decreased
mitofusion-1 (MFN-1) in crude gastrocnemius muscle, which was also reported in
isolated mitochondria highlighting changes to mitochondrial dynamics by gp130. This
was followed up by an increase in Beclin-1 and P62, without changes in LC3II/I ratio,
identifying dysfunctional clearance of the autophagosome (Fix et al., 2018). We have
shown in cell culture that the mitochondrial quality control dynamic changes are not
directly attributed to decreased STAT3 highlighting the multifactorial nature of gp130.
Lastly, Akt phosphorylation T308 was significantly induced in gp130 knockout mice
without effecting downstream mTORC1 signaling (Puppa, Gao, et al., 2014). It can be
hypothesized that a further induction of mTORC1 signaling in the basal condition is
unlikely to be affected by gp130 loss alone, especially since AMPK signaling was not
altered. Taken together, these data highlight that gp130 loss has regulatory function on
mitochondrial dynamics with minimal alterations to Akt/mTORC1/AMPK signaling
following a brief fast.
In chronic disease induced cachexia, gp130 protein expression was elevated in
Kaposi’s sarcoma; a common cancer in AIDs patients (Morris et al., 2008). Furthermore,
in several models of cancer induced cachexia, gp130 downstream signaling was also
upregulated (Bonetto et al., 2012; Puppa, Gao, et al., 2014; White, Baynes, et al., 2011).
Interestingly, gp130 loss in neurons reduced LLC induced pain (Andratsch et al., 2009).
Several studies have implicated the role of gp130 signaling on preventing and/or treating
cancer induced cachexia. First, skeletal muscle-specific STAT loss prevented LLC
induced muscle wasting and grip strength loss, without altering tumor mass (Silva et al.,
2015). Interestingly, in a genetic model of cancer induced cachexia (Apc Min/+ mice), IL-6
receptor antibody preserved some body weight and muscle mass loss (White, Baynes, et
al., 2011). Furthermore, IL-6 receptor antibody was sufficient in reducing STAT3 and
AMPK signaling without rescuing the suppression of mTORC1. We have previously
administered PDTC (anti-inflammatory) to mice injected with LLC cells, while muscle
STAT3 was reduced muscle mass was not preserved (Puppa, Gao, et al., 2014).
Interestingly, we have previously reported muscle gp130 loss prevented LLC induced
muscle wasting and restored STAT3 and MAPK signaling, however the mTORC1
downstream signaling was not rescued (Puppa, Gao, et al., 2014). Lastly, IL-6 induced
mitochondrial dysfunction and fatigue requires skeletal muscle gp130 (VanderVeen et al.,
2019). Interestingly, cachexia has known disruptions in mitochondrial function prior to
muscle wasting (Brown et al., 2017) and theses disruptions to the muscle mitochondria
are known to induce AMPK, thereby accelerating muscle wasting (VanderVeen et al.,
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2017). Given that muscle gp130 can regulate mitochondrial quality control (Hardee,
Counts, et al., 2018), whether these are linked to cachexia disruption of protein turnover
by feeding are warranted.
Cancer cachexia is a multifactorial wasting condition and can lead to systemic and
tissue specific metabolic dysfunction (Fonseca et al., 2020; Kunzke et al., 2020). Indirect
calorimetry and energy expenditure have long been used to anticipate and/or assess
metabolic dysfunction (Lam & Ravussin, 2016). Indirect calorimetry provides
identification of fuel source through exchange of gases, allowing for a noninvasive
method to indirectly identify oxygen consumption, carbon dioxide production,
predominate fuel source, and energy expenditure. We have known for quite some time
that lung cancer patients exhibit increased energy expenditure and the association to body
weight loss (Eden et al., 1984). It is well known that the tumor’s metabolic instability can
result in tumor cells reprogramming or inability to respond to treatment (Vanhove et al.,
2019), likely resulting in discrepancies between decreased survival in whole body
hypometabolic (Jatoi et al., 1999; Jebb et al., 1994) or hypermetabolic patients (Vazeille
et al., 2017). These discrepancies have led to the inability to provide therapeutic options
to mitigate metabolic disruptions that are greatly influenced by tumor stage and
therapeutic treatments. Thus, highlighting the need to further understand the metabolic
dysfunctions attributed to lung cancer. The following sections will highlight the
disruptions that occur during cancer cachexia with the mitochondria and the important
regulation of AMPK in these processes.
Mitochondria
Mitochondria are highly plastic, dynamic, adaptable, and necessary for proper
skeletal muscle function. Mitochondria are often termed the “powerhouse” of the cell,
while not their only function, they predominantly manage ATP production. In addition,
mitochondria regulate signaling for protein turnover, autophagy, and apoptosis
(Romanello & Sandri, 2010). The mitochondria are a complex network, having two
distinct subfractions; subsarcolemmal (SS) and intermyofibrillar (IMF) fractions (Attardi
& Schatz, 1988). The SS accounts for 20% of the muscle’s mitochondria and is located
directly under the plasma membrane to provide the energy to transport substrates and
initiate signaling. Next, the IMF is located between myofibrils to provide ATP for muscle
contraction. Both subfractions are necessary for proper mitochondria function. To meet
energy demands, mitochondria are upregulated to compensate. The increase in
mitochondrial size or number; mitochondrial biogenesis, occurs in response to stress
(Jornayvaz & Shulman, 2010). The stress imposed on the muscle can active the energy
sensor AMPK to provide energy for mitochondrial biogenesis by suppressing protein
synthesis. Furthermore, mitochondria regulate protein degradation through mitochondrial
fission to activate AMPK thereby regulating FOXO3 (Romanello et al., 2010). The
increase in AMPK induces peroxisome-proliferator gamma-activated receptor coactivator
(PGC-1α) (Jager et al., 2007). The increase in PGC-1α regulates nuclear encoding
mitochondrial proteins (NUGEMPs) (Wu et al., 1999), but also regulates itself by
mTORC1 activity (Cunningham et al., 2007). The importance of mTORC1 in
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mitochondrial homeostasis is further supported by the inhibition of mTORC1 that
reduced muscle oxidative capacity and function (Morita et al., 2017; Schieke et al.,
2006).
Mitochondrial dynamics is regulated through mitochondrial fission and fusion
(Yaffe, 1999). First, mitochondrial fission occurs through the separation of mitochondria
into two. Mitochondrial fusion occurs by having two mitochondria coming together to
form one. Mitochondrial fission is regulated by dynamin related protein-1 (DRP1) and
fission 1 protein (Fis1). DRP1 locates on the outer mitochondrial membrane to interact
with Fis 1 an adaptor protein and mitochondrial fission factor to elicit fission (Benard &
Karbowski, 2009). DRP1forms a ring at fission sites and constricts by GTP hydrolysis. A
recent study has shown that DRP1 loss in skeletal muscle induces abnormal calcium
handling, increased mitochondrial calcium uniporter (MCU), and resulted in muscle
weakness and atrophy (Favaro et al., 2019), highlighting the necessary function of DRP1.
While the mechanism is not completely known, Fis 1 inhibition has been shown to reduce
autophagy (Romanello et al., 2010) and has been implicated in the maintenance of health
by targeting dysfunctional mitochondria (Iglewski et al., 2010). Mitochondrial fusion is
regulated by outer-membrane GTPases mitofusin 1 and 2 (Mfn1/Mfn2), and innermembrane GTPase optic atrophy protein 1 (OPA1). Mfn1/2 work by tethering
mitochondria through and OPA1 acts as the anchor during fusion (Zorzano & Claret,
2015). Mfn1 and 2 have suggested to have overlapping function and their activity suggest
to being tissue specific. For example, both Mfn 1 and 2 are found in skeletal muscle, but
Mfn2 is more active (Santel et al., 2003). Inhibition of mitochondrial fusion in mice leads
to decreases in mitochondrial DNA and ultimately muscle atrophy (Chen & Chan, 2010).
Furthermore, Mfn2 has been shown to be regulated by PGC-1α (Soriano et al., 2006).
Taken together mitochondrial dynamics is a very plastic process and has been implicated
as regulatory point in chronic disease (Chan, 2020). Mitochondrial loss and dysfunction
are prominent features of muscle wasting (Argiles et al., 2015; Gamboa et al., 2016;
Picca et al., 2017; VanderVeen et al., 2017). In addition, cachectic muscle exhibit
decreased mitochondrial control (Marzetti et al., 2017) and has been shown in both
oxidative and glycolytic hindlimb muscles (White, Baltgalvis, et al., 2011; White et al.,
2012). Interestingly, we have shown insulin resistance in cachectic mice (Lombardi et al.,
2012), suggesting a link between the inability to clear glucose and dysfunctional
mitochondria.
Recent work has identified that LLC mice exhibit disrupted whole body insulin
and glucose signaling prior to wasting (Han et al., 2020). In addition, skeletal muscle
mitochondrial dysfunction onset occurs prior to muscle wasting (Brown et al., 2017).
Taken together, these studies identify that muscle and whole-body metabolism associated
disruptions are likely contributing to the wasting progression. Furthermore, we have
consistently shown cachexia decreases mitochondrial fusion with a corresponding
increase in fission (White, Baltgalvis, et al., 2011), suggesting a pivotal role in the
regulation of skeletal muscle mass. Others have shown cachexia decreases muscle
oxidative capacity, but was not associated to altered ATP production (Julienne et al.,
2012). Furthermore, ATP production is decreased in tumor-bearing mice (Tzika et al.,
2013), likely contributing to increased fatigue during cachexia. However, PGC-1α
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transgenic mice were not sufficient to prevent muscle wasting despite an increase in
mitochondrial content (Wang et al., 2012). Interestingly, overexpression of PGC-1α4 was
able to prevent severe cachexia progression and improve glucose metabolism and force
production (Ruas et al., 2012). Furthermore, overexpression of mitofusin partially
attenuated muscle mass loss highlighting the therapeutic potential of restoring
mitochondrial content and dynamics (Xi et al., 2016). Systemic inflammation has been
implicated in the regulation of mitochondrial dysfunction. During cachexia progression,
IL-6 receptor antibody given after the initiation of cachexia was sufficient to lower
mitochondrial fission and increase fusion, while also increasing mitochondrial biogenesis
(White et al., 2012). In addition, systemic inhibition of NFκB and MAPK was sufficient
to prevent body wasting, muscle mass loss, tumor burden, improve strength, and improve
mitochondrial complex activity (Fermoselle et al., 2013). The use of these systemic
inhibitors was sufficient to decrease tumor mass or number thus making it difficult to
understand the regulation of these systemic inhibitors on muscle mitochondria. Taken
together, mitochondria’s role in skeletal muscle mass during cancer cachexia has only
minimally been explored and requires further understanding.
Metabolism is a very broad term and encompasses a range of chemical reactions
in response to fuel availability to maintain cell homeostasis (DeBerardinis & Thompson,
2012). 5’ adenosine monophosphate-activated protein kinase (AMPK) plays a crucial role
in energy metabolism and cellular homeostasis (Romanello et al., 2010; Romanello &
Sandri, 2015). AMPK is a highly functional protein complex activated by nutrient
deprivation, hypoxia, and toxins that disrupt mitochondrial transport chain (Viollet et al.,
2010). Additionally, the duration of AMPK activity is critical in understanding the
mechanism of action and potential implication. Chronic elevated AMPK signaling;
specifically in skeletal muscle during aging (Mulligan et al., 2005) cancer cachexia
(White, Baynes, et al., 2011) and COPD (Balnis et al., 2020) has been implicated as a
negative consequence of the disease and therapeutic strategies to circumvent this chronic
activation has been sought after for decades. Alternatively, exercise is a known acute
inducer of AMPK, however the induction of AMPK is dependent on the exercise
intensity and duration (Kjobsted et al., 2018). It is important to distinguish between the
adverse chronic consequences of elevated AMPK compared to the necessary AMPK
induction for exercise adaptations.
AMPK is a heterotrimeric enzyme comprised of two alpha (α) subunits (1 and 2),
two scaffolding beta (β) subunits (1 and 2), and three regulatory gamma (γ) subunits (1,2
and 3) (Fuchsberger et al., 2016). The phosphorylation of AMPK T172 involves
physiological activity by the AMPK alpha catalytic subunit and is a major site for
AMPK’s activity. To date, only 3 subunit combinations exist in humans (α1β2γ1,
α2β2γ1, and α2β2γ3) (Birk & Wojtaszewski, 2006) and 5 have been reported in mice
(α2β2γ1, α2β2γ3, α1β2γ1, α1β1γ1, α1β1γ1) (Kjobsted et al., 2018). Predominate
expression combination for both human and mouse consist of α2β2γ1. The α subunit of
AMPK can be activated by liver kinase B1 (LKB1), calcium/calmodulin-dependent
kinase 2 (CaMKK2), TGF β -activated kinase 1 (TAK1), protein phosphatase 2A (PP2A),
protein phosphatase 2C (PP2C), and magnesium dependent protein phosphatase 1E
(PPM1E) (Jeon, 2016). Increased energy induces low AMP/ATP and ADP/ATP ratios,
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thereby allowing phosphatases to access T172 keeping it unphosphorylated, however
when levels of AMP and ADP increase and bind to cystathionine β -synthase (CBS3) at
the gamma subunit, this prevents the phosphatases from binding to T172. AMP and ADP
binding to CBS3 stimulate LKB-1 to phosphorylate AMPK T172 on the β subunit (Scott
et al., 2004). Furthermore, calcium activates AMPK through CaMKK2 activity. Insulin
inhibits AMPK by phosphorylating AKT which phosphorylates one of two AMPK α
subunit sites therefore blocking upstream kinases from phosphorylating T172.
Additionally, the hormone leptin acts similar as AKT but through p70S6K. Lastly,
protein kinase A (PKA); activated by the binding of cyclic AMP to its R subunit, inhibits
AMPK phosphorylation sites on the α subunit. Additionally, increases in reactive oxygen
species (ROS) regulate AMPK, the mechanism is thought to occur through glucose
depletion and decreased antioxidant capacity however the exact mechanisms still remains
elusive (Jeon, 2016). AMPK can also be regulated by activating the peroxisome
proliferator activated receptor gamma coactivator 1alpha (PGC1alpha)-hypoxia inducible
factor 1alpha (HiF1). This activity activates the sestrin family of proteins to induce
TSC1/2 signaling thereby inhibiting downstream target mTORC1. Altogether, there are
several mechanisms of action to elicit AMPK and the process is very complex, thus
understanding AMPK’s specificity is crucial to understanding and interpretating a
treatment or conditions response by altering AMPK.
Once activated, AMPK elicits several downstream cascades. First, AMPK has
known regulation on lipid metabolism by inhibiting new fatty acid synthesis through
phosphorylating acetyl-Cao carboxylase 1 (ACC1) to disrupt the fatty acid synthesis rate
limiting step of malonyl-Cao. The second method of inhibiting fatty acid synthesis is the
activity of sterol regulatory element-binding protein 1c (SREBP1c) to promote lipogenic
enzymes. Additionally, triglyceride synthesis is catalyzed by glycerol-3phopshate
acyltransferase which inhibits AMPK, while AMPK inhibits cholesterol synthesis
through blocking phosphorylation of HMG-CoA reductase (Motoshima et al., 2006).
AMPK’s known activity to promote lipid catabolism is induced by carnitine
palmityltransferase-1 (CPT-1) which increases from AMPK’s phosphorylation of ACC2.
ACC2 is localized to the outer mitochondrial membrane to inhibit production of malonylCoA that in turn will inhibit the allosteric inhibitor of CPT-1 therefore inducing fatty acid
oxidation (Hardie & Pan, 2002). Additionally, AMPK has regulation on glucose uptake
through TCB1D1 phosphorylation. Tab-GTPase-activating protein (TCB1D1) is a RabGTPase activating protein that inhibits GLUT4 through rab protein inactivity (Miinea et
al., 2005). Phosphorylation of TCB1D1 dissociates from GLUT4, thereby aiding in
GLUT4’s translocation. Taken together, AMPK is the control center for several
metabolic associated perturbations to induce fatty acid lipolysis.
The role of AMPK has long been sought after given its multiple mechanisms of
action and several inputs. Understanding the mechanisms of AMPK have been
extensively reviewed regarding the importance and impact of AMPK (Fuchsberger et al.,
2016; Jeon, 2016; Kjobsted et al., 2018; Steinberg & Jorgensen, 2007). First, it is
necessary to understand that whole body AMPK α1/α2 loss is embryonic lethal and βsubunit 1 and 2 loss are embryonic lethal (Quinn et al., 2010) identifying the importance
of α and β for development. However, AMPK α 2 whole body loss is not lethal, which is
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likely due to other subunits function given that AMPK α1 expression was present
(Viollet, Andreelli, Jorgensen, Perrin, Geloen, et al., 2003). Additionally, while AMPK
alpha 2 loss did impair fat oxidation during exercise recovery, it remains unclear if
AMPK α2 is essential or if there is feasibility of other subunits to upregulate when one
subunit is lost (Fritzen et al., 2015). Additionally, despite observing a 50% decrease in
AMPK T172 phosphorylation in skeletal muscle, whole body AMPK α2 loss exhibited
increased muscle AMPK α1 activity suggesting a potential confounder when
investigating the role of AMPK (Jorgensen et al., 2007). Furthermore, whole body β1/2
loss mice exhibit decreased respiratory exchange ratio and suppressed glucose update
(O'Neill et al., 2011), highlighting the specificity of the beta subunit function on whole
body metabolism. It is important to mention, that the authors directed the disruption on
the systemic adrenergic response and not specifically a role from skeletal muscle. Lastly,
whole body loss of γ3 subunit had capacity to decrease AMPK activity at rest, during
exercise, and fasting without altering insulin sensitivity under these conditions,
identifying the regulation of insulin on AMPK might be through another subunit (Barnes
et al., 2004). Overall, AMPK loss of any subunit has the potential to disrupt normal
metabolism, and it is necessary to consider the subunit manipulation and tissue of interest
to fully determine the role of AMPK’s function.
The role of AMPK in skeletal muscle has long been investigated in chronic
disease and in response to exercise. A recent review has extensively examined the effects
and implications of AMPK loss (KO) in skeletal muscle (Kjobsted et al., 2018; Viollet et
al., 2009). Disrupted skeletal muscle AMPK α or β subunits are commonly investigated.
Whole body AMPK α2 KO was sufficient to reduce AMPK activity in skeletal muscle
with only modest changes in AMPK α1 (O'Neill, 2013). Interestingly, whole body
AMPK α1 KO mice did not alter muscle AMPK activity, identifying that α2 subunit is
the predominant and subunit 2 is the predominant source of AMPK’s activity (Viollet,
Andreelli, Jorgensen, Perrin, Flamez, et al., 2003). It is necessary to mention that when a
metabolic demand is placed on the mouse by high fat diet, insulin resistance is
exacerbated by AMPK α2 KO (Fujii et al., 2008), however the loss of AMPK α2 in
skeletal muscle was not sufficient to accelerate insulin resistance alone (Beck Jorgensen
et al., 2009). Furthermore, whole body AMPK β 2 KO was sufficient to decrease basal
muscle AMPK activity, however β1 and α1 subunits were increased to compensate
(Steinberg et al., 2010). It is important to mention that whole body β1/2 loss was
sufficient to make AMPK activity non-detectable at rest and during exercise, therefore
identifying the importance of β1 and β2 subunits. Additionally, deletion of both β
subunits decreased α subunits resulting in disrupted muscle mitochondrial homeostasis
and an impaired response to exercise, without altering myosin heavy chain content
(O'Neill et al., 2011).
While several studies have investigated the role of whole-body AMPK loss
effects in muscle, several of these studies have limited interpretation to do the systemic
wide loss of AMPK, thus limiting our understanding of AMPK’s functional disruptions.
Despite this, several studies exhibit decreased functional outcomes either run to fatigue,
daily wheel distance, or cage activity in AMPK α2 heart and skeletal muscle KO mice
(Maarbjerg et al., 2009; Morissette et al., 2014; Zwetsloot et al., 2008). Furthermore,
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muscle-specific AMPK α2 loss was sufficient to decrease running capacity, without
disrupting fatty acid oxidation during endurance exercise (Miura et al., 2009).
Interestingly, muscle AMPK α2 KO decreased VEGF expression suggesting AMPK’s
role in adrenergic pathways, however muscle AMPK α2 KO did not inhibit the exercise
response thus suggesting that under basal conditions the blood flow to the muscle might
be regulated through AMPK (Zwetsloot et al., 2008). Furthermore, muscle-specific
AMPK β1/2 KO decreased muscle fiber size, reduced capillary density, and lowered
nitric oxide synthase (Thomas et al., 2014). Lastly, the γ3 subunit of AMPK is
predominately expressed in glycolytic fibers, suggesting AMPK’s differential role in
muscle types (Barnes et al., 2004). Studies utilizing γ3 KO show decreased glycogen and
PGC1α mRNA expression during fasting and exercise, suggesting a regulatory role of
AMPK gamma 3 in glycogen stores and utilization (Canto et al., 2010).
Cancer cachexia is a known chronic inducer of AMPK. Elevated skeletal muscle
AMPK has been reported in cancer patients and in several murine models of cancer
induced cachexia (Hall et al., 2018; Puppa, Gao, et al., 2014; Segatto et al., 2017; Talbert
et al., 2019; White et al., 2013). We have previously shown in Apc Min/+ mice that AMPK
activity and phosphorylation are induced with increasing cachexia severity (White,
Baynes, et al., 2011). We have previously shown that IL-6 receptor antibody in the
cachectic environment was sufficient to improve mitochondrial dynamics and biogenesis
highlighting the impact of IL-6 on driving muscle wasting (White et al., 2012).
Interestingly, IL-6 was sufficient to chronically induce AMPK in wildtype mice,
highlighting a role for inflammation in the chronic activation of AMPK in skeletal
muscle (White et al., 2013). Furthermore, in a C26 model of cancer cachexia, AMPK
agonist AICAR was able to impair tumor growth and prevent skeletal muscle mass loss
(Hall et al., 2018). While metformin, AMPK activator, did not alter tumor mass, it was
sufficient to prevent the induction of AMPK in skeletal muscle (Oliveira & GomesMarcondes, 2016). Recent work has highlighted SNARKs; an AMPK kinase, therapeutic
role in regulating muscle wasting with cancer cachexia (Alves et al., 2019), however
further work is needed to fully understand the implication of SNARK during cachexia
progression. However, chronic metformin use has recently been shown to induce muscle
mass loss (Kang et al., 2021), suggesting negative consequences on muscle mass with
long-term AMPK activation. Taken together, the role of AMPK is not yet clear and
recent articles highlight the importance of AMPK activation has preventative measure vs
therapeutic treatment. Lastly, there has been sufficient evidence to identify that AMPK is
elevated during cachexia and is associated to elevated inflammation, however there is
little evidence in determining the mechanism of AMPK loss during cancer cachexia.
Nutrition
Overall nutrition
An oncology patient’s quality of life is becoming an important topic to consider
due to increased survival from early detection and successful therapeutic treatments. The
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nutritional status of the cancer patient is an important consideration and nutritional
interventions should be initiated to prevent or offset malnutrition (van Bokhorst-de van
der Schueren, 2005). Furthermore, nutritional status can greatly impact skeletal muscle
homeostasis, especially since cancer patients (pre-cachexia) exhibit malnutrition.
Therefore, there have been several studies to determine if nutritional supplemental is
sufficient to prevent and treat cancer cachexia. Briefly, oral supplementation is often
administered if the patient is unable to meet the necessary nutritional requirements from
their normal food consumption (Ravasco et al., 2003) and has been suggested as an
additional method to prevent further weight loss in cachectic cancer patients (Fearon et
al., 2003). Eicosapentaenoic acid (EPA) supplementation has been implicated as a
potential therapeutic due to its anti-inflammatory properties, immune enhancing effect,
and attenuation of lipid-mobilizing factor (van Bokhorst-de van der Schueren, 2005),
however future work is needed to determine if EPA supplementation is a viable
therapeutic to offset wasting. Moreover, antioxidants have long been sought after to
offset chemotherapy toxicity to prevent wasting. While cachexia is termed irreversible
with nutritional support, we need to take a step back and have a better understanding if 1)
the patient is malnourished 2) the composition of the patient’s diet 3) the patient’s dietary
habits (are there periods of fasting) to fully understand the implications of nutritional
status on cancer cachexia progression.
The first sign of disrupted protein synthesis in cachectic cancer patients was
reported in 1984. Cachectic cancer patients showed reduced muscle protein synthesis
even in the fed condition, without changes in whole body protein synthesis (Emery et al.,
1984). While whole body protein turnover measurements in cachectic cancer patients
have been shown to be elevated at baseline, the whole body and muscle anabolic
response to feeding is suppressed in cachectic cancer patients (van Dijk et al., 2015). To
circumvent the issues with performing tracer studies in cachectic cancer patients, most
data related to muscle protein synthesis has been collected in rodent models of cancer
cachexia. Taken together, patient nutritional status should be accounted for given the
impact of nutrients on regulating skeletal muscle mass, and the next few sections will
highlight the regulation of feeding and fasting, and how cachexia might alter these
responses.
Feeding
Skeletal muscle’s capacity for protein synthesis and degradation is highly
sensitive to the local and systemic stimuli that are integrated intracellularly through
mTORC1 and AMPK signaling (Frost & Lang, 2007). Oscillations in protein synthesis
and breakdown occur throughout the day due to feeding, fasting, and activity (Breen &
Phillips, 2011). These oscillations in feeding and fasting behaviors arise from the
regulation by the central nervous system. Leptin and ghrelin are two opposing hormones
regulating energy balance (Klok et al., 2007). Leptin is produced and released from fat
cells in response to food intake, the increase in leptin elicits a reduction in appetite.
Alternatively, ghrelin is produced and released mainly from gastrointestinal mucosa
(Sakata & Sakai, 2010), but has been located in the pancreas, ovary, adrenal cortex, and
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the brain. The release of ghrelin promotes food intake. Furthermore, feeding elicits an
increase in circulating glucose to promote insulin release by the pancreas thereby
translocating GLUT4 to the muscle’s membrane to remove circulating glucose (Richter
& Hargreaves, 2013) and circulating insulin can also directly bind to IGF-1 resulting in a
confirmational change to induce downstream phosphorylation of IRS/AKT/mTORC1
(Boucher et al., 2014). Feeding can directly target mTORC1 by increasing the amino acid
pool to promote protein synthesis (Liu & Sabatini, 2020). Additionally, a common
suppressor of AMPK is nutrient stimulation through the consumption of glucose, a mixed
meal (feeding), or amino acids (Koh et al., 2008; Long & Zierath, 2006).
Feeding has been widely investigated as a regulator of mTORC1 and AMPK. The
consumption of glucose or a mixed meal will induce a glucose and insulin response
activating the IGF-1/AKT signaling cascade (Sengupta et al., 2010). AKT will then
phosphorylate TSC2 releasing its inhibition of mTORC1(Sengupta et al., 2010). AMPK
and mTORC1 negatively regulate one another, for example during energy demand
AMPK is activated thereby suppressing energy consuming pathways (mTORC1) and
stimulating energy generating pathways (ULK-1, FOXO3a) (Koh et al., 2008; Long &
Zierath, 2006; Sanchez et al., 2012). Muscle mTORC1 signaling is activated with both
exercise and feeding and will phosphorylate ULK-1 at Ser 757 and inhibit the ULK-1
activation of downstream autophagy signaling (Laker et al., 2017; Sanchez et al., 2012).
While the above-mentioned physiological changes to feeding and fasting occur
throughout the day in healthy populations, significant barriers still exist in our
understanding of how cachexia progression disrupts the feeding response.
While cancer patients demonstrate an increase in muscle protein synthesis after
protein ingestion, there is sufficient evidence to support that the responsiveness to protein
administration is strongly reduced during cancer cachexia (Deutz et al., 2011; Emery et
al., 1984). Interestingly, following tumor resection, the post-prandial anabolic response
was restored highlighting the impact of the tumor environment on the feeding response in
muscle (Williams et al., 2012). Thus, this anabolic resistance to feeding attenuates the
postprandial rise in muscle protein synthesis and most likely contributes to the loss of
muscle mass observed in cancer cachexia. In pre-clinical models, our laboratory has
demonstrated altered protein turnover occurs through suppressed anabolic signaling via
mTORC1 and coinciding with this suppression is the chronic activation of AMPK
(White, Baynes, et al., 2011). Recent work from our lab, has shown that mTORC1
signaling exhibits diurnal fluctuations in response to changes throughout the day in
feeding and activity (Counts et al., 2020). Interestingly, the cachectic environment
disrupts these diurnal fluctuations, and suggest a link between disruptions in feeding and
activity behaviors to the progression of cachexia and altered mTORC1 signaling (Counts
et al., 2020). Furthermore, a bolus of glucose was sufficient to improve muscle mTORC1
signaling and lower AMPK in cachectic skeletal muscle, albeit to a lower extent
compared to wildtype controls (White et al., 2013), thus providing evidence that
cachectic muscle has the capacity to respond to an anabolic stimulus. Following low dose
leucine supplementation in LLC mice’s diet, muscle mass loss was not preserved, but
leucine was able to prevent disrupted mitochondrial biogenesis signaling (Lee et al.,
2019). Interestingly, ghrelin administration in clinical trials has provided sparing of body
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weight loss (Ali et al., 2013), and might have therapeutic potential in patients
experiencing anorexia (Guillory et al., 2013). In a transgenic animal model, ghrelin
induction prevented fasting, and disuse induced atrophy (Porporato et al., 2013).
Additionally, when administered, ghrelin prevented body weight and muscle mass loss
during cancer cachexia progression in LLC mice, likely through increased food
consumption that resulted in improved proteins synthesis and lowered protein
degradation (Chen et al., 2015). Recent work has highlighted ghrelin’s impact on
preventing white adipose tissue inflammation, increased food intake, and preserving fat
mass in cachectic mice (Liu et al., 2020). However, it is currently unknown if ghrelin can
be used as a therapeutic to rescue or attenuate cancer induced cachexia but provides as a
promising therapy for anorexia associated cachexia. Taken together, skeletal muscle
regulation by cachexia in the presence of nutrients is complex and has yet to be fully
elucidated.
Fasting
Fasting is known to induce AMPK thereby activating E3 ligases, while
simultaneously suppressing IGF-1 signaling in vitro (Sandri et al., 2004). While several
studies have examined the regulation of fasting on metabolism and associated muscle
signaling, it is essential to understand that most pre-clinical studies using fasting use a
long-term fast (24-48hrs) (de Theije et al., 2018), not to be confused with starvation.
They are distinguishable because starvation studies typically encompass a 72hr fast or are
related to animal hibernation. Nevertheless, fasting in pre-clinical models elicits an
energy stress demand resulting in increased muscle AMPK signaling thereby inducing
autophagy and E3 ligase activity which coincides with mTORC1 suppression (Bujak et
al., 2015). Increased AMPK activity during fasting has the capacity to induce the ratio of
ATP/ADP resulting in glucose metabolism, autophagy and lipid oxidation in order to
replenish ATP stores (Herzig & Shaw, 2018). Interestingly, fasting has been implicated
in increasing AMPK mediated autophagy (Bagherniya et al., 2018; Dethlefsen et al.,
2018). While the E3 ligase activation of AMPK has been considered a negative regulator
of muscle mass, the autophagy response to fasting has been implicated as a method for
cellular renovation and homeostasis (Bagherniya et al., 2018). In addition, IL-6 has also
been implicated in response to fasting (Gudiksen et al., 2017). A brief fast was sufficient
to increased muscle IL-6 mRNA without altering AMPK or P38 phosphorylation
suggesting an early event in the fasting regulation of muscle protein turnover.
Furthermore, fasting induced circulating IL-6 corresponded with increased plasma free
fatty acids and reduced respiratory exchange ratio highlighting the fasting induction’s
role of lipolysis might be regulated by IL-6 (Wueest et al., 2014). Taken together, the
effect of fasting on skeletal muscle mass regulation has been largely attributed to AMPK
induced E3 ligase and autophagy signaling; however, less is understood about the role of
cancer cachexia during fasting.
While repeated fasting; resulting in reduced caloric intake has been proposed to
have beneficial effects in aging populations (Stekovic et al., 2019) and some cancers
(Nencioni et al., 2018), less is understood about an acute fasting’s role in the regulation
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of protein turnover in cachectic muscle. Our understanding of the skeletal muscle’s
signature in the cancer environment is examined following a short term fast. While this is
beneficial in understanding the basal condition of muscle in the cachectic environment,
some studies report a reduction of 20% in food intake at the end of life in cachectic
animals therefore these studies are now investigating an anorexia model (Samuels et al.,
2001) further confounding the data. Therefore, greater clarity within the literature is
needed along with improved animal techniques. To date, our lab and others have
demonstrated that the cachectic environment elevates skeletal muscle AMPK following a
5 hour fast, showing that a very short period of fasting is capable of inducing AMPK in
the cancer environment and suggestive of metabolic dysregulation (Frost & Lang, 2007).
Concomitant with the induction of AMPK, our laboratory has demonstrated mTORC1
suppression during cancer cachexia, signifying a role for AMPK in the suppression of
anabolic signaling (Hardee, Fix, et al., 2018; Hardee et al., 2016; White et al., 2013).
However, significant barriers still exist in our understanding of cachectic skeletal
muscle’s protein turnover response by fasting.
Skeletal Muscle Contraction
One of skeletal muscle’s main function is to elicit muscle contractions to generate
force and movement for locomotion, breathing, and swallowing to survive. Skeletal
muscle consists of multinucleated muscle fibers further dividing into myofibrils. Ttubules form deep invaginations within myofibrils that surround the muscles membrane.
Myofibrils contain contractile proteins, thick and thin filaments (Squire, 2019). Thick
filaments are large protein myosin and thin filaments are composed of actin,
tropomyosin, and troponin (Ohtsuki & Morimoto, 2008). To elicit a contraction, an action
potential travels to the motoneuron thereby depolarizing and resulting in the voltagegated calcium channels to open. The influx of calcium releases acetylcholine at the
neuromuscular junction where acetylcholine will bind to the nicotinic receptors thereby
eliciting an action potential in the muscle fiber. This action potential reaches the muscle
cell membrane where the action potential is spread down the t-tubule to reach the interior
of the muscle fiber. The t-tubule receptors will undergo a confirmational change that
interacts the ryanodine receptors thereby opening and allowing calcium to be released
from the sarcoplasmic reticulum. Calcium will attach to troponin thereby displacing
tropomyosin from the myosin-binding site (Ohtsuki & Morimoto, 2008) thus allowing for
the cross-bridge cycle. ATP binds to the myosin head eliciting a confirmational change in
myosin thus decreasing its affinity for actin, thereby disassociating from actin allowing
myosin to become cocked toward the sarcomere. ATP bound to myosin becomes
hydrolyzed to ADP and Pi. While myosin is still in the cocked position, it will bind to a
new site on actin creating a power stroke that pulls the actin filaments. ADP and Pi are
released, and myosin returns to original state where it is bound to ATP (Fitts, 2008). The
cross-bridge cycles are a series of events pulling thin filaments toward the center of the
sarcomere each the action potential arrives at the neuromuscular junction. While the
biochemistry of muscle contraction is well known, less is understood how the cachectic
environment effects contractile properties and the exercise response. The next few
sections will highlight what is known about skeletal muscle contractile properties in the

25

cachectic environment and what current mechanisms explain exercise interventions as a
potential therapeutic to offset wasting.
Cancer cachectic exhibits reduced volitional activity, whole body weakness, and
fatigue in cancer patients and in pre-clinical models (Baltgalvis et al., 2010; Murphy et
al., 2012; Toth et al., 2016). Furthermore, contractile decrements have also been reported
(Christensen et al., 2014; Roberts, Frye, et al., 2013), and is highly important given that
force production and fatigue are directly related to life quality in disease (al-Majid &
McCarthy, 2001; Barreiro & Gea, 2015; Siegel, 1989). We and others have recently
shown that cachectic skeletal muscle develops a slow-fatigable contractile phenotype
during cancer cachexia progression (Murphy et al., 2012; Roberts, Frye, et al., 2013;
VanderVeen et al., 2018). Furthermore, the regulation of muscle’s contractile properties
was strongly related to the muscle’s inflammatory signaling highlighting the regulation of
muscle contraction by inflammation during disease (VanderVeen et al., 2019).
Interestingly, cachectic muscle exhibits increased SERCA1 and calsequesterin mRNA in
cachectic skeletal muscle (VanderVeen et al., 2018), further supporting the transition to a
more faster muscle phenotype (Khodabukus & Baar, 2015). While fatigue and weakness
are the most commonly reported consequences in cancer patients, we have only scratched
the surface on trying to understand how this may occur (Chang et al., 2000).
Interestingly, recent work has highlighted exercise’s therapeutic role in improving muscle
fatigability in patients and pre-clinical models (Kessels et al., 2018; Vanderveen et al.,
2020). However, the mechanisms of how exercise can be a therapeutic have to yet to be
fully understood.
Exercise has been hypothesized to be potential therapeutic option for cancer
induced cachexia (Hardee et al., 2019). Voluntary wheel and treadmill running are the
predominant methods of exercise used within the literature to offset cancer induced
cachexia in pre-clinical models. Several indices of cachexia progression are attenuated in
rodents given access to a running wheel by attenuating muscle mass loss and improving
myofiber cross-sectional area (Coletti et al., 2016; Pigna et al., 2016). These studies
highlight the improved ex vivo force production and reduced inflammatory environment
likely attributing to the prevention of cachexia. In addition, treadmill training has also
been shown to offset indices of cancer induced cachexia. Treadmill training was
sufficient to decrease total polyp number (Mehl et al., 2005), likely through reducing
immune infiltration, apoptosis, and beta-catenin signaling (Baltgalvis et al., 2010).
Furthermore, exercise training prior to and during IL-6 overexpression prevented muscle
mass loss, improved systemic glucose, and restored mTORC1 signaling (Lombardi et al.,
2012; White et al., 2013). Interestingly, high intensity treadmill training improved
survival rate and prevented muscle mass loss during cachexia progression (Jee et al.,
2016) and recent work has supported that a potential exercise threshold might be required
to reduce cachexia associated fatigue (Vanderveen et al., 2020). Alternatively, treadmill
training was not sufficient to prevent muscle mass loss but was able to improve strength
and muscle oxidative capacity (Pin et al., 2018). While there are discrepancies within the
literature, it can be possibly attributed to the exercise modality, intensity, and basal
capacity of the mouse given that cancer in tumor-bearing mice exhibit reduce volitional
activity. However, there is sufficient evidence to suggest that exercise training prior to
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and during cancer progression can attenuate muscle mass and strength loss, which may be
related to improved oxidative metabolism.
After an acute bout of exercise PGC-1α is rapidly up-regulated leading to a
subsequent increase in mitochondrial associated gene transcription and mitochondrial
biogenesis (Baar et al., 2002; Pilegaard et al., 2003). Up-regulation of these genes persists
for up to 4 hours before returning to baseline levels. Since the effects are short lived it
shows the importance of regular physical activity to increase mitochondrial capacity. As
well as increases in mitochondrial capacity, insulin sensitivity is increased immediately
following an acute bout of exercise, in part due to the up regulation of genes regulating
glycolysis and fatty acid oxidation and overall improvements of metabolic flexibility
(Koves et al., 2013). For example, an acute bout of exercise insulin sensitivity is
increased for at least 16 hours and lasting up to 48 hours (Bird & Hawley, 2016).
Furthermore, an acute bout of exercise is known to elicit a myokine “storm” known to aid
in the beneficial effects of exercise and physical activity (Ost et al., 2016). Recent work
has highlighted the potential therapeutic effect of myokines on cancer cachexia
progression (Daou, 2020; Re Cecconi et al., 2019), however this has yet to be fully
understood. Furthermore, an acute bout of exercise and exercise training are known
regulators of muscle mitochondrial quality control (Yan et al., 2012). An acute bout of
exercise (eccentric contractions) immediately induced AMPK and mTORC1 signaling in
the cachectic environment (Hardee, Counts, et al., 2018). Interestingly, 3hrs post
contraction AMPK began to decrease while mTORC1 signaling remained elevated.
Additionally, eccentric contraction training induced mitochondrial biogenesis and
oxidative capacity further supporting the acute induction of AMPK on mitochondrial
regulation. Although there is little research on the acute effects of exercise on
mitochondrial dynamics during cancer cachexia, it can be hypothesized that exercise
training would restore the altered expression of mitochondrial fusion proteins and
decrease mitochondrial fission proteins.
Exercise training (repeated exercise bouts) is a known inducer of anabolic
signaling through mTORC1 (Burd et al., 2009) and reduces chronic inflammation
(Beavers et al., 2010). Furthermore, skeletal muscle contractions are sufficient to induce
glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and protein synthesis
(Egan & Zierath, 2013). The accumulation of lipids in the body can inhibit insulin
sensitivity thus providing another benefit of regular exercise. Exercise training has a large
impact on mitochondrial capacity in skeletal muscle. One of the main changes in skeletal
muscle with exercise training is the increase in mitochondrial content and capacity
(Holloszy & Coyle, 1984). Repeated bouts of exercise show sustained increases in
several mitochondrial proteins such as PGC-1α, mitochondrial transcription factor A
(Tfam), and nuclear respiratory factors (NRF), thus allowing for mitochondrial
biogenesis and increased mitochondrial function (Baar et al., 2002; Garnier et al., 2005;
Hood et al., 2006). Furthermore, exercise is known to improve insulin sensitivity, and is
often used to treat insulin resistance (Hawley, 2004). These improvements in insulin
sensitivity are most likely derived from increases in skeletal muscle glucose transporter
type 4; as GLUT4 can be stimulated both by insulin and by contraction. While muscle
GLUT4 expression is unchanged in insulin resistant individual, these individual’s show
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suppressed insulin signaling when stimulated (Handberg et al., 1990). The acute effects
of exercise on glucose uptake occur in an insulin independent manner and rely mainly on
the contraction stimulated increase in GLUT4 translocation (Brozinick et al., 1992). PI3K
has been shown to be decreased in insulin resistant individuals (Luo et al., 2006) and is
one reason for the decrease in insulin stimulated translocation of GLUT4 with insulin
resistance. Exercise increases PI3K signaling potentially through increases in the insulin
receptor substrate; however, the evidence is variable (Hawley & Lessard, 2008).
Skeletal muscle mitochondrial function plays a pivotal role in muscle glucose
uptake, and impairments in the oxidative capacity have been associated with insulin
resistance (Lanza & Nair, 2009). Alterations to mitochondrial content reduce the ability
of muscle to efficiently oxidize fats, leading to disrupted metabolic flexibility
(Goodpaster & Sparks, 2017). The loss of muscle oxidative capacity during cancer
cachexia corresponded with insulin resistance, despite this exercise training in the
cachectic environment was sufficient to improve mitochondrial oxidative capacity
(Lombardi et al., 2012). Exercise training allows for the ability to maintain mitochondria
and ability to respond to stimulus that have capacity to impair metabolic flexibility.
AMPK is a critical regulator for the exercise response in skeletal muscle. Exercise
training increases protein levels of AMPK, but despite this exercise training induced an
increase in muscle protein synthesis even in the cachectic environment. Exercise is also
able to attenuate the chronic activation of AMPK that is seen with severe muscle wasting
(Lombardi et al., 2012). The improvements in the regulation of AMPK activity may be
due to the improvements in glucose uptake which could alleviate the energy stress that is
placed on the muscle due to the cancer environment and metabolic inflexibility. More
research needs to be done to examine the effects of exercise on muscle after the initiation
of cachexia and if exercise can rescue mitochondrial dynamics and function. However,
this has yet to be elucidated since most exercise interventions are used as a prevention.
To account for the baseline variability in treadmill and wheel exercise, electrical
stimulation is another exercise modality used to elicit skeletal muscle contractions.
Skeletal muscle’s metabolic and growth response to contraction has been examined using
electrical muscle stimulation (Baar & Esser, 1999; Nader & Esser, 2001; Puppa, Murphy,
et al., 2014; Witkowski et al., 2010). In pre-clinical models, electrical stimulation is
performed in an unconscious animal, which electrodes are used to stimulate a nerve at
specific frequency. High-frequency electrical muscle stimulation (HFES) has examined
muscle signaling associated with hypertrophy (Baar & Esser, 1999; Hardee et al., 2016;
Sato et al., 2019). In contrast, low-frequency electrical muscle stimulation (LFES) has
been used to examine the acute and training adaptations to endurance like muscle
contractions (Nader & Esser, 2001; Puppa, Murphy, et al., 2014). Increased physical
activity and repeated contractions impact skeletal muscle differently, for example high
frequency stimulation (100Hz, 20 minutes) is a potent inducer of p70S6K 3hrs and 6hrs
post in the TA, however no changes were observed in the soleus (Nader & Esser, 2001).
An acute exercise bout of low or high frequency stimulation has capacity to induce
p70S6K, however HFES elicited a greater increased in p70S6K immediately post and 3
hour post stimulation compared to LFES (Tsutaki et al., 2013). Furthermore, p70S6Kwas
induced 3hrs post LFES (10Hz, 30 minutes), while an acute bout of running did not alter
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p70S6K in the soleus or TA thus concluding differentiational regulation of mTORC1 by
exercise and muscle type. In human populations, a single bout of LFES improved glucose
uptake (Hamada et al., 2003) and 4weeks of LFES induced markers of glucose
metabolism and oxidative capacity (Theriault et al., 1994). Furthermore, 4wks of LFES
improved fatigue resistance following spinal cord injury (Harridge et al., 2002). Taken
together, LFES has therapeutic potential in understanding the molecular mechanisms of
exercise in chronic disease.
Recent work has established a role for electrical stimulation to promote muscle
hypertrophy and fiber type shifts in breast cancer patients, highlighting the clinical
impactful role of electrical stimulation on muscle homeostasis in disease (Toth et al.,
2020). Electrical stimulation has great therapeutic potential given the lack of volitional
effort required and ability to provide a similar stimulus to non-tumor and tumor-bearing
animals. We have shown that 2 wks. of eccentric contraction were sufficient to increase
muscle mass in the cachectic environment, highlighting the ability of cachectic muscle to
respond (Hardee et al., 2016). We have recently shown that repeated eccentric
contractions are sufficient to induce anabolic signaling in the cachectic environment,
coinciding with suppressed inflammatory signaling (Hardee et al., 2020). While eccentric
contractions show promising results in preclinical models, the supraphysiological nature
of eccentric contractions is not replicable of daily features. To this end, we completed an
acute bout of low frequency stimulation in pre-clinical models of cancer induced
cachexia. Interestingly, an acute bout of low frequency stimulation was capable of
inducing rpS6, cytochrome C, and PGC1-alpha in wild-type mice, however this was
blocked in the cachectic mouse (Puppa, Murphy, et al., 2014). Taken together, repeated
contractions were sufficient to improve oxidative capacity, implementing improved
mitochondrial function, and highlights that cachectic muscle has the plasticity to respond
to contraction stimulus. However, we have only began to understand the therapeutic
potential of repeated muscle contractions on muscle oxidative capacity and significant
barriers still exist in our understanding of repeated muscle contraction’s effect on protein
turnover in the cachectic environment. Furthermore, low frequency stimulation has been
used for decades to understand the mechanical signaling of skeletal muscle (Scott et al.,
1985) and is a plausible therapeutic option to combat disease. However, the effect of
repeated low frequency stimulation on skeletal muscle homeostasis during cancer
cachexia is unexplored.
Conclusion
Taken together, the current body of literature displays many gaps in
understanding the regulation of skeletal muscle protein turnover during cancer cachexia
progression by fasting and feeding and the direct role of muscle gp130 and AMPK.
While we understand that cancer-induced cachexia disrupts skeletal muscle protein
synthesis in the basal condition, we do not fully understand the regulation of feeding
during cancer cachexia progression. A wide body of literature shows that inflammation is
a key mediator of cancer-induced cachexia leading to disrupted mitochondrial dynamics,
thereby activating AMPK. However, is it currently unknown if gp130’s regulation of
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AMPK is linked to disrupted protein synthesis by feeding. Lastly, exercise interventions
have shown promise in preventing cancer induced cachexia and is sufficient to improve
mitochondrial function, induce anabolic signaling, and suppress inflammatory signaling.
However, significant barriers still exist in our understanding if cachectic muscle has the
capacity to respond to an acute bout of low frequency stimulation and feeding, and if it
can improve muscle metabolic function and rescue the protein synthesis fasting. The
current proposal aimed to understand if aberrant gp130 and AMPK signaling could alter
the feeding and fasting regulation of muscle protein synthesis during cancer cachexia
progression, and if muscle contraction could regulate this response.
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CHAPTER 3. EXAMINATION OF WHETHER SKELETAL MUSCLE AMPK
REGULATION BY FEEDING DISRUPTED EARLY IN CANCER CACHEXIA
PROGRESSION IS RELATED TO EARLY DISRUPTIONS IN SYSTEMIC
METABOLISM
Introduction
Cancer-induced cachexia is defined as the unintentional loss of muscle mass with
or without fat loss and is irreversible with nutritional support alone (Evans et al., 2008;
Myers et al., 2019). Lung cancer is the second most common cancer type in the United
States (Siegel et al., 2021), with 50% of lung cancer patients developing cachexia (Jafri et
al., 2015). The Lewis lung carcinoma (LLC) model is a widely used implantable
syngeneic model to evaluate lung cancer progression (Kellar et al., 2015). Skeletal
muscle mass maintenance during cachexia’s progression has been linked to improved
survival and quality of life (Bye et al., 2017). Cancer-induced disruption of muscle
protein turnover is a negative consequence of the disease and a well-established driver of
cachexia (White, Baynes, et al., 2011). There are currently no approved treatments to
prevent or attenuate cachexia’s progression, which is likely due to the complexity
brought on by tumor heterogeneity and the cancer-induced systemic environment
(Anderson et al., 2017). Accounting for skeletal muscle sensitivity to feeding could
underlie some of these inconsistencies (Harfmann et al., 2015). Studies examining
skeletal muscle protein synthesis during cancer cachexia have often either not controlled
for feeding or examined after a brief fast. While we have made advances in
understanding mechanisms of muscle wasting, we still lack sufficient information on how
the progression of cachexia impacts the muscle’s response to feeding as this has
significant implications in understanding the potential therapeutic response.
Skeletal muscle’s capacity for protein synthesis and degradation is highly
sensitive to local and systemic stimuli that are integrated intracellularly through
mTORC1 and AMPK signaling (Frost & Lang, 2007). Oscillations in protein synthesis
and breakdown occur throughout the day in response to feeding and fasting (Breen &
Phillips, 2011). Cancer-induced cachexia disrupts skeletal muscle protein turnover in the
basal condition (decreasing protein synthesis and increasing protein degradation). In preclinical models, our laboratory has demonstrated altered protein turnover through the
suppression of anabolic signaling via mTORC1 which coincided with chronic activation
of AMPK (White, Baynes, et al., 2011). Interestingly, mTORC1 signaling exhibits
diurnal fluctuations in response to changes throughout the day in feeding and activity
(Counts et al., 2020). Furthermore, the cachectic environment disrupts these diurnal
fluctuations, and suggest a link between disruptions in feeding and activity behaviors to
the progression of cachexia and altered mTORC1 signaling (Counts et al., 2020). Feeding
elicits an increase in circulating glucose to promote insulin release by the pancreas
thereby translocating GLUT4 to the muscle’s membrane to remove circulating glucose
(Richter & Hargreaves, 2013) and circulating insulin can also directly bind to IGF-1
resulting in a confirmational change to induce downstream phosphorylation of
IRS/AKT/mTORC1 (Boucher et al., 2014). Feeding can directly target mTORC1 by
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increasing amino acid pool to promote protein synthesis (Liu & Sabatini, 2020).
Alternatively, fasting in pre-clinical models (24-48hrs) elicits an energy stress demand
resulting in increased muscle AMPK signaling (Bujak et al., 2015). These findings have
significant implications because more evidence is identifying a potential therapeutic
window based on the time of day (Zhao et al., 2020) and nutritional state of the patient
(Lammers et al., 2020). However, significant barriers still exist in our understanding of
feeding’s regulation of skeletal muscle protein synthesis during cancer cachexia.
AMPK is a regulatory point of interaction due to its numerous effects on muscle
protein turnover by lowering ATP consumption of anabolic pathways and increasing
catabolic pathways to produce ATP. AMPK is activated by energy stress when ATP
bound to AMPK subunit is displaced with AMP. Throughout the day in healthy tissue,
ATP:ADP ratios are in constant flux and exhibit a circadian rhythm with AMPK lowered
after the dark cycle (Um et al., 2011). To disrupt these ratios, either there is an
interference of ATP production or increased ATP consumption (Hardie, 2003). During
periods of fasting, blood glucose levels begin to fall which interferes with ATP
production, therefore, an increase of glucose results from activating glycogen use.
Furthermore, during longer periods of fasting (starvation models >16hrs) after glycogen
stores have been depleted, metabolism of triglycerides are used through beta oxidation
and ketogenesis to produce ATP (Herzig & Shaw, 2018). While these physiological
changes to feeding and fasting occur throughout the day in healthy populations,
significant barriers still exist in our understanding of how cachexia progression regulates
AMPK signaling by feeding.
It is without question, that AMPK activity and associated signaling is necessary
for maintaining metabolic flexibility and proper cell function (Fuchsberger et al., 2016;
Jeon, 2016; Kjobsted et al., 2018; Steinberg & Jorgensen, 2007). Additionally, it is
necessary to highlight the adverse effects of AMPK loss in cardiac and skeletal muscle
(Kjobsted et al., 2018; Viollet et al., 2009), which decreased functional outcomes in run
time to fatigue, daily wheel distance, and cage activity (Maarbjerg et al., 2009; Morissette
et al., 2014; Zwetsloot et al., 2008). AMPK α2 muscle-specific knockout (Miura et al.,
2009) and AMPK α2 kinase dead in skeletal muscle (Moller et al., 2016) decreased
running capacity, AMPK β1/β2 muscle loss decreased muscle fiber size and capillary
density (Thomas et al., 2014), and AMPK γ3 loss decreased glycogen content (Canto et
al., 2010). These studies highlight the importance of AMPK in skeletal muscle under
normal physiological conditions. Under conditions of chronic disease, the effect of
AMPK loss is less understood which is partially due to the desire to increase AMPK
activity acutely either pharmacologically or by an acute bout of exercise (Jeon, 2016).
However, it is important to consider disease conditions such as cancer cachexia which
exhibit chronically elevated AMPK signaling (Fix et al., 2021; White et al., 2013), which
is different than the acute activation elicited by drugs or exercise. It is ill-advised to
suggest the therapeutic potential to knockout AMPK to treat cachexia, however the loss
of AMPK in skeletal muscle alone allows us to determine the importance of AMPK
signaling in response to an acute stress (12hr fast) and an anabolic stimulus in hopes to
understand AMPK’s regulation. Additionally, it is necessary to mention there are limited
number of studies that examined the effect of whole-body AMPK activation throughout
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cachexia progression. Briefly, AMPK activators, such as AICAR and Metformin
administered before cachexia initiation, have been examined with some preclinical
models of cancer cachexia. AICAR administration prevented muscle mass loss in tumorbearing mice (Hall et al., 2018; Pigna et al., 2016) and lower E3 ligase gene expression
and autophagy indices (Pigna et al., 2016), however AICAR inhibited tumor growth as
well. Metformin can also prevent indices of cachexia (Hall et al., 2018; Oliveira &
Gomes-Marcondes, 2016). Despite these facts, there is a limited understanding of
AMPK’s regulation in differential nutrient conditions in skeletal muscle during cancer
cachexia progression.
Taken together, cachexia suppresses muscle protein synthesis which coincided
with an increase in muscle AMPK signaling in the basal condition. Therefore, we
extended previous studies by examining if tumor-bearing mice have the capacity for
feeding to increase muscle protein synthesis, and if the fasting suppression of protein
synthesis is regulated by AMPK in tumor-bearing mice. Therefore, the purpose of this
study was to determine if skeletal muscle AMPK regulation by feeding is disrupted early
in cancer cachexia progression and is related to early disruptions in systemic metabolism.
We hypothesized that feeding could reduce AMPK signaling and cancer cachexia
progression would inhibit this response. We also hypothesized that disrupted AMPK
signaling would be associated to early disruptions in systemic metabolism.
Methods
Effect of feeding in tumor-bearing mice
Male C57BL/6J (B6; N=42) mice were bred at the University of Tennessee
Health Science Center Animal Resource Facility. B6 mice were initially purchased from
Jackson Labs (Bar Harbor, ME, USA). Mice were kept on a 12:12h light/dark cycle
beginning at 6:00AM and were given rodent chow ad libitum (Harlan Teklad Rodent
Diet, #8604, Harlan, Indianapolis, IN, USA). All mice were fasted for 12hrs during the
dark cycle. At the start of the light cycle, mice were either given ad libitum access to a
food pellet (fed) or sacrificed at the end of fast (fast).
Lewis lung carcinoma cell inoculation
Between 11-12 weeks of age, B6 mice were injected with either phosphate
buffered saline (PBS) or 1 x 106 Lewis lung carcinoma (LLC) cells (ATCC CRL-1642)
subcutaneously in the right flank under anesthesia for less than 3 minutes (Puppa, Gao, et
al., 2014). A total of 26 mice were injected with LLC cells and 16 mice were injected
with PBS. Ninety-two percent of the LLC injected mice reached the studies endpoint. A
mouse reached the studies endpoint if the following criteria were met (1) mouse reached
30 days post tumor inoculation, (2) >20% body weight loss from day 10 after day 25, or
(3) had a tumor >3cm in width or length after day 25, or (4) the tumor was close to
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breaking through the skin (ulcerated) after day 25. Once an endpoint was achieved, the
mouse was prepared for tissue collection and euthanized within 24 hrs. At day 21, 1
mouse had an ulcerated tumor and was not included in the analysis and 1 mouse died
unexpectedly at day 24. To be included in the study, mice needed to achieve at least 25
days post tumor inoculation. Therefore, a total of 24 male LLC injected mice were used
in these experiments. Tumor volume and body weight were measured every 5 days to
calculate tumor growth. Tumor volume was calculated by the same investigator and
caliper using the following equation: ½ (width2xlength) (Jensen et al., 2008).
Muscle-specific AMPK loss in tumor-bearing mice
To examine the regulation of AMPK loss in tumor-bearing mice, AMPKa1a2
knockout mice and floxed controls were generated (see next section for details). Mice
were kept on a 12:12h light/dark cycle beginning at 6:00AM and were given rodent chow
ad libitum (Harlan Teklad Rodent Diet, #8604, Harlan, Indianapolis, IN, USA). Between
17-18wks of age, male AMPKa1a2 knockout or floxed controls either injected with PBS
or LLC cells were sacrificed. All mice were fasted for 12hrs during the dark cycle. At the
start of the light cycle, mice were either given ad libitum access to a food pellet (fed) or
sacrificed at the end of fast (fast).
Generation of AMPKa1a2 skeletal muscle deletion
To generate a skeletal muscle-specific knockout of AMPKa1a2, mice that
contained individually floxed alleles for AMPKa1and AMPKa2 were a kind gift from Dr.
Hoh-Jin Koh at the University of South Carolina. Utilizing the skeletal actin (HSA)
promoter-driven expression of a Cre recombinase flanked by mutated estrogen receptors
(HSA- MCM) (McCarthy et al., 2012). Tamoxifen inducible Mer Cre Mer driven by a
human skeletal actin promoter (HSA) mouse were purchased from Jackson Laboratories
(Bar Harbor, ME, USA). Male tamoxifen-inducible skeletal muscle AMPKα1α 2 (KO)
knockout mice and floxed (Flox) controls were produced. This genetic approach provides
viable, healthy mice and has been successfully used by others to study muscle-specific
inducible loss of AMPK in skeletal muscle (Hingst et al., 2020; Lantier et al., 2020). At
approximately 10-11 weeks of age, all AMPK KO and floxed control mice received
tamoxifen injection (I.P. 2mg) daily for 5 consecutive days (Harfmann et al., 2016), and
then underwent a 2-week washout period before PBS or LLC injections. Finally, the
AMPKα1α2 HSA Cre (AMPK KO) mice or AMPKα1α2 (floxed control) mice were
injected with PBS or LLC, following a similar study design as experiment 1.
Lewis lung carcinoma cell inoculation in muscle-specific AMPK mice
Between 13-14 weeks of age, AMPK mice were injected with either phosphate
buffered saline (PBS) or 1 x 106 Lewis lung carcinoma (LLC) cells subcutaneously in the
right flank under anesthesia for less than 3 minutes (Puppa, Gao, et al., 2014). A total of

34

38 mice were injected with LLC cells and 32 mice were injected with PBS. Ninety-two
percent of the LLC injected mice reached the studies endpoint. A mouse reached the
studies endpoint if the following criteria were met (1) mouse reached 30 days post tumor
inoculation, (2) >20% body weight loss from day 10 after day 25, or (3) had a tumor
>3cm in width or length after day 25. Once an endpoint was achieved, the mouse was
prepared for tissue collection and euthanized within 24 hrs. At day 22-23, 3 mice had
ulcerated tumors and was not included in the analysis. To be included in the study, mice
needed to achieve at least 25 days post tumor inoculation. Therefore, a total of 35 male
LLC injected mice were used in these experiments. Tumor volume and body weight were
measured every 5 days to calculate tumor growth. Tumor volume was calculated by the
same investigator and caliper using the following equation: ½ (width2xlength) (Jensen et
al., 2008).
Tissue collection
Mice were anesthetized and ~500 ul of retro-orbital blood was collected.
Following eye bleeds, under anesthesia mice underwent cervical dislocation and muscles
were immediately excised within 4 minutes. A second method of euthanasia was heart
removal, then organs were collected. Hindlimb muscles and organs (eWAT, liver,
stomach, heart, kidney, and spleen) were rapidly excised, cleared for excessive
connective tissue, weighed, and snap frozen in liquid nitrogen.
Plasma interleukin-6
Immediately prior to sacrifice, blood was collected via retro-orbital sinus with
heparinized capillary tubes, placed on ice, and centrifuged (10,000 x g for 10 min at 4°C).
The supernatant was removed, and plasma IL-6 concentrations were determined using an
enzyme-linked immunosorbent assay kit according to the manufacturer’s instructions
(Catalog #KMC0061, ThermoFisher Scientific, Waltham, MA).
Blood glucose and plasma insulin
Immediately prior to ad libitum access to a food pellet, mice had their tail
snipped. The initial blood was wiped with a Kim wipe and blood glucose was determined
using a standard and readily available glucometer (Contour Next, Parsippany, NJ). Blood
was collected with a heparinized capillary tube, placed on ice, and centrifuged (10,000 x
g for 10 min at 4°C). The supernatant was removed, and plasma insulin concentrations
were determined using a two-site enzyme immunoassay assay kit according to the
manufacturer’s instructions (Catalog #10-1247, Mercodia, Uppsala, Sweden). Blood
glucose and plasma insulin measurements were taken again 1-hr after access to the food
pellet but prior to anesthesia at sacrifice.
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Protein synthesis measurement
The Surface Sensing of Translation (SUnSET) technique was used to determine
estimated muscle protein synthesis rates, as previously described (Goodman et al., 2011)
(Hardee, Counts, et al., 2018). Briefly, puromycin (EMD Millipore, catalog no.
MABE343) was dissolved in sterile saline and delivered by intraperitoneal injection (0.04
µmol/g body wt.) 30 min before euthanasia. Puromycin incorporation into newly
synthesized peptides, reflecting estimated global protein synthesis rates, and was
analyzed by Western blot.
Western blot
Western blot analysis was performed as previously described (Hardee et al., 2014)
and extensive methodology can be found in extended methods section. Briefly, frozen red
and white gastrocnemius muscle was homogenized in lysis buffer and protein
concentration was determined by the Bradford method. Crude gastrocnemius muscle
homogenates were fractionated on 8-12% SDS-polyacrylamide gels and transferred to
PVDF membranes. Membranes were stained with Ponceau red to verify equal loading
and transfer. Membranes were then blocked at room temperature for 1hr. in 5% non-fat
milk or 5% BSA-Tris-buffered saline with 0.1% Tween-20 (TBST). Commercially
available phosphorylated and total protein primary antibodies for rpS6, AKT, AMPK,
ACC, FOXO3a, ULK1, and DRP1 were raised in rabbit. RpS6, AKT, AMPK, ACC,
FOXO3a, ULK1, and DRP1 phosphorylation antibodies were expressed relative to total
protein on the same gel and quantified as phosphorylation to total ratio. Commercially
available total protein primary antibodies for MuRF-1, Atrogin-1, PGC1α, OPA1, and
FIS1 were raised in rabbit. Puromycin incorporation was purchased from Millipore and
raised in mouse. Briefly, primary antibodies were incubated overnight in 5% TBST milk
or 5% TBST BSA. Membranes were then incubated in 5% milk-TBST containing antirabbit or anti-mouse IgG horseradish-peroxidase conjugated secondary antibody
purchased from cell signaling for 1h at room temperature. Enhanced chemiluminescence
(ECL) (GE Healthcare Life Sciences, Piscataway, NJ) was used to visualize the antibodyantigen interactions. Immunoblot images were collected using a digital imager
(Invitrogen iBright, Waltham, MA) and quantified by densitometry using imaging
software (Image J; NIH). Please see end of document for details of fcatalogue numbers,
companies, dilutions, incubation durations, and secondary substrate (Figure A-1).
Body composition and indirect calorimetry
Fifteen days post tumor inoculation, a subset of mice (PBS n=5, LLC n=6) were
individually housed and placed in the Comprehensive Laboratory Animal Monitoring
System (CLAMs) cages for 5-consecutive days (Stephenson et al., 2016). To allow for
acclimatization, the first 24hrs were removed from the analysis and the average of days 2,
3, and 4 were used for analysis. Mice were removed from the cages on day 5. Data are
presented as daily average, and the average of each light and dark cycle. In mice, light
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cycle refers to the time when mice are resting (rest phase) and consuming little to no
food. While the dark cycle, refers to the active phase when they consume most of their
daily food consumption (Counts et al., 2020; Jensen et al., 2013). Prior to individual
housing, mice were weighed between 7:00-9:00 AM and body composition was
determined in conscious mice by magnetic resonance (EchoMRI 1100, EchoMRI,
Houston, TX). Using the CLAMs system (Columbus Instruments, Columbus, OH)
physical activity, oxygen consumption (VO2), carbon dioxide production (VCO2), and
respiratory exchange ratio (RER; VCO2/VO2) were determined. Physical activity was
quantified as the 3-day average of the hourly sum of XY beam breaks. The temperature
was maintained at 22°C throughout the experiment. The Lusk equation in Oxymax
software (Columbus Instruments, Columbus, OH) was used to determine energy
expenditure. Carbohydrate and lipid oxidation were based on published equations that
assume negligible protein oxidation (Peronnet & Massicotte, 1991). Before use in the
equation, VO2 and VCO2 were converted from ml/kg lean mass/hr to ml/min. Equations
are as follows: carbohydrate oxidation (g/min): (4.585*VCO2) -(3.226*VO2) and lipid
oxidation (g/min) (1.695*VO2) -(1.701*VCO2), and negative values indicate unusable
time points which were removed from the analysis.
Glucose tolerance test
After a 6hr fast, mice received a single glucose bolus (2 g/kg lean mass) via
intraperitoneal injection, and blood glucose concentrations were monitored at 15 or 30min intervals throughout the subsequent 120 min. Aliquots of blood were collected at pre,
15-, 30-, 60-, and 120-min post injection.
Statistical analysis
Pre-planned unpaired T-Test were used to compare PBS and LLC mice. Preplanned unpaired T-Test were used to compare the feeding response and knockout
signaling in PBS and LLC mice. Two-way ANOVA’s (Tumor x Feeding) were used and
Tukey’s post-hoc analysis was used when appropriate. Pearson spearman correlations
were used to associate AMPK signaling and signaling with cachexia progression,
systemic metabolism, and physical activity. Prism 8 (GraphPad) was used for statistical
analysis. All results are reported as means ± standard error of mean (SEM). Statistical
analyses were performed using GraphPad (Prism 8 for Mac OS X, La Jolla, Ca). Level of
significance for all measures was set at p ≤ 0.05.
Study approval
All experiments were approved by the University of Tennessee Health Science
Center’s Institutional Animal Care and Use Committee (protocol #19.001).
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Results
LLC characterization
Between 11-12 weeks of age C57BL/6J (B6) mice were injected with PBS C cells
and were then sacrificed 25-30 post injection. There were no differences in age or study
duration between PBS (N=16) and LLC (N=24) mice (Table 3-1). The study was
initiated at approximately 12 weeks of age and completed at approximately 15 to 16
weeks of age. PBS and LLC mice bodyweights were similar before tumor inoculation
(p=0.515) and 10 days post tumor inoculation (p=0.445). While there were no differences
in absolute body weight at the end of the study (p=0.397), after accounting for tumor
mass, LLC mice had decreased body weight compared to PBS mice (p=0.001) (Figure
3-1). LLC mice had a greater body weight change from day 10 when accounting for
tumor mass (-5.7%) compared to PBS mice (0.4%) (Figure 3-1G). Body weight change
from day 10 was chosen because the tumor is initially palpable but prior to the rapid
tumor growth phase (days 15-25). LLC mice had decreased gastrocnemius muscle mass
(Figure 3-1H), total hindlimb muscle mass (p=0.008) (Table 3-1), and eWAT mass
(Figure 3-1) compared to PBS mice. LLC mice had increased spleen mass and plasma
IL-6 (Table 3-1) compared to PBS mice. Tumor volume and tumor mass were used to
validate tumor development. Tumor volume was measured every 5 days throughout the
study and was measurable 10 days post tumor inoculation (Figure 3-1). Utilizing the
LLC model's rapid tumor growth phase, we calculated the slope of tumor growth from
days 15-25. Tumor growth rate ranged from 0.090 to 0.383 cm3/5days (Figure 3-1C).
Tumor mass ranged from 0.745 to 5.15 grams (Figure 3-1). Tumor growth rate from
days 15-25 and tumor mass were not associated (r=0.387, p=0.062).
We then compared common proteins elevated in cachectic skeletal muscle: STAT3, P65,
and Atrogin-1. LLC mice had elevated STAT3 0.9-fold, P65 0.6-fold, and Atrogin-1 0.7fold compared to PBS mice (Figure 3-1J). Taken together, these results provide evidence
of pre-cachectic tumor-bearing mice (Figure B-1). To examine the effect of feeding on
systemic metabolism and muscle signaling, we first need to examine if there are
differences in animal characteristics between the fast and fed condition in both PBS and
LLC treated mice (Table 3-2). In PBS mice, there were no differences in body weight
throughout the study, gastrocnemius muscle mass, eWAT mass, or tibia length between
the fast and fed condition. Additionally, in LLC mice, there were no differences in body
weight throughout the study, gastrocnemius muscle mass, eWAT mass, or tibia length
between the fast and fed condition. Importantly, there were no. differences in tumor
growth, tumor growth rate, nor tumor mass in LLC mice in the fast and fed condition
Given that there were no differences between the fast and fed condition of PBS and LLC
mice, we can compare the whole-body and muscle response to feeding between groups
of PBS and LLC mice, we can compare the whole-body and muscle response to feeding
between groups.
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Table 3-1.

Animal characteristics of LLC tumor-bearing male mice
PBS
LLC
Characteristics
N=16
N=24
p-Value
BW Pre-treatment (g)
25.5 (0.6)
24.9 (0.3)
0.362
BW d10 (g)
26.5 (0.5)* 25.7 (0.3)* 0.180
BW End of Study (g)
26.6 (0.4)
27.0 (0.3)
0.370
BW End of Study
26.6 (0.4) * 24.2 (0.4)# <0.001
Tumor Mass (g)
2.8 (0.3)
4.6 (1.4)
2.6 (1.6)
0.003
BW∆ During Treatment (%)
0.4 (0.8)
-5.7 (1.3)
0.001
BW∆ d10 (%)
3
0.42 (0.09)
Tumor Volume d15 (cm )
Plasma IL-6 (pg/ml)
3.9 (0.0)
15.3 (2.2)
0.001
HMM (mg)
192 (4)
175 (3)
0.002
eWAT (mg)
328 (30)
240 (16)
0.008
Testes (mg)
199 (4)
203 (3)
0.386
Heart (mg)
153 (5)
137 (4)
0.023
Spleen (mg)
73 (6)
220 (27)
<0.001
Tibia Length (mm)
16.8 (0.1)
16.8 (0.1)
0.810

Notes: Data are presented as mean±SEM. Abbreviations: BW: body weight, mg:
milligrams, eWAT: epididymal white adipose tissue, PBS: phosphate buffered saline,
LLC: Lewis lung carcinoma, mm: millimeter, g: grams, HMM: hindlimb muscle mass.
Unpaired T-Test were used to compare differences between PBS and LLC mice. Oneway repeated measures ANOVA was used to compare within PBS and LLC mice body
weight over the course of the study (BW End of study is not included in analysis) *
Different from Pre within treatment group, # Different from BW d10 within treatment
group. One-way repeated measures ANOVA was used to compare tumor volume over the
course of the study. * Different from d15 within treatment group, # Different from d20
within treatment group Statistically significant p<0.05.
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Figure 3-1. LLC tumor-bearing male mice exhibit several indices of cachexia and
increased skeletal muscle inflammatory signaling
Notes: Data are presented as mean ± SEM. A. Study Design. Male C57Bl/6J mice were
injected with PBS or LLC cells between 10-11 wks. of age. Tumor volume and body
weight were taken every 5 days until sacrifice (28-30 days post tumor inoculation). B.Tumor volume during the study in LLC male mice. C. Tumor growth rate from days 1525. D. Body mass during the study in LLC and PBS male mice. E. Tumor Mass at
sacrifice. F. Body weight at the end of study accounting for tumor mass. G. Body weight
change from Day 10 post tumor inoculation. Body weight is calculated as the sacrifice
body weight minus the tumor mass divided by day 10 body weight. H. Gastrocnemius
muscle mass at sacrifice. I. eWAT mass at sacrifice. J. Cachectic skeletal muscle
signaling in mixed gastrocnemius muscle. Abbreviations: BW: body weight, mg:
milligrams, PBS: phosphate buffered saline, LLC: Lewis lung carcinoma, g: grams.
Unpaired t-test was used to compare PBS to LLC. * Different between groups. Pearson
Correlation Coefficient was used for correlations. Statistical significance was set a
p<0.05.
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Table 3-2.
condition

Animal characteristics of PBS and LLC male mice in the fast and fed

PBS
Fast
Fed
Characteristics
N=7
N=9
BW Pre-treatment (g)
25.3 (1.0) 25.7 (0.6)
BW d10 (g)
26.5 (0.9)a 26.5 (0.6)a
BW End of Study (g)
26.5 (0.8) 27.1 (0.6)
BW End of Study
26.4. (0.8) 26.7 (0.5)
Tumor Mass (g)
4.3 (1.7)
BW∆ During Treatment (%) 5.0 (2.4)
-0.3 (1.1)
0.9 (1.1)
BW∆ d10 (%)
Tumor Volume d15 (cm3)
Tumor Volume d20 (cm3)
Tumor Volume d25 (cm3)
Tumor Slope Rate d15-25
Plasma IL-6 (pg/ml)
3.9 (0.0)
3.9 (0.0)
HMM (mg)
193 (8)
191 (5)
eWAT (mg)
365 (45)
310 (35)
Testes (mg)
201 (7)
197 (5)
Heart (mg)
151 (9)
154 (7)
Spleen (mg)
86 (8)
62 (5)
Tibia Length (mm)
16.9 (0.1) 16.8 (0.1)

LLC
Fast
Fed
N=10
N=14
24.5 (0.6)
25.3 (0.4)
26.1 (0.5)a
25.4 (0.4)
26.5 (0.5)
27.2 (0.4)
24.5 (0.5)b$
24.2 (0.5)b$
2.3 (0.4)
3.1 (0.4)
-0.7 (2.9)^
-4.4 (1.9) ^
-5.8 (1.6)^
-4.1 (1.9) ^
0.17 (0.05)
0.60 (0.03) *
1.19 (0.27)a
1.69 (0.36)a
a,b
2.00 (0.35)
2.57 (0.35)a,b
0.182 (0.034) 0.197 (0.027)
10.6 (2.6)^
18.6 (3.0)^
181 (5)^
171 (3)^
256 (23)^
229 (22)^
204 (5)
202 (3)
147 (7)^
130 (3)^
248 (62)^
200 (14)^
16.9 (0.1)
16.8 (0.1)

Notes: Data are presented as mean±SEM. Abbreviations: BW: body weight, mg:
milligrams, eWAT: epididymal white adipose tissue, PBS: Phosphate buffered saline,
LLC: Lewis lung carcinoma, mm: millimeter, g: grams, ME: Main Effect, HMM:
Hindlimb muscle mass. One-way repeated measures ANOVA was used to compare within
LLC fast and fed mice body weight over the course of the study (BW End of study is not
included in analysis/ BW end of study accounting for tumor mass is included).
a=Different from Pre within treatment group, b=Different from BW d10 within treatment
group. One-way repeated measures ANOVA was used to compare tumor volume over the
course of the study. a=Different from d15 within treatment group and b=Different from
d20 within treatment group. Statistically significant p<0.05. Two-way ANOVA was used
to compare PBS and LLC in the Fast and Fed condition. # Main Effect of Feed. $Main
effect of LLC. Unpaired T-test were used to compare tumor growth and mass in the fed
and fast condition of LLC mice. * Different from LLC fast.
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Whole-body response to feeding during cancer cachexia progression
After 4 weeks of tumor inoculation, mice were fasted for 12-hrs during the dark
cycle, then sacrificed (fast) or given access to a food pellet for 1-hr ad libitum (fed)
(Figure 3-2). There were no differences in pellet consumption in fed PBS and LLC mice
(Figure 3-2). There was an interaction for stomach mass and stomach content to increase
in both PBS and LLC mice in the fed condition (Table 3-3). Interestingly, PBS mice
increased stomach mass to a greater extent than LLC mice (Table 3-3). There were no
differences in empty stomach mass. There was a main effect for blood glucose to increase
by feeding in both PBS and LLC mice (Figure 3-2). We completed a pre-planned t-test
within treatment groups (PBS or LLC) to validate the insulin response by feeding. We
report that plasma insulin increased in the PBS fed (p=0.002) compared to PBS fast mice.
Plasma insulin was increased in the LLC fed (p<0.001) compared to LLC fast mice.
When comparing PBS and LLC in the fast and fed condition, there was an interaction for
plasma insulin to increase in the PBS fed mice, however the insulin induction by feeding
was not present in LLC mice (Figure 3-2).
We next examined the feeding response in skeletal muscle. We first validated
direct downstream insulin signaling, phospho-AKT T308 (Figure B-2). There was a
main effect for feeding to increase AKT 3.5-fold compared to fast, and a main effect for
PBS mice to have increased AKT 1.5-fold compared to LLC (Figure 3-2). Next, we
examined downstream mTORC1 signaling, rpS6. There was a main effect for feeding to
increase rps6 4.2-fold compared to fast, and a main effect for PBS mice to have increased
rpS6 1.3-fold compared to LLC mice (Figure 3-2). Lastly, we examined the effect of
feeding on skeletal muscle protein synthesis. There was a main effect for feeding to
increase puromycin incorporation 2-fold compared to fasting, and a main effect for PBS
mice to have increased puromycin incorporation 1.7-fold compared to LLC mice (Figure
3-2). Taken together these results validate the anabolic response to feeding in PBS mice
(non-tumor-bearing mice) by an increase in blood glucose, plasma insulin, muscle
AKT/mTORC1 signaling, and muscle protein synthesis. Additionally, we report that
tumor-bearing mice can elicit an increase blood glucose and plasma insulin in response to
feeding. Importantly, LLC tumor-bearing mice do have the ability to increase in
AKT/mTORC1 and protein synthesis following feeding, however LLC mice have overall
lower anabolic muscle signaling independent of fast or fed condition.
Muscle Akt/mTORC1 and protein synthesis association to cachexia progression
We next asked the question if anabolic signaling in the fasting condition was
associated with cachexia progression (common indices of cachexia: gastrocnemius mass,
eWAT, and body weight change). AKT in LLC fast mice was not associated with
gastrocnemius muscle mass (r=-0.479, p=0.230), eWAT mass (r=-0.408, p=0.315) nor
body weight change from day 10 (r=0.554, p=0.154). RpS6 in LLC fast mice was not
associated with gastrocnemius muscle mass (r=0.479, p=0.230), eWAT mass (r=-0.408,
p=0.315) nor body weight change from day 10 (r=0.554, p=0.154). Lastly, puromycin
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Figure 3-2. LLC tumor-bearing mice exhibit whole-body and muscle-specific
anabolic response to 1-hr ad libitum feeding
Notes: Data are presented as mean ± SEM. A. Study Design. Male C57Bl/6J mice were
injected with PBS or LLC cells between 10-11 wks. of age. Tumor volume and body
weight were taken every 5 days until sacrifice (28-30 days post tumor inoculation). Pellet
consumption in Fed PBS and LLC mice. C. Blood glucose at Sacrifice. D. Plasma Insulin
at Sacrifice. E. Gastrocnemius muscle phoshpo-AKTT308 to total protein expression
ratio. F. Gastrocnemius muscle phospho-rpS6S240/244 to total protein expression ratio.
G. Gastrocnemius muscle puromycin incorporation protein expression. H. Representative
western blots. Abbreviations: BW: body weight, mg: milligrams, PBS: phosphate
buffered saline, LLC: Lewis lung carcinoma, g: grams. Unpaired t-test was used to
compare PBS to LLC. * Different between groups. Pearson Correlation Coefficient was
used for correlations. Statistical significance was set a p<0.05. N=7 PBS fast, 9 PBS Fed,
12 LLC. #Main effect of Fed, $ Main effect of LLC.
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Table 3-3.

Whole body response to feeding in PBS and LLC male mice

Outcomes

Pellet Consumption (g)
Blood Glucose (mg/dl)
Plasma Insulin (ng/mL)
Liver Mass (g)
Stomach Mass (mg)
Empty Stomach (mg)
Stomach Content (mg)

Fast
N=7

PBS

92 (10)
0.385 (0.055)a
1.2 (0.1)
375 (41)a
206 (12)
169 (33)a

Fed
N=9

0.63 (0.06)
169 (8)#
2.256 (0.421)b
1.2 (0.0)
855 (112) b
158 (8)
697 (114)b

Fast
N=10

LLC

77 (4)
0.238 (0.013)a
1.3 (0.0)$
390 (32) a
180 (8)
209 (26)a

Fed
N=14

0.53 (0.09)
187 (9)#
0.967 (0.151)a
1.3 (0.0)$
573 (41)a
135 (6)
434 (43)c

Notes: Data are presented as mean±SEM. Abbreviations: mg: milligrams, PBS:
phosphate buffered saline, LLC: Lewis lung carcinoma, g: grams, mg/dl: milligrams per
deciliter, ng/mL: nanograms per milliliter. Unpaired T-test was used to compare PBS and
LLC fed pellet consumption. Two-way ANOVAs were used to compare PBS and LLC in
the Fast and Fed condition. # Main Effect of Fed. $ Main effect of LLC. If an interaction
was present; different letters were used to differentiate differences between groups.
Statistically significant p<0.05.
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incorporation in LLC fast mice was not associated with gastrocnemius muscle mass (r=0.166, p=0.695), eWAT mass (r=0.079, p=0.853), nor body weight change from day 10
(r=0.259, p=0.536). Taken together, these results suggest that fasting Akt/mTORC1
signaling and protein synthesis are not associated with common indices of cachexia.
We then examined if the feeding induction of Akt/mTORC1 and protein synthesis
response was associated with cachexia progression. While AKT in LLC fed mice was not
associated with gastrocnemius muscle mass (r=-0.174, p=0.564) or body weight change
from day 10 (r=-0.219, p=0.472), it was negatively associated with eWAT mass (r=0.563, p=0.045). Additionally, rpS6 in LLC fed mice was not associated with
gastrocnemius muscle mass (r=-0.321, p=0.284) or body weight change from day 10 (r=0.232, p=0.445), however rpS6 was negatively associated with eWAT mass (r=-0.688,
p=0.009). In summary, these data suggest that the greater increase in AKT and rpS6 was
associated with reduced fat mass. While puromycin incorporation in LLC fed mice was
not associated with gastrocnemius muscle mass (r=0.508, p=0.076) or body weight
change from day 10 (r=0.323, p=0.281), it was positively associated with eWAT mass
(r=0.709, p=0.007) suggesting that greater increase in protein synthesis were associated
with greater fat mass. Several studies have implicated fat wasting as an initial phenotype
of cancer cachexia, these data would suggest that altered protein synthesis by feeding
occurs early during cachexia progression. Interestingly, there is a disconnect between the
association of Akt/mTORC1 and protein synthesis signaling cascades to fat wasting.
Effect of feeding on AMPK signaling
AMPK is a known metabolic checkpoint which can inhibit mTORC1 signaling.
Therefore, we examined if muscle AMPK and direct downstream signaling was
dysregulated by LLC and if feeding altered this response. There was a main effect for
LLC to increase AMPK 1.7-fold (p<0.001) compared to PBS mice, and a main effect for
feeding to lower AMPK 0.6-fold (p<0.001) (Figure 3-3). FOXO3a S413 is a downstream
target of AMPK. Feeding was sufficient to lower FOXO3a S413 in the LLC mice
(Figure 3-3). Atrogin-1, a ubiquitin ligase, is commonly elevated in cachectic conditions,
and it was increased with LLC and reduced by feeding (Figure 3-3). Taken together,
these data highlight LLC mice have elevated muscle AMPK and feeding can lower
AMPK in LLC mice. We next examined if these alterations by LLC and feeding were
associated with cachexia progression. AMPK in the fed condition was not associated with
body weight change from day 10 (r=-0.632, p=0.068), gastrocnemius muscle mass (r=0.536, p=0.137), nor eWAT mass (r=-0.353, p=0.351). Given that LLC mice have overall
reduced protein synthesis which coincided with elevated AMPK, and feeding was
sufficient to induce protein synthesis and lower AMPK, it is within reason to speculate
that the suppression of protein synthesis is impacted by AMPK. Therefore, we next
sought out to investigate the fasting regulation of AMPK by LLC (Figure 3-4).
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Figure 3-3. 1-hr of ad libitum feeding is sufficient to lower skeletal muscle AMPK
in LLC tumor-bearing mice
Notes: Data are presented as mean ± SEM. A. Study Design. Male C57Bl/6J mice were
injected with PBS or LLC cells between 10-11 wks. of age. Tumor volume and body
weight were taken every 5 days until sacrifice (28-30 days post tumor inoculation). B.Phospho-AMPK T172 in mixed gastrocnemius muscle of PBS and LLC mice in the fast
and fed condition. C. Phospho-FOXO3a S413 in mixed gastrocnemius muscle of PBS
and LLC mice in the fast and fed condition. D. Atrogin-1 in mixed gastrocnemius muscle
of PBS and LLC mice in the fast and fed condition. Phospho- proteins were normalized
to total protein. #Main effect of Fed, $ Main effect of LLC. If there was an interaction:
*-Different between groups.
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Figure 3-4. Increased AMPK signaling by fasting is associated to fat wasting in
LLC tumor-bearing mice
Notes: Data are presented as mean ± SEM. A. Study Design. Male C57Bl/6J mice were
injected with PBS or LLC cells between 10-11 wks. of age. Tumor volume and body
weight were taken every 5 days until sacrifice (28-30 days post tumor inoculation). B.Mixed muscle AMPK signaling. C. Correlation of phospho-AMPK with body weight
change from day 10. D. Correlation of phospho-AMPK with gastrocnemius mass. E.Correlation of phospho-AMPK with eWAT mass. Unpaired T-test were used to compare
PBS and LLC fast mice. Phospho- proteins were normalized to total protein. * Different
from PBS. Correlations were used to compare phospho-AMPK with indices of cachexia
(body weight change from day 10, gastrocnemius muscle mass, and eWAT mass.
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LLC tumor-bearing mice exhibit elevated AMPK T172, ULK1 S555, and FOXO3a S413
(Figure 3-4). Fasting AMPK was not associated with body weight change from day 10
(Figure 3-4) or gastrocnemius muscle mass (Figure 3-4). Interestingly, fasting AMPK
was strongly associated with eWAT mass (Figure 3-4). FOXO3a in the fast condition
was not associated to body weight change from day 10 (r=-0.517, p=0.159),
gastrocnemius muscle mass (r=0.489, p=0.182), nor eWAT mass (r=0.242, p=0.531).
ULK1 in the fast condition was not associated with body weight change from day 10
(r=0.511, p=0.196), gastrocnemius muscle mass (r=0.161, p=0.704), nor eWAT mass (r=0.252, p=0.557). Taken together, these data suggest that following an overnight fast, LLC
tumor-bearing mice have elevated AMPK in pre-cachectic tumor-bearing mice.
Early onset whole body metabolism and physical inactivity in tumor-bearing mice
Cancer cachexia is known to disrupt whole body metabolism and physical
activity. We sought to determine if there were early disruptions in physical activity and
whole-body metabolism in LLC tumor-bearing mice, and if these disruptions were
associated to end stage muscle signaling (Figure B-3). LLC tumor-bearing mice have
increased blood glucose following a glucose tolerance test 15 days post tumor
inoculation. Interestingly, there was negative association of eWAT mass at the end study
with early onset glucose intolerance (Table B-1). Lastly, glucose tolerance test area
under the curve was not associated with muscle AMPK associated signaling at the end
study (Table B-2). LLC tumor-bearing mice exhibit early onset physical inactivity during
the dark cycle (Figure B-1). Additionally, physical inactivity in LLC mice was positively
associated with gastrocnemius muscle mass and fat mass at the end of study (Table B-1).
As expected, lipid oxidation decreased, and carbohydrate oxidation increased during the
dark cycle in both PBS and LLC mice. There were no differences in lipid or carbohydrate
oxidation between PBS and LLC mice. Interestingly, lipid nor carbohydrate oxidation
was not associated with indices of cachexia (Table B-1). Taken together, LLC tumorbearing mice exhibit early onset glucose intolerance and physical inactivity, which are
associated with early indices of cachexia.
Muscle-specific role of AMPK
AMPK𝛼1 and AMPK𝛼2 floxed mice were generously given to Dr. Carson by Dr.
Hoh Jin Ko at the University of South Carolina. Mice were transferred to the University
of Tennessee Health Science Center for breeding. We then crossed the AMPK𝛼1 with the
AMPK𝛼2 to generate the AMPK𝛼1𝛼2 floxed mouse. We then crossed the AMPK𝛼1𝛼2
with the transgenic mouse HSA mer-cre-mer mouse. The crossing of these mice
produced ~50% AMPK𝛼1𝛼2 and ~50% AMPKα1α2 hsac/+ (Figure 3-5). Genotyping
was confirmed by tail snips after 21 days neonatal (Figure 3-5). Around 10 weeks of age,
mice were given tamoxifen injection once a day for 5 consecutive days to bring the
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Figure 3-5.

Muscle-specific AMPK loss in male PBS mice

Notes: Male C57Bl/J mice were used from UTHSC breeding colony. A. Breeding
schematic to produce AMPK ɑ1+/+ ɑ2+/+ with and without HSA mer-cre-mer. B.
Example of tail snip confirmation of animal genotype. C. Study Design. Created with
BioRender.com. D. Protein expression of phospho-AMPK loss and immediate
downstream signaling in WT and KO PBS male mice. Direct downstream targets ACC
and FOXO3a. N=7-8 per group. Phospho- proteins were normalized to total protein.
Abbreviations: AMPK: Adenosine Monophosphate protein kinase, WT: Wildtype AMPK ɑ1+/+ ɑ2+/+ , KO: Knockout, AMPK ɑ1-/- ɑ2-/- (KO), PBS: phosphate buffered
saline, LLC: Lewis lung carcinoma, ULK: Unc-51 like autophagy activating kinase 1,
FOXO: Forkhead box O3, p: Phosphorylation.
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LoxP-MerCreMer bound binding sites together to remove the floxed genes of interest.
After a two-week washout period, mice were injected with either PBS or LLC cells and
monitored for 4 weeks (Figure 3-5).
To validate the efficacy of knocking out AMPK and associated signaling. Tail
snips were conducted at neonatal 21 days and mice was determined as having the double
floxing of AMPK𝛼1𝛼2 with or without the presence of hsac/+. To validate the loss of
AMPK on AMPK targets we analyzed phospho-AMPK, phospho-ULKS555,
FOXO3aS413, and ACC. Phospho-AMPK was decreased 91%, phospho-ACC1 S212
decreased by 27%, and FOXO3aS413 decreased by 32% in AMPK𝛼1𝛼2 KO mice
compared to AMPK𝛼1𝛼2 PBS mice (Figure 3-5 and Figure B-4). Importantly, there
were no differences in body weight over time, skeletal muscle mass (gastrocnemius or
hindlimb muscle mass), eWAT mass, or tibia length in AMPK WT mice compared to
AMPK KO mice (Table 3-4). These data highlight the ability to decrease AMPK and
associated signaling in skeletal muscle, which does not alter tissue mass and body size in
PBS treated male mice.
Effect of AMPK loss on skeletal muscle signaling in non-tumor-bearing mice
To understand how AMPK loss alters skeletal muscle signaling in tumor-bearing
mice, we first need to determine what AMPK loss does to skeletal muscle signaling in
non-tumor-bearing male mice in the fast condition. All mice were sacrificed at the start of
the light cycle following an overnight 12-hr fast. First, we examined the effect of AMPK
loss on autophagy associated signaling (P62, LC3BII/I, and Beclin-1). Interestingly, P62
and Beclin-1 were not altered by AMPK loss, while LC3BII/I ratio was induced. The
induction of LC3BII/I ratio is due to an increase in LC3BII (p=0.006) without any
changes in LC3BI (p=0.514). AMPK has known regulation to inhibit mTORC1 therefore
we examined if AMPK played a role in basal skeletal muscle anabolic signaling (Figure
B-4). As expected, AKT T308 was not altered by AMPK loss. RpS6 S240/244 was
increased 2.3-fold in AMPK KO mice compared to wild-type. Puromycin incorporation
was increased 0.7-fold in AMPK KO mice compared to wild-type mice. Taken together,
we highlight that following a 12-hr fast, AMPK is regulating rpS6 and protein synthesis.
Lastly, it is well known that AMPK induces mitochondrial biogenesis. Therefore, we
examined markers of mitochondrial quality control (Figure B-4). PGC1α a marker of
mitochondrial biogenesis was reduced by AMPK KO. Additionally, DRP1 S616 and FIS1, markers of mitochondrial fission, were reduced by AMPK KO. Interestingly, OPA-1, a
marker of mitochondrial fusion, was reduced by AMPK KO. Collectively, we further
support the regulation of skeletal muscle mitochondrial quality control by AMPK.
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Table 3-4.
Muscle-specific AMPK loss does not alter animal characteristics in
PBS treated male mice
AMPK α1+/+ α2+/+ (WT) AMPK α1-/- α2-/- (KO)
Characteristics
N=15
N=17
p-Value
Age Inoculated with PBS (wks)
14.1 (0.3)
13.5 (0.4)
0.258
Days in Study (days)
26.9 (0.5)
25.8 (0.06)
0.060
BW Pre-tamoxifen (g)
23.9 (0.4)
23.4 (0.3)
0.321
BW Post-tamoxifen (g)
24.0 (0.4)
23.3 (0.4)
0.216
BW Pre-inoculation (g)
25.9 (0.5)*
24.4 (0.6)*
0.058
BW d10 (g)
27.0 (0.4)*
25.6 (0.6)*
0.091
BW End of Study (g)
28.4 (0.4)*
27.4 (0.5)*
0.106
BW∆ During Tamoxifen (%)
0.52 (1.1)
-0.17 (0.60)
0.575
BW∆ from d10 (%)
5.6 (1.3)
7.2 (1.5)
0.424
Gastrocnemius Weight (mg)
122 (2)
117 (3)
0.059
Tibialis Anterior Weight (mg)
45 (1)
43 (1)
0.254
HMM (mg)
203 (4)
195 (3)
0.109
Testes Weight (mg)
194 (3)
186 (5)
0.234
Seminal Vesicle Weight (mg)
254 (8)
256 (12)
0.892
Seminal Vesicle Weight (mg)
254 (8)
442 (49)
0.752
eWAT (mg)
421 (45)
69 (2)
0.876
Spleen Mass (mg)
68 (4)
4.4 (1.1)
0.092
Plasma IL-6 (pg/ml)
4.8 (0.9)
17.2 (0.1)
0.412
Tibia Length (mm)
17.0 (0.1)
13.5 (0.4)
0.258

Notes: Data are presented as Mean +/- SEM. Male C57Bl/J mice were used from UTHSC
breeding colony. 32 mice were randomly assigned to PBS injections with the genotypes
of AMPK ɑ1+/+ ɑ2+/+ (WT; N=15) AMPK ɑ1-/- ɑ2-/- (KO; N=17). Abbreviations:
SEM: Standard error of the mean, g: grams, mg: milligrams, BW: body Weight, TW:
tumor weight, ∆: Change, %: Percent, PBS: Phosphate Buffered Saline, mm: millimeters,
HMM: hindlimb muscle mass. Statistical Significance p<0.05. Unpaired T-Test was used
to compare PBS WT and PBS KO male mice. Two-way repeated measures ANOVA (2 x
5) was used to compare body pre-tamoxifen, post-tamoxifen, pre-inoculation, BW Day
10, and BW end of study. There was a main effect of time without differences between
WT and KO mice. When determining which groups were different, *Notes statistically
significant from all other time points within WT and KO mice.
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Validation of muscle-specific AMPK loss in LLC tumor-bearing mice
To validate the efficacy of knocking out AMPK and associated signaling in LLC
tumor-bearing mice. Tail snips were conducted at neonatal 21 days and mice was
determined as having the double floxing of AMPK𝛼1𝛼2 with or without the presence of
hsac/+. After tamoxifen washout, mice were injected with either PBS or LLC cells and
sacrificed 4-weeks later (Figure 3-6). We first validated all mice by showing the absence
of total AMPK in PBS and LLC AMPK WT and AMPK KO male mice (Figure 3-6).
Importantly, AMPK loss in LLC tumor-bearing mice was sufficient to reduce the
increased in phospho-AMPK, FOXO3a, and Atrogin-1 (Figure 3-6).
Muscle-specific AMPK loss in LLC tumor-bearing male mice does not alter tumor
growth, tumor mass, or indices of cachexia
Tumor volume increased from days 10-25 in AMPK WT and KO mice (p<0.001)
with no difference between WT and KO mice (p=0.402) (Figure 3-7). There were no
differences in tumor growth rate between WT and KO LLC mice (p=0.211). There were
no differences in tumor mass between WT and KO LLC mice (p=0.109). There was a
main effect of time (p<0.001) for body weight during the study to increase at each time
point (Table 3-5). When accounting for tumor mass, there was a main effect for LLC
mice to have decreased body weight at the end of the study (p<0.001), without
differences between WT and KO mice (p=0.131). There was a main effect for LLC mice
to have more body weight change from day 10 (p<0.001), without differences between
WT and KO mice (p=0.713). There was a main effect for LLC mice to have decreased
gastrocnemius muscle (p<0.001), without differences between WT and KO mice
(p=0.076). There was a main effect for LLC mice to have decreased eWAT mass
(p=0.002), without differences between WT and KO mice (p=0.458).
Effect of AMPK loss on Akt/mTORC1 signaling and protein synthesis in LLC
tumor-bearing male mice
Given the known suppression of basal Akt/mTORC1 signaling and protein
synthesis in LLC mice compared to PBS mice, and AMPK’s known regulation of
mTORC1 signaling it is within reason to speculate that in tumor-bearing mice when
AMPK is elevated, by lowering the elevated AMPK signaling we can improve mTORC1
signaling and protein synthesis. Therefore, we examined the effect of AMPK loss in
the fasting condition in PBS and LLC mice (Figure 3-8). There was a main effect for
LLC mice to have decreased puromycin incorporation compared to PBS (p=0.008) and a
main effect for KO to increase puromycin incorporation (p=0.027). There was a main
effect for LLC mice to have decreased rps6 compared to PBS (p=0.008) and a main
effect for KO to increase rps6 (p=0.027; Figure 3-8). There was a main effect for
LLC mice to have decreased AKT compared to PBS (p=0.006), without any effects of
KO (p=0.353; Figure 3.8). Taken together we highlight that AMPK is regulating
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Figure 3-6. Increased AMPK signaling can be reduced by muscle-specific AMPK
loss in LLC tumor-bearing mice
Notes: Data are presented as mean ± SEM. A. Study Design. Created with
BioRender.com. Male C57Bl/6J mice were injected with PBS or LLC cells between 1011 wks. of age. Tumor volume and body weight were taken every 5 days until sacrifice
(28-30 days post tumor inoculation). B. Validation of total AMPK loss in KO PBS and
LLC mice. C.-Protein expression of phospho-AMPK loss and immediate downstream
signaling in WT and KO PBS and LLC male mice. N=7-11 per group. Phospho- proteins
were normalized to total protein. Abbreviations: BW: body weight, mg: milligrams,
PBS: phosphate buffered saline, LLC: Lewis lung carcinoma, g: grams. Unpaired t-test
was used to compare PBS to LLC. Two-way ANOVA (PBS or LLC vs WT or KO) was
used. If there was an interaction; different letter note groups are different. # Main effect
of KO, $ Main effect of LLC.
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Figure 3-7. Muscle-specific AMPK loss in LLC tumor-bearing mice does not alter
tumor mass, tumor growth, or indices of cachexia
Notes: Data are presented as mean ± SEM. A. Study Design. Male C57Bl/6J mice were
injected with PBS or LLC cells between 10-11 wks. of age. Tumor volume and body
weight were taken every 5 days until sacrifice (28-30 days post tumor inoculation). B.Tumor growth rate from days 15-25. C. Tumor Mass at sacrifice. D. Body weight pre
injection in PBS and LLC WT and KO mice. E. Body weight end of study accounting for
tumor mass in PBS and LLC WT and KO mice. F. Body weight change from Day 10 post
tumor inoculation. Body weight is calculated as the sacrifice body weight minus the
tumor mass divided by day 10 body weight. G. Gastrocnemius muscle mass at sacrifice.
H. eWAT mass at sacrifice. Abbreviations: BW: body weight, mg: milligrams, PBS:
phosphate buffered saline, LLC: Lewis lung carcinoma, g: grams. Unpaired t-test was
used to compare PBS to LLC. Two-way (Genotype x LLC) repeated measures ANOVA.
$ Main Effect of LLC. Two-way repeated measures ANOVA was used to compare tumor
volume overtime in LLC WT and KO mice. Different letters note a difference between
time points within each condition.
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Table 3-5.
Effect of muscle-specific AMPK loss on animal characteristics in LLC
tumor-bearing mice

Characteristics
Age Inoculated (wks)
BW Pre-tamoxifen (g)
BW Post-tamoxifen (g)
Days in Study (days)
BW Pre-inoculation (g)
BW d10 (g)
BW End of Study (g)
Tumor Weight (TW) (g)
BW – TW (g)
BW∆ from d10 (%)

3

Tumor Volume d15 (cm )
3
Tumor Volume d20 (cm )
3
Tumor Volume d25 (cm )
3
Tumor Growth Rate (cm /5days)
Soleus Weight (mg)
Gastrocnemius Weight (mg)
Tibialis Anterior Weight (mg)
HMM (mg)
Testes Weight (mg)
Seminal Vesicle Weight (mg)
eWAT (mg)
Spleen Mass (mg)
Plasma IL-6 (pg/ml)
Tibia Length (mm)

PBS
WT
KO
N=15
N=17
14.1 (0.3)
13.5 (0.4)
23.9 (0.4)
23.4 (0.3)
24.0 (0.4)
23.3 (0.4)
26.7 (0.3)
25.9 (0.3)
a

26.0 (0.4)
b
26.7 (0.4)
28.4 (0.4)
c
28.4 (0.4)
5.6 (1.3)
7.2 (0.3)
122 (2)
45 (1)
203 (4)
194 (3)
254 (8)
421 (45)
68 (4)
4.8 (0.9)
17.0 (0.1)

a

24.6 (0.5)
b
25.6 (0.6)
^c
27.4 (0.5)
c
27.4 (0.5)
7.2 (1.5)
7.9 (0.2)
115 (3)
43 (1)
195 (3)
186 (5)
256 (12)
442 (49)
69 (2)
7.3 (1.1)
17.2 (0.1)

LLC
WT
KO
N=16
N=19
14.0 (0.3)
13.9 (0.3)
23.0 90.5)
23.5 (0.4)
23.9 (0.5)
24.5 (0.4)
@
@
25.8 (0.4)
25.4 (0.3)
a,b
a
26.2 (0.3)
26.0 (0.4)
a
b
26.8 (0.4)
26.7 (0.5)
@
@^
29.6 (0.4)
28.7 (0.5)
3.4 (0.4)
3.2 (0.4)
@b
@a
25.8 (0.4)
25.5 (0.4)
@
@
-4.1 (1.3)
-4.3 (1.2)
a
a
0.708 (0.104) 1.062 (0.153)
b
b
1.942 (0.249) 2.742 (0.370)
c
c
4.239 (0.508) 3.951 (0.378)
0.363 (0.049) 0.289 (0.033)
7.7 (0.4)
7.5 (0.3)
@
@
107 (3)
106 (3)
@
@
38 (1)
38 (1)
@
@
177 (4)
176 (4)
183 (3)
183 (4)
@
@
210 (11)
218 (10)
@
@
262 (27)
314 (42)
#
#
229 (28)
162 (14)
@
@
18.0 (3.0)
16.3 (2.1)
16.9 (0.2)
17.2 (0.1)

Notes: Data are presented as mean ± SEM. Male C57Bl/J mice were used from UTHSC
breeding colony. 67 mice were randomly assigned to either PBS (N:32) or LLC (N:35)
then at the time of sacrifice were either fasted or Fed. Abbreviations: SEM: Standard
error of the mean, cm3: centimeters cubed, mg: milligrams, BW: body Weight, TW:
tumor weight, ∆: Change, %: Percent, LLC: Lewis lung carcinoma, PBS: Phosphate
Buffered Saline, mm: millimeters, HMM: Hindlimb muscle mass. Statistical Significance
p<0.05. Two-way ANOVA (2 Treatments x 2 nutrient conditions) was used to compare
across groups. ME of Genotype: ^, ME of LLC@, One-way repeated measures ANOVA
was used to compare body weight overtime within each treatment and genotyped.
Different letters mean there was an interaction and different from other letters. One-way
ANOVA was used to compare tumor volume overtime within each genotype group of
LLC mice. Different letters mean there was an interaction and different from other letters.
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Figure 3-8. Muscle-specific AMPK loss is sufficient to increase muscle protein
synthesis in LLC tumor-bearing mice following a 12hr fast
Notes: Data are presented as mean ± SEM. A. Study Design. Male C57Bl/6J mice were
injected with PBS or LLC cells between 10-11 wks. of age. Tumor volume and body
weight were taken every 5 days until sacrifice (28-30 days post tumor inoculation). Mice
were fasted during the dark cycle and sacrificed at the start of the light cycle following a
12hr fast. B. Puromycin incorporation in PBS and LLC AMPK WT and AMPK KO
mice. C. Phospho-rpS6 to total ratio in PBS and LLC AMPK WT and AMPK KO mice.
D Phospho-AKT to total ratio in PBS and LLC AMPK WT and AMPK KO mice. White
gastrocnemius muscle was for protein expression. Phospho- proteins were normalized to
total protein. Abbreviations: PBS: phosphate buffered saline, LLC: Lewis lung
carcinoma. Two-way (Genotype x LLC) was used. $ Main Effect of LLC. # Main Effect
of AMPK KO.
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the fasting suppression of mTORC1 signaling and protein synthesis in LLC tumor bearing mice.
Effect of feeding on skeletal muscle protein turnover
Due to different animal cohorts being used because of tamoxifen use, we first
need to validate the feeding response in PBS mice (Table 3-6). Feeding suppressed
AMPK 0.4-fold without altering common downstream targets of AMPK (Figure B-5).
Regarding autophagy associated signaling, LC3BII/I ratio was reduced with feeding
which was due to an increase in LC3BI (p=0.002) without changes in LC3B II (p=0.518).
As expected, feeding increased AKT 0.4-fold, rpS6 6.2-fold, and protein synthesis 0.9fold compared to fast mice (Figure B-3). Lastly, feeding did not alter PGC1α or OPA-1,
but was sufficient to marginally reduce DRP1 S616 0.3-fold and FIS-1 0.4-fold (Figure
B-3). Taken together, these data highlight the anabolic response of 1-hr feeding in nontumor-bearing mice that received tamoxifen confirming that tamoxifen treatment (used to
knockout AMPK in skeletal muscle) did not alter feeding associated signaling.
Effect of muscle-specific AMPK loss on skeletal muscle’s feeding regulation of
skeletal muscle protein turnover
We have previously shown that feeding and muscle-specific AMPK loss
increased muscle protein synthesis independently. We next sought to determine if AMPK
loss regulated the feeding response. AMPK loss suppresses AMPK, ACC, and FOXO3a,
which is not further lowered by feeding in the tumor-bearing mouse (Figure B-6). To
validate the feeding response, AKT phosphorylation increased in both fed conditions
(Figure 3-9). Interestingly, AKT phosphorylation was further increased in the fed
condition in AMPK KO mice (Figure 3-9). RpS6 was increased by feeding in AMPK
WT mice compared to AMPK WT fast mice (Figure 3-9). AMPK KO fast and fed mice
had increased rpS6 compared to AMPK WT fast mice. Interestingly, puromycin
incorporation was not further increased with feeding in AMPK KO PBS mice (Figure
3-9). Taken together, these data suggest that AMPK loss does not further induce the
mTORC1 and protein synthesis response to feeding in PBS mice. Interestingly, LC3BII/I
ratio was suppressed by feeding, and occurs independent of AMPK (Figure B-5). We
next sought to determine AMPK’s regulation of the feeding response in LLC mice. We
have previously shown that Akt/mTORC1 signaling and protein synthesis are suppressed
in fast and fed LLC mice compared to PBS mice. Additionally, we have shown that the
loss of AMPK in LLC mice can improve mTORC1 and protein synthesis in the fast
condition compared to PBS. We report that there were main effects of feeding to increase
AKT and rpS6 phosphorylation and protein synthesis without any effects by AMPK KO
(Figure 3-9). These data identify that AMPK’s regulation of feeding’s regulation on
muscle Akt/mTORC1 and protein synthesis is not additive, suggesting that feeding and
AMPK loss in the fast condition are independently capable of increasing muscle proteins
synthesis.
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Table 3-6.

Whole-body response to feeding in PBS and LLC male mice

Outcomes

Pellet Consumption (g)
Blood Glucose (mg/dl)
Plasma Insulin (ng/mL)
Stomach Mass (mg)
Empty Stomach (mg)
Stomach Content (mg)

Fast
N=17

PBS

99 (5)
0.211 (0.006)a
428 (18)
154 (4)
274 (19)

Fed
N=15

0.40 (0.04)
222 (9)#
0.830 (0.083)b
677 (68)#
147 (2)#
530 (67)#

Fast
N=20

LLC

90 (5)
0.253 (0.025)a
349 (22)
156 (8)
192 (20)

Fed
N=15

0.40 (0.04)
222 (8) #
0.439 (0.076)a
637 (43)#
136 (5)
501 (40) #

Notes: There were no effects of AMPK KO on whole-body response to feeding therefore
PBS and LLC AMPK WT and AMPK KO mice in the fast or fed condition are combined
to show the summary data. Data are presented as Mean (SEM). Abbreviations: mg:
milligrams, PBS: phosphate buffered saline, LLC: Lewis lung carcinoma, g: grams,
mg/dl: milligrams per deciliter, ng/mL: Nanograms per milliliter, and ME: Main Effect.
Unpaired T-test was used to compare PBS and LLC fed pellet consumption. Two-way
ANOVAs were used to compare PBS and LLC in the Fast and Fed condition. #ME of
Fed. If an interaction was present; different letters were used to differentiate differences
between groups. Statistically significant p<0.05.
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Figure 3-9. Effect of muscle-specific AMPK loss on skeletal muscle’s feeding
regulation of Akt/mTORC1 signaling and protein synthesis
Notes: Data are presented as mean ± SEM. A. Study Design. Male C57Bl/6J mice were
injected with PBS or LLC cells between 10-11 wks. of age. Mice were fasted during the
dark cycle and sacrificed at the start of the light cycle in the fast condition or given access
to a food pellet for 1hr (fed) then sacrificed. B. Phospho-AKT to total ratio in PBS
AMPK WT and AMPK KO mice in the fast or fed condition. C. Phospho-rpS6 to total
ratio in PBS AMPK WT and AMPK KO mice in the fast or fed condition. D. Puromycin
incorporation in PBS AMPK WT and AMPK KO mice in the fast or fed condition. E.Phospho-AKT to total ratio in LLC AMPK WT and AMPK KO mice in the fast or fed
condition. F. Phospho-rpS6 to total ratio in LLC AMPK WT and AMPK KO mice in the
fast or fed condition. G. Puromycin incorporation in LLC AMPK WT and AMPK KO
mice in the fast or fed condition. White gastrocnemius muscle was for protein expression.
Phospho- proteins were normalized to total protein. Abbreviations: PBS: phosphate
buffered saline, LLC: Lewis lung carcinoma. Two--way (Genotype x LLC) was used #Main Effect of Fed. If there was an interaction, different letters were used to determine
what groups were different
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Discussion
Cancer-induced cachexia disrupts skeletal muscle protein turnover in the basal
condition (decreasing protein synthesis and increasing protein degradation). In preclinical models, our laboratory has demonstrated altered protein turnover through the
suppression of anabolic signaling via mTORC1 which coincided with the chronic
activation of AMPK (White, Baynes, et al., 2011). We have recently reported that
mTORC1 signaling exhibits diurnal fluctuations in response to changes throughout the
day in feeding and activity (Counts et al., 2020). Furthermore, the cachectic environment
disrupts these diurnal fluctuations, and suggest a link between disruptions in feeding and
activity behaviors with the progression of cachexia and altered mTORC1 signaling
(Counts et al., 2020). Taken together, cachexia suppresses muscle protein synthesis
which coincides with an increase in muscle AMPK signaling in the basal condition.
Therefore, we extended previous studies by examining if tumor-bearing mice had the
capacity for feeding to increase muscle protein synthesis. We report that pre-cachectic
tumor-bearing mice increased muscle Akt/mTORC1 signaling and protein synthesis in
response to feeding. Interestingly, feeding was sufficient to lower the elevated AMPK in
pre-cachectic tumor-bearing mice. Tumor-bearing mice have overall suppressed
Akt/mTORC1 signaling and protein synthesis, independent of the fast or fed condition
and AMPK regulates the fasting suppression of muscle protein synthesis in pre-cachectic
tumor-bearing mice. These findings provide novel insight into the regulation of
Akt/mTORC1 signaling and protein synthesis in response to feeding.
Anabolic resistance is defined as the reduced stimulation to an anabolic stimulus
(Morton et al., 2018). Cancer cachexia has been routinely considered to produce anabolic
resistance in skeletal muscle (Hardee et al., 2017). It is generally understood that cancer
cachexia induces muscle catabolic signaling and is consistent within the field, however
far less is understood about anabolic signaling (Penna, Ballaro, Beltra, et al., 2019). To
date, the evidence is equivocal, and this can largely be attributed to the variability within
the cancer patient population (Antoun & Raynard, 2018; Paulussen et al., 2021). For
example, in the patient population considerations such as cancer type, treatments, time
since diagnosis, age, and stage of cachexia are contributing to the equivocal patient data.
Furthermore, in rodent models of cancer cachexia, we know that suppressed anabolic
signaling is associated to cancer cachexia progression (Hardee, Counts, et al., 2018;
White, Baynes, et al., 2011) and glucose administration (White et al., 2013). Importantly,
recent data has highlighted the disruption in diurnal behaviors and muscle mTORC1
signaling in cachectic mice (Counts et al., 2020) therefore we extend these findings by
reporting that LLC tumor-bearing mice can induce Akt/mTORC1 signaling and protein
synthesis in response to feeding. It is possible, that the increased amino acid availability
from feeding induced mTORC1 and protein synthesis, and it is well known that feeding
induces insulin to activate AKT; both identifying that pre-cachectic mouse muscle has the
ability to response to feeding. Future studies are required to examine if insulin and amino
acid availability are both required to induce muscle protein synthesis in pre-cachectic
tumor-bearing mice. In agreement with previous studies, we show that mTORC1
signaling and protein synthesis were overall lower in LLC tumor-bearing mice,
independent of the fast or fed condition. We also show that the suppressed mTORC1
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signaling is associated to fat mass; consistently mentioned as a phenotypic change that
occurs early during cancer cachexia progression. It is interesting to speculate that
cachectic skeletal muscle has the capacity to respond to an anabolic stimulus and
improving the basal condition (herein the fast condition) is of more importance.
Furthermore, herein we used a robust anabolic stimulus of a mixed meal and future
studies should investigate if single nutrients are sufficient, and if cachexia progression
disrupts the response.
Our lab and others have shown that the cachectic environment induces chronic
activation of aberrant AMPK (Penna, Ballaro, Martinez-Cristobal, et al., 2019; White,
Baynes, et al., 2011). Feeding is sufficient to lower muscle AMPK and the loss of AMPK
is sufficient to induce mTORC1 signaling (Bujak et al., 2015). Therefore, we wanted to
examine if the suppressed mTORC1 signaling in the basal condition was regulated by
AMPK. We used the skeletal muscle inducible mouse to knockout AMPK only in
skeletal muscle (Fix et al., 2021). We found that muscle-specific AMPK loss in the
tumor-bearing mouse was sufficient to induce mTORC1 signaling and protein synthesis,
suggesting that fasting suppression of mTORC1 and protein synthesis in tumor-bearing
mice is in part, regulated by AMPK. These findings have significant implications because
we know AMPK is elevated across a wide range of pre-clinical cachexia models and in
the patient population, thus identifying to be a consistent cachexia phenotype in muscle.
While we highlight the regulation of AMPK in skeletal muscle, given the range of
functions of AMPK we are not suggesting developing pharmacological targets to inhibit
AMPK but report a regulatory point of interaction. Future studies should determine the
direct connection between AMPK and mTORC1 to provide a more targetable approach.
Additionally, we are reporting the effects of AMPK loss, it would also be beneficial to
determine what is activating AMPK during fasting in cachectic skeletal muscle in hopes
of finding the regulator of AMPK in pre-cachectic muscle. Feeding is a sufficient
stimulus to lower AMPK. We extend these findings by identifying that tumor-bearing
mice can lower the elevated muscle AMPK by feeding. Additionally, in the fasting
condition, mTORC1 signaling and protein synthesis are suppressed which can be
improved by AMPK loss. Interestingly, we found that AMPK loss and feeding are not
additive in further increasing mTORC1 signaling and protein synthesis in tumor or nontumor-bearing mice. It is interesting to speculate if mTORC1 signaling and protein
synthesis had achieved their peak activity, thus not allowing for an additive effect. This
would further support the idea of completing multiple anabolic insults to improve
anabolic signaling. It is possible that TSC1/2 is the regulatory point of interaction
because AMPK and AKT both signaling through TSC1/2 to alter mTORC1, however this
is outside the scope of this study and requires further investigation. These findings are
important because it suggest that one of these stimuli are sufficient to improve muscle
protein synthesis, but together are not additive. Future studies should further understand
why AMPK loss and feeding do not additively increase muscle protein synthesis in precachectic mice. Lastly, future studies should determine if cachectic skeletal muscle has
the capacity to increase muscle protein synthesis in response to feeding.
Skeletal muscle AMPK has known regulation to not only inhibit mTORC1, but
can also induce glycogen synthesis, autophagy, and mitochondrial biogenesis (Steinberg
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& Jorgensen, 2007). While whole body AMPK loss is embryonic lethal (Viollet et al.,
2009), muscle-specific loss of AMPK has a range of phenotypes and functions dependent
on the isoforms lost (Kjobsted et al., 2018). In summary, the loss of AMPK subunit α or
β result in impaired muscle function and substrate utilization whereas γ functions are less
known because α or β will compensate. Interestingly, muscle mass changes with subunit
loss are inconsistent, likely due to knockout durations and efficacy of the knockout and
subunit compensation. We report that AMPK loss did not prevent muscle wasting in LLC
mice, despite elevated mTORC1 signaling and protein synthesis. There are several
potential reasons for this; first, there were no differences in tumor mass or growth rate in
LLC AMPK WT and LLC AMPK KO mice therefore the tumor and its surrounding
environment are still developing thereby secreting tumor derived factors that can alter the
muscle’s environment. In addition, skeletal muscle mTORC1 and protein synthesis
oscillate throughout the day in response to feeding and activity. It is interesting to
speculate that throughout the day, mTORC1 and protein synthesis are similar in AMPK
KO and AMPK WT mice, and once there is a stress (herein used as a 12hr fast), the stress
is less in the AMPK KO mice. It is has been hypothesized that basal lowering of
mTORC1 and protein synthesis overtime can result in decreased muscle mass (Yoon,
2017), possibly further supporting the evidence that LLC AMPK KO mice might not be
regulating the daily fluctuations in mTORC1 and protein synthesis, but only elicit
regulation during stressed conditions. Nonetheless, this does not discount our data as we
highlight that when we stress the system by a 12hr fast in tumor-bearing mice, we can
induce muscle protein synthesis by knocking out muscle AMPK. In summary, regulators
of AMPK and AMPK’s regulation are very complex, future studies should determine
what upstream regulators and downstream effectors are eliciting altered muscle signaling,
as this would provide a more targetable outcome.
Skeletal muscle AMPK is known to directly target ACC, FOXO3a, and ULK1.
We report that AMPK subunit α loss reduces downstream ACC and FOXO3a, without
altering ULK1. Phosphorylation of ACC S79 has known regulation to inhibit ACC’s
function causing a reduction in malonyl-CoA and increase fatty acid oxidation and
phosphorylation of FOXO3a S413 activates transcription of energy-producing pathways.
Interestingly, we report that ULK1S555 was not reduced by AMPK KO mice. It’s
interesting to speculate the effect of AMPK loss on its downstream mechanisms. For
example, muscle AMPK subunit α loss does not alter basal whole body oxygen
consumption or fuel utilization, whereas muscle AMPK subunit α loss does alter whole
body and muscle’s response to fasting and exercise (Fentz et al., 2015). Alternatively,
AMPK subunit β loss impairs volitional activity and mitochondrial biogenesis. With
respect to signaling, AMPK subunit β suppressed ULK1S555 and ACC2, while AMPK
subunit α loss does not alter ULKS555 but does reduce ACC and FOXO3a (Fix et al.,
2021). It is interestingly to speculate the role of each subunit under healthy conditions,
but due to the compensatory mechanism of AMPK this might provide difficulty.
Additionally, given the known elevation in AMPK and associated signaling in cachectic
skeletal muscle, understanding the functionality of each AMPK subunit during
differential conditions (herein we used fasting) can aid in providing a more therapeutic
target. However, future studies are warranted to understand AMPK subunit function
during cancer cachexia progression.
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Each study is not without limitations. A limitation of this study is that we
examined males, not females. Sex as a biological variable, especially during cancer
cachexia has only minimally been investigated. While this warrants further examination
there are several considerations that need to be addressed. First, we used tamoxifeninducible muscle-specific knockout mice, tamoxifen binds to the estrogen receptors
throughout the body thereby inhibiting the receptors effects on tissues. It has yet to be
considered if the sudden loss of estrogen associated signaling impact on skeletal muscle,
in an environment with high estrogen levels, females. Next, indices of cachexia are less
common in female mice compared to male mice, which has been linked to
hypogonadism. Additionally, there is a possibility that the 1-hr time difference between
fed and fast conditions could intrinsically be different. However, there is sufficient
circadian rhythm data to identify that 1-hr difference between sacrifice times will not
elicit an intrinsic difference in muscle signaling. Therefore, it is very unlikely that the 1hr time difference is going to alter skeletal muscle signaling. The LLC model is not an
orthotopic model of lung cancer. There are potential alternative approaches to examining
lung cancer in pre-clinical models however, orthotopic models of lung cancer are
commonly completed in Balb/c mice or immunodeficient mice, which does not allow for
examination of muscle-specific inducible models or for the normal immune response.
Lastly, some transgenic models of cancer cachexia utilize tamoxifen administration, a
tumor inducer, and would be a significant confounder when using to elicit a musclespecific knockout (Kellar et al., 2015; Safari & Meuwissen, 2015). Importantly, the LLC
model is commonly used due to its tumorigenic properties, responsiveness to
chemotherapy, and ability to metastasize to the lungs and liver (Kellar et al., 2015), thus
allowing us to use a well characterized model to examine cancer cachexia progression.
Conclusion
In conclusion, feeding has regulation to increase muscle Akt/mTORC1 and
protein synthesis, while lowering AMPK signaling. We report the novel finding that precachectic LLC tumor-bearing do have the capacity to elicit an increase in muscle
Akt/mTORC1 signaling and protein synthesis. Importantly, LLC tumor-bearing mice
have overall suppressed muscle Akt/mTORC1 signaling and protein synthesis in the fast
and fed condition. Lastly, muscle-specific AMPK loss has regulation on the fasting
suppression of muscle mTORC1 and protein synthesis in pre-cachectic muscle. Future
studies should examine if cachectic muscle has the capacity to increase muscle
Akt/mTORC1 signaling and protein synthesis. Additionally, further work is required to
determine why muscle AMPK loss in combination with feeding did not restore impaired
muscle protein synthesis in pre-cachectic tumor-bearing mice.
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CHAPTER 4. EXAMINATION OF WHETHER MUSCLE GP130 SIGNALING
AFFECTS THE FEEDING REGULATION OF AMPK DURING CANCER
CACHEXIA
Introduction
Inflammation has been implicated as a key mediator of cancer-induced cachexia
leading to chronic elevation of skeletal muscle STAT3 and MAPK activity (Deans &
Wigmore, 2005). Glycoprotein-130 (gp130) is a regulatory point of interaction between
systemic inflammation and JAK/STAT and MAPK muscle signaling (White & Stephens,
2011). We have previously reported muscle gp130 loss prevented LLC induced muscle
wasting and restored STAT3 and MAPK signaling (Puppa, Gao, et al., 2014).
Interestingly, the LLC model has known disruptions in mitochondrial function prior to
muscle wasting (Brown et al., 2017). Additionally, disruptions to the muscle
mitochondria are known to induce AMPK, thereby accelerating muscle wasting
(VanderVeen et al., 2017). Given that muscle gp130 can regulate mitochondrial quality
control (Hardee, Counts, et al., 2018), identifying if these are linked to cachexia’s
disruption of muscle protein synthesis are warranted.
While it is well established that muscle protein breakdown is activated during
wasting, whether suppressed protein synthesis regulation contributes to muscle mass loss
during cachexia is less known. To date, only a few studies have examined muscle protein
synthesis in cancer patients (Dworzak et al., 1998; Emery et al., 1984; van Dijk et al.,
2015; van Dijk et al., 2019). While there are only a few human studies, it has been
concluded that changes in both basal and postprandial muscle protein synthesis and
breakdown rates contribute to the muscle wasting observed in cachectic cancer patients
(Brook et al., 2017; Horstman et al., 2016). A majority of our understanding of protein
synthesis during cachexia is examined in murine models, but reports have also shown
protein synthesis rates reduced in cachectic patients (Dworzak et al., 1998). We have
routinely shown suppressed protein synthesis during the progression of cachexia in Apc
Min/+
mice, and this suppression corresponded to a reduction in muscle protein mTORC1
and IGF1 (White, Baynes, et al., 2011). This early suppression of protein synthesis during
cachexia did not correspond to an initial change in AMPK, since AMPK activity does not
increase till late-stage cachexia under basal conditions (White, Baynes, et al., 2011).
Interestingly, IL-6 receptor antibody was sufficient to attenuate muscle mass loss
and AMPK signaling, however IL-6 antibody was not sufficient to restore protein
synthesis or mTORC1 (White, Baynes, et al., 2011). Additionally, we have examined a
role for systemic IL-6 in suppressing protein synthesis during cachexia (White et al.,
2013). Cytokine dosing is commonly used in cell culture to provide a high inflammatory
environment. We have previously shown that IL-6 exposure has the capacity to decrease
C2C12 myotube diameter and suppress mTORC1 signaling, and when AMPK is blocked
the IL-6 suppression of protein synthesis is relieved (White et al., 2013). In the LLC
tumor model, downstream targets of mTORC1; 4EBP-1 and rpS6, are suppressed during
cachexia (Puppa, Gao, et al., 2014). Interestingly, gp130 loss did not improve the
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suppressed mTORC1 signaling, but did prevent muscle wasting (Puppa, Gao, et al.,
2014). Furthermore, LLC tumor derived media on C2C12 myotubes suppressed protein
synthesis which coincided with STAT3 and AMPK phosphorylation (Gao & Carson,
2016). AMPK, but not gp130 inhibition rescued protein synthesis suppression.
Collectively, these studies highlight that suppressed muscle protein synthesis and
mTORC1 signaling is linked to IL-6/STAT3, but alone is not sufficient to restore protein
synthesis during cachexia progression.
Several studies have implicated the role of gp130 signaling on preventing and/or
treating cancer induced cachexia. First, skeletal muscle-specific STAT loss prevented
LLC induced muscle wasting and grip strength loss, without altering tumor mass (Silva et
al., 2015). Interestingly, in a genetic model of cancer induced cachexia (Apc Min/+ mice),
IL-6 receptor antibody preserved some body weight and muscle mass loss (White,
Baynes, et al., 2011). Furthermore, IL-6 receptor antibody was sufficient in reducing
STAT3 and AMPK signaling without rescuing the suppression of mTORC1. We have
previously administered PDTC (anti-inflammatory) to mice injected with LLC cells,
while muscle STAT3 was reduced, muscle mass was not preserved (Puppa, Gao, et al.,
2014). Lastly, IL-6 induced mitochondrial dysfunction and fatigue requires skeletal
muscle gp130 (VanderVeen et al., 2019). Interestingly, cachexia has known disruptions
in mitochondrial function prior to muscle wasting (Brown et al., 2017) and theses
disruptions to the muscle mitochondria are known to induce AMPK, thereby accelerating
muscle wasting (VanderVeen et al., 2017). Given that muscle gp130 can regulate
mitochondrial quality control (Hardee, Counts, et al., 2018), whether gp130 is linked to
cachexia’s disruption of protein synthesis by feeding is warranted. Therefore, the purpose
of aim 2 examined if muscle gp130 signaling regulates the feeding regulation of AMPK
during cancer cachexia. We hypothesized that gp130 signaling would be required for the
feeding regulation of AMPK during cancer cachexia and would be early event in cancer
cachexia.
Methods
Animals
To examine the regulation of gp130 loss in tumor-bearing mice, gp130 knockout
mice and floxed controls were generated (see next section for details). Mice were kept on
a 12:12h light/dark cycle beginning at 6:00AM and were given rodent chow ad libitum
(Harlan Teklad Rodent Diet, #8604, Harlan, Indianapolis, IN, USA). Between 17-18wks
of age, male gp130 knockout or floxed controls were either injected with PBS or LLC
cells then sacrificed 4 weeks later. All mice were fasted for 12hrs during the dark cycle.
At the start of the light cycle, mice were either given ad libitum access to a food pellet
(fed) or sacrificed at the end of fast (fast).
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Generation of gp130 skeletal muscle deletion
To generate a skeletal muscle-specific knockout of gp130, mice that contained
individually floxed alleles for gp130 were a kind gift from Dr. Colin Stewart’s
Laboratory (Laboratory of Cancer and Development Biology, National Cancer Institute,
U.S. National Institutes of Health (NIH), Frederick, MD, USA) in collaboration with Dr.
Lother Hennighausen (Laboratory of Genetics and Physiology, National Institute of
Diabetes and Digestive and Kidney Disease, NIH, Bethesda, MD) (Zhao et al., 2004).
The skeletal actin (HSA) promoter-driven expression of a Cre recombinase flanked by
mutated estrogen receptors (HSA- MCM) (McCarthy et al., 2012). Tamoxifen inducible
Mer Cre Mer driven by a human skeletal actin promoter (HSA) mouse were purchased
from Jackson Laboratories (Bar Harbor, ME, USA). Male tamoxifen-inducible skeletal
muscle gp130 (KO) knockout mice and floxed (Flox) controls were produced. Finally,
the gp130 HSA Cre (gp130 KO) mice or gp130 (floxed control) mice were injected with
PBS or LLC. At approximately 10-11 weeks of age, all gp130 KO and floxed control
mice received tamoxifen injection (I.P. 2mg) once daily for 5 consecutive days
(Harfmann et al., 2016), and then underwent a 2-week washout period before PBS or
LLC injections (Figure 4-1).
Lewis lung carcinoma cell inoculation
Between 13-14 weeks of age, gp130 mice were injected with either phosphate
buffered saline (PBS) or 1 x 106 Lewis lung carcinoma (LLC) cells subcutaneously in the
right flank under anesthesia for less than 3 minutes (Puppa, Gao, et al., 2014). A total of
38 mice were injected with LLC cells and 32 mice were injected with PBS. Ninety-two
percent of the LLC injected mice reached the studies endpoint. A mouse reached the
studies endpoint if the following criteria were met (1) mouse reached 30 days post tumor
inoculation, (2) >20% body weight loss from day 10 after day 25, or (3) had a tumor
>3cm in width or length after day 25. Once an endpoint was achieved, the mouse was
prepared for tissue collection and euthanized within 24 hrs. At day 22-23, 4 mice had
ulcerated tumors and was not included in the analysis. To be included in the study, mice
needed to achieve at least 25 days post tumor inoculation. Therefore, a total of 35 male
LLC injected mice were used in these experiments. Tumor volume and body weight were
measured every 5 days to calculate tumor growth. Tumor volume was calculated by the
same investigator and caliper using the following equation: ½ (width2xlength) (Jensen et
al., 2008).
Cell culture experiments
All cells were purchased through ATCC (Manassas, VA) and after pass #5 and within the
10 passages. Murine C2C12 myoblasts (CRL-1772) or Lewis lung carcinoma (LLC;
CRL-1462) cells were maintained at 37C, 5% CO2 in Growth Media (GM): Dulbecco’s
Modified Eagle Media (DMEM; Gibco #11995-065) supplemented with 10% FBS,
50U/ml penicillin, and 50 g/ml streptomycin.
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Figure 4-1.

Muscle-specific loss of gp130 in male mice

Notes: Data are presented as mean ± SEM. Male C57Bl/J mice were used from UTHSC
breeding colony. A. Breeding schematic to produce gp130 +/+ with and without HSAmer-cre-mer. Created with BioRender.com. B. Study Design. C. Example of tail snip
confirmation of animal genotype. D. Muscle-specific loss of gp130 and associated
downstream signaling. Phospho- proteins were normalized to total protein.
Abbreviations: gp130: glycoprotein 130, WT: Wildtype – gp130 +/+ (WT), KO:
Knockout – gp130 -/- (KO), PBS: phosphate buffered saline, LLC: Lewis lung
carcinoma, mg: milligrams
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C2C12 myotube differentiation and conditioned media collection
C2C12 myoblasts were seeded on type I collagen-coated plates at a density of
9.0x10 cells per well (6-well plate) in Growth Media (GM): Dulbecco’s Modified Eagle
Media (DMEM; Gibco #11995-065) supplemented with 10% FBS, 50U/ml penicillin,
and 50 g/ml streptomycin. To induce myoblast differentiation, cells were rinsed with
PBS and switched to differentiation media (DM): DMEM supplemented with 2% heatinactivated horse serum, 50U/ml penicillin, and 50 g/ml streptomycin to form
myotubes. Media was replenished every 48 h, and experiments were performed starting at
day 5 of differentiation when multinucleated contractile myotubes are present.
4

LLC cells, a murine model that promotes cachexia in mice, was cultured as
described above. Briefly, 2x106 cells were seeded in 100 mm tissue culture-treated plates
in GM. Tumor cell CM was collected at ~90% confluence 48 h post cell seeding and
spun down at 4000 rpm for 5 min to remove cell debris. Cells on the plate were pelleted
and counted via trypan blue exclusion test to ensure an equivalent number of cells on the
plate, with a final density averaging from 7.0 – 9.0 x 106 cells per culture dish. CM was
stored for one-time use in aliquots at -20C and used within 2 months, then thawed in a
warm water bath at the time of the experiment. GM with no cells was used as a media
control.
Treatment of myotubes
At the time of the experiment, GM control or LLC CM is diluted with 50%
serum-free DMEM for a final serum concentration of 5% FBS. 50% CM was chosen as it
has been shown to produce significant myotube atrophy (Pin et al., 2018; Zhong et al.,
2019). It should be noted that myotubes were differentiated up to day 5 in 2% Horse
Serum, thus upon CM addition, myotubes were switched to a higher serum environment,
which can induce myotube hypertrophy (von Walden et al., 2016). CM was replenished
after 24hr. In a separate experiment, differentiated myotubes at day 5 were treated with
50% GM or LLC CM (LLC + GM) for 48hrs. After 48hrs, media was removed, and cells
were placed in minimal essential media to quiesce the myotubes. After 60minutes, 20nM
of insulin was dosed on the cells for 60 minutes and then cells were scraped. Differentiated C2C12 myotubes were treated with 10ng/ml of IL-6 (Sigma-Aldrich) or LIF
(Thermo Scientific, Waltham, MA) for 24hrs. After 24hrs, media was removed, and cells
were placed in minimal essential media to quiesce the myotubes. After 60minutes, 20nM
of insulin was dosed on the cells for 60 minutes and then cells were scraped.
Myotube diameter
Myotube diameter was quantified as previously described (Gao & Carson, 2016)
with the following modifications. C2C12 myotube diameter was quantified using ImageJ
software (National Institutes of Health, Bethesda, MD). Digital images were captured at
20X objective brightfield. Five non-overlapping images were captured within each well,
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and three images were randomly chosen for analysis. The analysis used unmodified tiff
images accessed in NIH ImageJ software. A blinded investigator randomly took diameter
measurements of 6 myotubes per image based on pre-set inclusion/exclusion criteria:
elongated structure with distinct membrane outlines, little to no cellular debris, no
branching points. The average diameter per myotube was calculated as the mean of 8
measurements taken along the myotube length.
Western blot
Western blot analysis was performed as previously described (Hardee et al., 2014)
and extensive methodology can be found in extended methods section. Briefly, frozen red
and white gastrocnemius muscle was homogenized in lysis buffer and protein concentration was determined by the Bradford method. Crude gastrocnemius muscle
homogenates were fractionated on 8-12% SDS-polyacrylamide gels and transferred to
PVDF membranes. Membranes were stained with Ponceau red to verify equal loading
and transfer. Membranes were then blocked at room temperature for 1hr. in 5% non-fat
milk or 5% BSA-Tris-buffered saline with 0.1% Tween-20 (TBST). Commercially
available phosphorylated and total protein primary antibodies for rpS6, AKT, AMPK,
STAT3, ERK, P65, P38, gp130 were raised in rabbit. RpS6, AKT, AMPK, STAT3, ERK,
P65, and P38 phosphorylation antibodies were expressed relative to total protein on the
same gel and quantified as phosphorylation to total ratio. Commercially available total
protein primary antibodies for MuRF-1, Atrogin-1, PGC1α, OPA1, and FIS1 were raised
in rabbit. Puromycin incorporation was purchased from Millipore and raised in mouse.
Briefly, primary antibodies were incubated overnight in 5% TBST milk or 5% TBST
BSA. Membranes were then incubated in 5% milk-TBST containing anti-rabbit or antimouse IgG horseradish-peroxidase conjugated secondary antibody purchased from cell
signaling for 1h at room temperature. Enhanced chemiluminescence (ECL) (GE
Healthcare Life Sciences, Piscataway, NJ) was used to visualize the antibody-antigen
interactions. Immunoblot images were collected using a digital imager (Invitrogen
iBright, Waltham, MA) and quantified by densitometry using imaging software (Image J;
NIH). Please see end of document for details of fcatalogue numbers, companies,
dilutions, incubation durations, and secondary substrate (Figure B-1).
Statistical analysis
Pre-planned unpaired T-Test were used to compare PBS and LLC mice. Preplanned unpaired T-Test were used to compare to validate the feeding response and
knockout signaling Two-way (Tumor x Feeding) (Feeding x Genotype) ANOVAs were
used, and Tukey’s post-hoc analysis was used when appropriate. Prism 8 (GraphPad) was
used for statistical analysis. All results are reported as means ± standard error of mean
(SEM). Statistical analysis was performed using GraphPad (Prism 8 for Mac OS X, La
Jolla, Ca). Level of significance for all measures was set at p ≤ 0.05.
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Results
Gp130 loss validation
Skeletal muscle-specific knockout of gp130, mice that contained individually
floxed alleles for gp130 were a kind gift from Dr. Colin Stewart’s Laboratory
(Laboratory of Cancer and Development Biology, National Cancer Institute, U.S.
National Institutes of Health (NIH), Frederick, MD, USA) in collaboration with Dr.
Lother Hennighausen (Laboratory of Genetics and Physiology, National Institute of
Diabetes and Digestive and Kidney Disease, NIH, Bethesda, MD) (Zhao et al., 2004).
Male tamoxifen-inducible skeletal muscle gp130 (KO) knockout mice and floxed (Flox)
controls were produced (Figure 4-1). Genotyping was confirmed by tail snips after 21
days neonatal (Figure 4-1). Around 10 weeks of age, mice were given tamoxifen
injection once a day for 5 consecutive days to bring the LoxP-MerCreMer bound binding
sites together to remove the floxed genes of interest. After a two-week washout period,
mice were injected with either phosphate buffered saline (PBS) or Lewis lung carcinoma
(LLC) cells and monitored for 4 weeks (Figure 4-1C). To validate gp130 loss and
associated signaling, white gastrocnemius muscle was used. Gp130 KO mice have
reduced gp130 (-47%), STAT3 (-83%), and ERK (-46%) without changes to P65 or P38
identifying the specificity of gp130 loss (Figure 4-1).
Effect of gp130 loss on skeletal muscle signaling in non-tumor-bearing mice
Importantly, there were no differences in body weight over time, skeletal muscle
mass (gastrocnemius or hindlimb muscle mass), eWAT mass, or tibia length in gp130
WT mice compared to gp130 KO mice (Table 4-1). We highlight the ability to decrease
gp130 and associated signaling in skeletal muscle, which does not alter tissue mass and
body size in PBS treated male mice. To understand how gp130 loss alters skeletal muscle
signaling in tumor-bearing mice, we first need to determine what gp130 loss did to
skeletal muscle signaling in non-tumor-bearing male mice in the fast condition. All mice
were sacrificed at the start of the dark cycle following an overnight 12-hr fast. It is well
known that gp130 can disrupt mitochondrial quality control. Therefore, we examined
markers of mitochondrial quality control in white gastrocnemius muscle (Figure B-7).
PGC1α a marker of mitochondrial biogenesis was not altered by gp130 loss.
Additionally, FIS-1, a marker of mitochondrial fission, were not affected by gp130 loss.
Lastly, mitochondrial complex proteins (Figure B-7) were not altered by gp130 loss.
Gp130 associated signaling has known regulation on mTORC1 signaling, therefore, we
examined if gp130 plays a role in basal skeletal muscle anabolic signaling (Figure B-7).
Interestingly, gp130 loss did not alter AMPK, ULK, E3 ligases (MuRF-1 or Atrogin-1),
AKT, rpS6 or protein synthesis. Taken together, we show that following a 12-hr fast,
gp130 loss has regulation on immediate downstream targets, but does not regulate
mitochondrial quality control, AMPK, or mTORC1 signaling in white gastrocnemius
muscle.
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Table 4-1.
Muscle-specific gp130 loss on non-tumor-bearing mice animal
characteristics
Characteristics
BW Pre-tamoxifen (g)
BW Post-tamoxifen (g)
BW Pre-injection (g)
BW d10 (g)
BW End of Study (g)
BW∆ During Tamoxifen (%)
BW∆ During Treatment (%)
BW∆ d10 (%)
HMM (mg)
eWAT (mg)
Testes (mg)
Heart (mg)
Spleen (mg)
Tibia Length (mm)

gp130 WT gp130 KO
p-Value
N=16
N=15
24.2 (0.4) 24.4 (0.5)
0.488
24.9 (0.3) 24.9 (0.5)
0.564
26.9 (0.3) 26.5 (0.6)
0.888
28.2 (0.4) 27.2 (0.6)
0.338
29.1 (0.4) 28.7 (0.7)
0.964
2.9 (3.1)
2.4 (0.9)
0.686
7.5 (1.3)
8.4 (1.1)
0.583
3.0 (0.9)
5.6 (1.2)
0.072
204 (4)
208 (4)
0.476
340 (32)
437 (37)
0.055
187 (4)
188 (6)
0.871
161 (5)
147 (5)
0.065
80 (4)
73 (3)
0.239
17.4 (0.1) 17.3 (0.1)
0.280

Notes: Data are presented as mean ± SEM. Abbreviations: gp130: glycoprotein 130, BW:
body weight, mg: milligrams, eWAT: epididymal white adipose tissue, PBS: phosphate
buffered saline, +/+: wild-type mouse, -/-: knockdown mouse, mm: millimeter, g: grams,
and HMM: Hindlimb muscle mass. Unpaired T-Test were used to compare WT and KO.
p<0.05.
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Validation of muscle-specific gp130 loss in LLC tumor-bearing mice
To validate the efficacy of knocking out gp130 and associated signaling in LLC
tumor-bearing mice. Tail snips were conducted at neonatal 21 days and mice were
determined as having the double floxing of gp130 with or without the presence of hsac/+.
After tamoxifen washout, mice were injected with either PBS or LLC cells and sacrificed
4-weeks later (Figure 4-2). We first validated all mice by showing the knockdown
expression of gp130 in PBS and LLC gp130 WT and gp130 KO male mice (Figure
4-2B). Importantly, gp130 loss in LLC tumor-bearing mice was sufficient to reduce
STAT3, ERK, and P65 (Figure 4-2).
Muscle-specific gp130 loss in LLC tumor-bearing male mice does not alter tumor
growth, tumor mass, or indices of cachexia
Tumor volume increased from days 10-25 in LLC gp130 WT and KO mice
(p<0.001) with no difference between WT and KO mice (p=0.829) (Figure 4-3). There
were no differences in tumor growth rate between gp130 WT and KO LLC mice
(p=0.859; Figure 4-3). There were no differences in tumor mass between gp130 WT and
KO LLC mice (p=0.880; Figure 4-3C). There was a main effect of time (p<0.001) for
body weight during the study to increase at each time point (Table 4-2). There was a
main effect for LLC mice to have greater body weight change from day 10 (p<0.001),
without differences between gp130 WT and KO mice (p=0.713). When accounting for
tumor mass, there was a main effect for LLC mice to have decreased body weight at the
end of the study (p<0.001), without differences between gp130 WT and KO mice
(p=0.897). There was a main effect for LLC mice to have decreased gastrocnemius mass
(p<0.001), without differences between WT and KO mice (p=0.756). There was an
interaction for eWAT mass (Figure 4-3); there were no differences within each genotype
of PBS or LLC mice. LLC WT mice had decreased eWAT mass compared to PBS KO.
LLC KO had decreased eWAT from both PBS groups.
Effect of gp130 loss on AMPK/Akt/mTORC1 signaling and protein synthesis in
LLC tumor-bearing male mice
We examined the effect of gp130 loss in the fasting condition in PBS and LLC
mice (Figure 4-4). Gp130 loss in white gastrocnemius muscle suppressed AMPK in LLC
tumor-bearing mice (Figure 4-4). Interestingly, there was a main effect of gp130 loss to
reduce ULK1 (Figure 4-4). Gp130 loss was not sufficient to lower elevated Atrogin-1 in
LLC tumor-bearing mice (Figure 4-4). Interestingly, gp130 loss was not sufficient to
improve the basal suppression of muscle protein synthesis in LLC tumor-bearing mice
(Figure 4-5). There was a main effect for LLC to have reduced rpS6 and a main effect
for gp130 loss to further reduce rpS6 (Figure 4-5). Lastly, there was a main effect for
AKT to be reduced in LLC (Figure 4-5). Taken together, we highlight that gp130 loss
was sufficient to reduce AMPK without improving suppressed protein synthesis or
mTORC1 signaling in LLC tumor-bearing mice.
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Figure 4-2. Validation of muscle gp130 knockdown and associated downstream
signaling in LLC tumor-bearing male mice
Notes: Data are presented as mean ± SEM. Male C57Bl/J mice were used from UTHSC
breeding colony. A. Study Design. B. Validation of muscle-specific knockdown
expression of gp130 in PBS and LLC mice. C. Validation of gp130 knockdown in KO
PBS and LLC male mice. White gastrocnemius muscle was used for analysis. Created
with BioRender.com. Phospho- proteins were normalized to total protein. Abbreviations:
gp130: glycoprotein 130, WT: Wildtype – gp130 +/+ (WT), KO: Knockout – gp130 -/(KO), PBS: phosphate buffered saline, LLC: Lewis lung carcinoma, mg: milligrams. #
Main effect of KO, $ Main effect of LLC. N=9-16 per group.
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Figure 4-3. Muscle-specific loss of gp130 in LLC tumor-bearing male mice does
not alter tumor growth, tumor mass, or indices of cachexia
Notes: Data are presented as mean ± SEM. A. Study design. male C57Bl/6J mice were
injected with PBS or LLC cells between 10-11 wks. of age. Tumor volume and body
weight were taken every 5 days until sacrifice (28-30 days post tumor inoculation). B.Tumor growth rate from days 15-25. C. Tumor Mass at sacrifice. D. Body weight preinjection of PBS or LLC. E. Body weight end of study accounting to tumor mass. F.Body weight is calculated as the sacrifice body weight minus the tumor mass divided by
day 10 body weight. G. Gastrocnemius muscle mass at sacrifice. H. eWAT mass at
sacrifice. Phospho- proteins were normalized to total protein. Abbreviations: BW: body
weight, mg: milligrams, PBS: phosphate buffered saline, LLC: Lewis lung carcinoma, g:
grams. Unpaired t-test were used to compare PBS to LLC. Two-way (Genotype x LLC)
ANOVAs were used. Different letters note differences between time points within WT
and KO mice). $ Main effect of LLC.
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Table 4-2.
Effect of muscle-specific gp130 loss on animal characteristics in LLC
tumor-bearing male mice

Characteristics

Age Inoculated (wks)
BW Pre-tamoxifen (g)
BW Post-tamoxifen (g)
Days in Study (days)
BW Pre-inoculation (g)
BW d10 (g)
BW End of Study (g)
Tumor Weight (TW) (g)
BW – TW (g)
BW∆ from d10 (%)
Tumor Volume d15 (cm3)
Tumor Volume d20 (cm3)
Tumor Volume d25 (cm3)
Tumor Growth Rate (cm3/5days)
Soleus Weight (mg)
Gastrocnemius Weight (mg)
Tibialis Anterior Weight (mg)
HMM (mg)
Testes Weight (mg)
Seminal Vesicle Weight (mg)
eWAT (mg)
Spleen Mass (mg)
Plasma IL-6 (pg/ml)
Tibia Length (mm)

WT
N=16

PBS

14.2 (0.5)
24.2 (0.4)
24.9 (0.3)
26.8 (0.5)
26.9 (0.3)
28.2 (0.4)
29.1 (0.4)
29.1 (0.4)
3.0 (0.9)
7.3 (0.8)
128 (3)
43 (1)
205 (4)
189 (4)
215 (10)
341 (30)a,b
80 (4.1)
5.0 (0.8)
17.4 (0.1)

KO
N=15

14.1 (0.3)
24.4 (0.5)
24.9 (0.5)
26.1 (0.3)
26.5 (0.6)
27.2 (0.6)
28.7 (0.7)
28.7 (0.7)
5.6 (1.2)
8.1 (0.3)
128 (2)
44 (1)
206 (4)
186 (6)
232 (8)
444 (39)a
73 (3)
4.7 (0.5)
17.3 (0.1)

WT
N=16

LLC

14.9 (0.4)
23.7 (0.6)
25.2 (0.3)
27.1 (0.3)
26.7 (0.5)
27.4 (0.5)
29.7 (0.5)
4.0 (0.6)
25.7 (0.4)
-5.8 (2.3)
0.69 (0.01)a
1.52 (0.27)b
4.18 (0.75)c
0.361 (0.068)
7.0 (0.4)
117 (3)#
41 (1)#
189 (5)#
184 (4)
187 (10)#
231 (17)b,c
226 (23)#
21.7 (2.4)#
17.2 (0.1)

KO
N=18

13.9 (0.4)
23.5 (0.4)
24.3 (0.4)
26.0 (0.4)
25.9 (0.4)
27.1 (0.6)
29.4 (0.7)
3.8 (0.5)
25.6 (0.6)
-5.9 (1.0)
0.71 (0.15)a
1.86 (0.33)b
4.18 (0.63)c
0.347 (0.059)
7.3 (0.3)
114 (4)#
38 (2)#
183 (6)#
178 (40
200 (7)#
205 (24)c
243 (24)#
16.4 (3.3)#
17.2 (0.1)

Notes: Data are presented as Mean ± SEM. Male C57Bl/J mice were used from UTHSC
breeding colony. Sixty-five mice were randomly assigned to either PBS (N=31) or LLC
(N=34) based on their genotype of gp130 WT or gp130 KO. Then at the time of sacrifice
were either fasted or fed. There were no differences within each fast or fed condition of
PBS or LLC in either genotype therefore groups are combined here. Abbreviations: SEM:
Standard error of the mean, cm3: centimeters cubed, mg: milligrams, BW: body Weight,
TW: tumor weight, ∆: Change, %: Percent, LLC: Lewis lung carcinoma, PBS: Phosphate
Buffered Saline, mm: millimeters, and HMM: hindlimb muscle mass. Statistical
Significance p<0.05. Two-way ANOVA (2 genotype x 2 tumor) was used to compare
across groups. ME Genotype: ^, ME Tumor: #. Different letters mean there was an
interaction and different from other letters. One-way repeated measures ANOVA was
used to compare body weight overtime within each treatment and genotyped. One-way
ANOVA was used to compare tumor volume overtime within each genotype group of
LLC mice. Different letters mean there was an interaction and different from other letters.
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Figure 4-4.
mice

Muscle-specific gp130 loss reduces AMPK in LLC tumor-bearing

Notes: Data are presented as mean ± SEM. A. Study Design B. Phospho-AMPK to total
ratio in PBS and LLC fasted mice either gp130 WT or gp130 KO. C. Phospho-ULK1 in
PBS and LLC fasted mice either gp130 WT or gp130 KO. D. Atrogin-1 in PBS and LLC
fasted mice either gp130 WT or gp130 KO. E. PGC1α protein expression in PBs and
LLC fasted mice either gp130 WT or gp130 KO. F. FIS-1 protein expression in PBS and
LLC fasted mice either gp130 WT or gp130 KO. Phospho- proteins were normalized to
total protein. Abbreviations: PBS: phosphate buffered saline, LLC: Lewis lung
carcinoma, g: grams. Two-way ANOVAs (PBS or LLC vs WT or KO) were used.
*Groups are different. # Main effect of KO, $ Main effect of LLC.
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Figure 4-5. Muscle-specific gp130 loss does not rescue suppressed protein
synthesis in LLC tumor-bearing mice
Notes: Data are presented as mean ± SEM. A. Study Design. B. Phospho-AMPK to total
ratio in PBS fast and fed gp130 WT and gp130 KO mice. C. Phospho-AMPK to total
ratio in LLC fast and fed gp130 WT and gp130 KO mice. Phospho- proteins were
normalized to total protein. Abbreviations: PBS: phosphate buffered saline, LLC: Lewis
lung carcinoma. Two-way ANOVAs (PBS or LLC vs WT or KO) were used. * Different
between groups.
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Effect of muscle-specific gp130 loss on skeletal muscle’s feeding regulation of
skeletal muscle protein turnover
Due to different animal cohorts being used because of tamoxifen use, we first
validated that there were no differences in gp130 WT and KO mice whole-body response
to feeding, therefore these outcomes are combined. Importantly, whole-body response to
feeding in PBS and LLC mice was similar to previous aim1 (Table 4-3). We have shown
gp130 loss can reduce AMPK in LLC tumor-bearing mice. We next sought to determine
if gp130 loss regulates the feeding regulation of AMPK. We report that gp130 loss
blunted the reduction in AMPK in PBS mice (Figure 4-6). Feeding was sufficient to
lower AMPK in LLC mice; however, this response was not altered in gp130 KO mice
(Figure 4-6). Taken together, our results suggest that in pre-cachectic tumor-bearing
mice, gp130 loss disrupts the feeding regulation of AMPK. Previously, we have shown
gp130 loss does not rescue the suppression of mTORC1 or protein synthesis in LLC
tumor-bearing mice. Interestingly, gp130 loss lowered mTORC1 signaling, suggesting
some regulation. Therefore, we next sought to determine if gp130 loss regulates the
muscle’s anabolic response to feeding. In PBS mice, there was a main effect for feeding
to increase AKT and main effect for gp130 loss to increase AKT (Figure 4-7). Gp130
loss did not alter the feeding response in LLC tumor-bearing mice (Figure 4-7). Gp130
loss did not alter the feeding induction of rpS6 or protein synthesis in PBS mice (Figure
4-7). Interestingly, there was a main effect for gp130 loss to reduce rpS6 in LLC mice
and a main effect for feeding to increase rpS6. Gp130 loss did not alter the feeding
induction of protein synthesis in LLC mice (Figure 4-7). Interestingly, feeding can
reduce STAT3 and P65 protein expression in tumor-bearing mice (Figure B-8). Taken
together we highlight that the feeding regulation of mTORC1 signaling and protein
synthesis is partially regulated by gp130 in tumor-bearing mice.
Effect of LLC-conditioned media on Akt/mTORC1 response to insulin in C2C12
myotubes
LLC-conditioned media is commonly used to examine the effects of tumor
derived factors on C2C12 myotubes. LLC conditioned media suppresses myotube
diameter and myosin heavy chain-fast (Figure 4-8) compared to growth media control.
LLC-conditioned media induced myotube STAT3 and ERK protein expression (Figure
4-8) compared to GM control. Following 48hrs of conditioned media, media was changed
to minimal essential media for 60 minutes, then insulin was given to the cells (Figure
4-9). We report that insulin significantly induced Akt and rpS6 in GM treated myotubes
(Figure 4-9). Insulin was sufficient to induce Akt and rpS6 in LLC treated myotubes,
however the overall response was lower compared to GM. We next sought to examine if
cytokines (tumor derived factors) were inhibiting the overall response (Figure 4-10).
Interestingly, neither IL-6 nor Lif were sufficient to suppress the Akt or rpS6 in C2C12
myotubes. IL-6 nor Lif altered the insulin induction of Akt or mTORC1, despite having
elevated STAT3. Taken together, these results suggest that IL-6 nor Lif alone are
sufficient to inhibit basal Akt/mTORC1 signaling.
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Table 4-3.

Whole-body response to feeding in PBS and LLC male mice

PBS
Fast
Fed
Outcomes
N=14
N=17
Pellet Consumption (g)
0.61 (0.07)
Blood Glucose (mg/dl)
100 (5)
157 (5)^
Plasma Insulin (ng/mL) 0.40 (0.09) 1.09 (0.17)^
Stomach Mass (mg)
399 (39)a
801 (74)b
Empty Stomach (mg)
166 (7)
162 (3)
Stomach Content (mg)
241 (44)
640 (75)^

LLC
Fast
Fed
N=17
N=17
0.49 (0.06)
126 (5)#
192 (9)^#
0.29 (0.04)# 0.82 (0.12)^#
375 (36)a
652 (58)c
169 (10)
143 (6)
206 (34)
509 (56)^#

Notes: There were no effects of gp130 KO on whole-body response to feeding therefore
PBS and LLC AMPK WT and AMPK KO mice in the fast or fed condition are combined
to show the summary data. Data are presented as Mean (SEM). Abbreviations: mg:
milligrams, PBS: phosphate buffered saline, LLC: Lewis lung carcinoma, g: grams,
mg/dl: milligrams per deciliter, ng/mL: nanograms per milliliter, and ME: Main Effect.
Unpaired T-test was used to compare PBS and LLC fed pellet consumption. Two-way
ANOVAs were used to compare PBS and LLC in the Fast and Fed condition. #ME of
Fed. If an interaction was present; different letters were used to differentiate differences
between groups. Statistically significant p<0.05.
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Figure 4-6.

Muscle-specific gp130 loss disrupts AMPK’s reduction by feeding

Notes: Data are presented as mean ± SEM. A. Study Design. B. Phospho-AMPK to total
ratio in PBS fast and fed gp130 WT and gp130 KO mice. C. Phospho-AMPK to total
ratio in LLC fast and fed gp130 WT and gp130 KO mice. Phospho- proteins were
normalized to total protein. Abbreviations: PBS: phosphate buffered saline, LLC: Lewis
lung carcinoma. Two-way ANOVAs (PBS or LLC vs WT or KO) were used. *-Different
between groups.
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Figure 4-7. Muscle-specific gp130 loss regulation of Akt/mTORC1 signaling and
protein synthesis response to feeding in LLC tumor-bearing mice
Notes: Data are presented as mean ± SEM. A. Study Design. B. Phospho-AKT to total
ratio in PBS fast and fed gp130 WT and gp130 KO mice. C. Phospho-rps6 to total ratio
in PBS fast and fed gp130 WT and gp130 KO mice. D. Puromycin Incorporation in PBS
fast and fed gp130 WT and gp130 KO mice. E. Phospho-AKT to total ratio in LLC fast
and fed gp130 WT and gp130 KO mice. G. Phospho-rps6 to total ratio in LLC fast and
fed gp130 WT and gp130 KO mice. H. Puromycin Incorporation in LLC fast and fed
gp130 WT and gp130 KO mice. LLC mice are normalized to PBS-gp130 WT Fast mice.
Statistical analysis was only completed within the LLC mice. Phospho- proteins were
normalized to total protein. Abbreviations: PBS: phosphate buffered saline, LLC: Lewis
lung carcinoma. Two-way ANOVAs (PBS or LLC vs WT or KO) were used. # Main
effect of Fed, $ Main effect of gp130 KO.
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Figure 4-8. LLC conditioned media suppresses myotube growth and induces
inflammatory associated signaling in C2C12 myotubes
Notes: Data are presented as mean ± SEM. A. Study Design. B. Myotube Diameter C.Myosin heavy chain – fast protein expression. D. Protein expression of gp130 and
phosphor- to total ratio of STAT3 Y705 and ERK1/2 Y202/Y204. E. Phospho-to total
ratio of AKT T308 and S473, rpS6 S240, and P70S6K T389 G. Protein expression of P62
and LC3B II/I ratio. Unpaired T-test were used to compare GM and LLC media.
*Different from GM. N=6/ 2 separate experiments.
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Figure 4-9. LLC conditioned media suppresses the insulin activation of Akt and
mTORC1 signaling in C2C12 myotubes
Notes: Data are presented as mean ± SEM. A. Study Design. B. Phospho-to total ratio of
AKT T308. C. Phospho-rpS6 to total ratio. Two-way ANOVAs were used to compare
LLC and GM with or without insulin. Different letters mean groups are different. # Main
effect of Insulin, $ Main effect of LLC. N=6/ 2 separate experiments.
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Figure 4-10. IL-6 nor lif were sufficient to suppress Akt/mTORC1 induction by
insulin in C2C12 myotubes
Notes: Data are presented as mean ± SEM. A. Study Design B. Phospho-to total ratio of
STAT3, Akt, and rpS6 protein expression in cells treated with IL-6 for 24hrs then given
insulin for 60 minutes. C. Phospho-to total ratio of STAT3, Akt, and rpS6 protein
expression in cells treated with Lif for 24hrs then given insulin for 60 minutes. Two-way
ANOVAs were used to compare with or without IL-6 or Lif and with or without insulin.
*Different from control, $ Different from all groups, ^ Main effect of Insulin, % Main
effect of Lif. N=6/ 2 separate experiments.
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Discussion
Inflammation has been implicated as a key mediator of cancer-induced cachexia
leading to chronic elevation of skeletal muscle STAT3 and MAPK activity (Deans &
Wigmore, 2005). Glycoprotein-130 (gp130) is a regulatory point of interaction between
systemic inflammation and JAK/STAT and MAPK muscle signaling (White & Stephens,
2011). We have previously reported muscle gp130 loss prevented Lewis Lung Carcinoma
(LLC) induced muscle wasting and restored STAT3 and MAPK signaling (Puppa, Gao,
et al., 2014). In pre-clinical models, our laboratory has demonstrated altered protein
turnover through the suppression of anabolic signaling via mTORC1 which coincided
with the chronic activation of AMPK (White, Baynes, et al., 2011). Interestingly,
cachexia has known disruptions in mitochondrial function prior to muscle wasting
(Brown et al., 2017) and theses disruptions to the muscle mitochondria are known to
induce AMPK, thereby accelerating muscle wasting (VanderVeen et al., 2017). We
report the novel finding that muscle gp130 loss reduced the elevated AMPK but was not
sufficient to rescue suppressed protein synthesis in pre-cachectic tumor-bearing mice..
Finally, gp130 loss did not alter the protein synthesis response to feeding in PBS or LLC
mice. Given the known regulation of gp130 and associated signaling on muscle wasting,
our findings suggest that gp130’s regulation of skeletal muscle’s response to anabolic
stimuli is likely more important in cachectic muscle.
Several studies have implicated the role of gp130 signaling on preventing and/or
treating cancer induced cachexia. Briefly, skeletal muscle-specific STAT3 loss prevented
LLC induced muscle wasting and grip strength loss, without altering tumor mass (Silva et
al., 2015). Interestingly, in a genetic model of cancer induced cachexia (Apc Min/+ mice),
IL-6 receptor antibody preserved some body weight and muscle mass loss (White,
Baynes, et al., 2011). Furthermore, IL-6 receptor antibody was sufficient in reducing
STAT3 and AMPK signaling without rescuing the suppression of mTORC1. Importantly
we have shown that gp130 loss prevented muscle wasting in LLC tumor-bearing mice
(Puppa, Gao, et al., 2014). Herein, we did not rescue muscle mass loss in gp130 KO LLC
mice. There are potentially several reasons for this. First, we report a 50% reduction in
crude muscle gp130 protein expression, crude muscle has several other tissue types, and
gp130 is ubiquitously expressed in all tissue types. Furthermore, a sufficient knockout of
gp130 is likely because we see downstream associated gp130 signaling reduced.
Secondly, since we did not see differences in tumor development, it’s possible that as the
tumor develops, the tumor is releasing factors which can contribute to muscle wasting. It
is important to mention that we report around 5% body weight loss, suggesting a precachectic phenotype in our gp130 WT mice, whereas as Puppa et al. show an average
body weight loss of 7-10% (moderate cachexia). Importantly, in Puppa et al, they
reported gastrocnemius muscle mass loss of -17%, whereas as we only report -9% further
supporting that our LLC tumor-bearing mice were pre-cachectic. Interestingly, this
provided an opportunity to understand what gp130 signaling regulates early during
cachexia development. Future studies should determine the importance of gp130
signaling in pre-cachectic tumor-bearing mice subjected to high inflammatory
environment (such as chemotherapy), as this has significant implications in clinical
populations.
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AMPK is chronically elevated during cancer cachexia progression and has shown
to regulate mTORC1 signaling and protein synthesis. Additionally, we have examined a
role for systemic IL-6 in suppressing protein synthesis during cachexia (White et al.,
2013). We have previously shown that IL-6 exposure has the capacity to decrease C2C12
myotube diameter and suppress mTORC1 signaling, and when AMPK is blocked the IL6 suppression of protein synthesis is relieved (White et al., 2013). We extend these
studies by highlighting that gp130 loss reduced AMPK in tumor-bearing mice, however
this inhibition was not sufficient to restore mTORC1 signaling and protein synthesis.
These findings agree with cell culture work showing AMPK, but not gp130 inhibition
rescued protein synthesis suppression. It is interestingly to speculate why the suppression
of AMPK by gp130 loss was not sufficient to improve protein synthesis. We know that
elevated AMPK signaling is associated with cachexia progression, therefore it’s possible
that during early cachexia, the stress induced by fasting does not regulate mTORC1,
however this is unlikely given previous data. It is also possible, that in these pre-cachectic
mice, AMPK reduction by gp130 loss mice regulates mitochondrial quality control or
autophagy prior to rescuing protein synthesis. Lastly, it is very possible that gp130 loss is
only minimally targeting AMPK. AMPK can be phosphorylated by LKB1 and
CAMKK𝛽 (Ca2+/ Calmodulin-dependent protein kinase B) (Kim et al., 2016). We know
that LKB1 phosphorylation of AMPK can be improved by binding of AMP to the gamma
subunit of AMPK; this alternative is less likely because all mice were fasted therefore,
we would suggest that the AMP/ATP ratios might be similar. However, these inquires
require further investigation. Alternatively, CaMKK𝛽 can phosphorylate AMPK when
cellular calcium levels change without changes to AMP/ATP. It is within reason to
speculate that the reduction in AMPK by gp130 loss can be attributed to altered calcium
within the cell early during cachexia development. However, future work is needed to
further understand the implications of lowered AMPK without improved protein
synthesis in the absence of muscle gp130 in tumor-bearing mice.
Cachexia has known disruptions in mitochondrial function prior to muscle
wasting (Brown et al., 2017) and theses disruptions to muscle mitochondria are known to
induce AMPK, thereby accelerating muscle wasting (VanderVeen et al., 2017). We
extend previous studies by highlighting that gp130 loss in pre-cachectic tumor-bearing
mice did not improve the PGC1𝛼 suppression. Given that muscle gp130 can regulate
mitochondrial quality control (Hardee, Counts, et al., 2018), it is within reason to
speculate that in these pre-cachectic mice, gp130’s regulation of mitochondrial quality
control is not exerted till later stages cachexia when the inflammatory environment is
increased. If is this true, then early disruptions to mitochondria are occurring independent
of gp130. This is likely further supported by the relatively low expression of circulating
IL-6, whereas previous studies highlighting beneficial effect of gp130 loss reported a 2fold greater induction of IL-6. It is interesting to speculate if the early disruptions in
mitochondrial biogenesis are due to impaired lipid oxidation (Counts et al., 2021).
Additionally, given the known regulation of increased physical activity on improving
mitochondrial biogenesis, and pre-cachectic patients and tumor-bearing mice exhibit
reduced physical activity, it is possible that early disruptions to mitochondria are
attributed to physical inactivity. However, future studies are needed to delineate the
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effects of physical inactivity and gp130’s regulation of mitochondria in order to further
understand the mitochondrial regulation during the progression of cachexia.
While a majority of our understanding of protein synthesis during cachexia is
examined in murine models, protein synthesis rates are reduced in cachectic patients
(Dworzak et al., 1998). We have routinely shown suppressed protein synthesis during the
progression of cachexia in Apc Min/+ mice, and this suppression corresponded to a
reduction in muscle protein mTORC1 and IGF1 (White, Baynes, et al., 2011). The early
suppression of muscle protein synthesis during cachexia did not correspond to an initial
change in AMPK, since AMPK activity does not increase till late-stage cachexia (White,
Baynes, et al., 2011). However, we have recently shown that tumor-bearing mice have an
accelerated fasting induction of AMPK signaling early during cachexia progression (Fix
et al., 2021). Herein we have extended previous studies by showing mTORC1 signaling
is suppressed in the fasting condition but is not regulated by gp130. Furthermore, gp130
loss did not alter the protein synthesis induction by feeding. Since we know that elevated
gp130 associated signaling can suppress mTORC1 signaling and protein synthesis, it is
interesting to speculate that under basal conditions gp130 loss is not required for the
feeding regulation mTORC1 and protein synthesis. Importantly, we show that in precachectic mice the anabolic suppression of mTORC1 and protein synthesis by feeding is
independent of gp130. Since we know STAT3 signaling is associated to cachexia
progression, it is interesting to speculate that during the transition to a more cachectic
phenotype, gp130 can regulate the muscle’s feeding response. While previous studies
have shown little regulation of mTORC1 by gp130 loss in cachectic muscle, it does not
discount the potential inhibitory role of gp130 following an anabolic stimulus. Therefore,
future studies should determine if gp130 regulates the feeding induction of mTORC1
signaling and protein synthesis during severe cachexia.
No study is without limitations. A limitation of this study is that we examined
males, not females. Sex as a biological variable, especially during cancer cachexia has
only minimally been investigated. While this warrants further examination there are
several considerations that need to be addressed. First, we used tamoxifen-inducible
muscle-specific knockout mice, tamoxifen binds to the estrogen receptors throughout the
body thereby inhibiting the receptors effects on tissues. It has yet to be considered if the
sudden loss of estrogen associated signaling impact on skeletal muscle, in an
environment with high estrogen levels, females. Next, indices of cachexia are less
common in female mice compared to male mice, which has been linked to
hypogonadism. Additionally, there is a possibility that the 1-hr time difference between
fed and fast conditions could intrinsically be different. However, there is sufficient
circadian rhythm data to identify that this 1-hr difference between sacrifice times will not
elicit an intrinsic difference in muscle signaling. Therefore, it is very unlikely that the 1hr time difference is going to affect skeletal muscle signaling. The LLC model is not an
orthotopic model of lung cancer. There are potential alternative approaches to examining
lung cancer in pre-clinical models however, orthotopic models of lung cancer are
commonly completed in Balb/c mice or immunodeficient mice, which does not allow for
examination of muscle-specific inducible models or for the normal immune response.
Furthermore, cachexia progression in female mice is initially IL-6/gp130/STAT3
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independent, therefore it does not appear necessary at this stage to examine the role of
gp130 during cachexia progression in female mice. Therefore, our study only used male
mice due to several of our methodologies can be differentially regulated or not effected in
the female tumor-bearing mouse. Lastly, some transgenic models of cancer cachexia
utilize tamoxifen administration, a tumor inducer, and would be a significant confounder
when using to elicit a muscle-specific knockout (Kellar et al., 2015; Safari & Meuwissen,
2015). Importantly, the LLC model is commonly used due to its tumorigenic properties,
responsiveness to chemotherapy, and ability to metastasize to the lungs and liver (Kellar
et al., 2015) thus allowing us to use a well characterized model to examine cancer
cachexia progression.
Conclusion
In conclusion, gp130 loss did not prevent muscle wasting in pre-cachectic tumorbearing mice. Interestingly, gp130 loss was sufficient to reduce elevated AMPK, without
improving downstream mTORC1 signaling and protein synthesis in pre-cachectic mice.
Importantly, gp130 loss did not impair the protein synthesis response to feeding in tumorbearing mice. Taken together, we provide the novel understanding that gp130’s
regulation of skeletal muscle’s response to anabolic stimuli is likely more important
during later stages of cachexia. Studies are needed to delineate the early effects of gp130
on skeletal muscle homeostasis in order to provide therapeutic targets to prevent
cachexia. Future studies should examine if STAT3 inhibition in cachectic muscle can
improve the fasting regulation of AMPK and protein synthesis. Additionally, future
studies are warranted to examine why gp130 loss lowers AMPK in pre-cachectic skeletal
muscle without improving the suppressed protein synthesis.
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CHAPTER 5. EXAMINATION OF WHETHER AN ACUTE BOUT OF
MUSCLE CONTRACTION CAN IMPROVE MUSCLE PROTEIN TURNOVER
RESPONSE TO FEEDING DURING THE PROGRESSION OF CACHEXIA
Introduction
Cancer cachexia exhibits reduced volitional activity, whole body weakness, and
fatigue in cancer patients and in pre-clinical models (Baltgalvis et al., 2010; Murphy et
al., 2012; Toth et al., 2016). Furthermore, contractile decrements have also been reported
(Christensen et al., 2014; Roberts, Frye, et al., 2013), and are highly important given that
force production and fatigue are directly related to life quality in disease (al-Majid &
McCarthy, 2001; Barreiro & Gea, 2015; Siegel, 1989). We and others have recently
shown that cachectic skeletal muscle develops a slow-fatigable contractile phenotype
during cancer cachexia progression (Murphy et al., 2012; Roberts, Frye, et al., 2013;
VanderVeen et al., 2018). Furthermore, the regulation of muscle’s contractile properties
are strongly related to the muscle’s inflammatory signaling highlighting the regulation of
muscle contraction by inflammation during disease (VanderVeen et al., 2019). While
fatigue and weakness are the most commonly reported consequences in cancer patients,
we have only scratched the surface on trying to understand how this may occur (Chang et
al., 2000). Interestingly, recent work has highlighted exercise’s therapeutic role in
improving muscle fatigability in patients and pre-clinical models (Kessels et al., 2018;
Vanderveen et al., 2020). Several indices of cachexia progression are attenuated in
rodents given access to a running wheel by attenuating muscle mass loss and improving
myofiber cross-sectional area (Coletti et al., 2016; Pigna et al., 2016). These studies
highlight the improved ex-vivo force production and reduced inflammatory environment
likely attribute to the prevention of cachexia. In addition, treadmill training has also been
shown to offset indices of cachexia and was sufficient to decrease total polyp number
(Mehl et al., 2005), likely through reducing immune infiltration, apoptosis, and betacatenin signaling (Baltgalvis et al., 2010). Furthermore, exercise training prior to and
during IL-6 overexpression prevented muscle mass loss, improved systemic glucose, and
restored mTORC1 signaling (Lombardi et al., 2012; White et al., 2013). Exercise has
recognized benefits for the prevention of some cancers and electrical muscle stimulation
has beneficial effects in critically ill patients (Gerovasili et al., 2009). However, the
mechanisms of how exercise can be a therapeutic have to yet to be fully understood.
Exercise training is a known inducer of anabolic signaling through mTORC1
(Burd et al., 2009) and reduces chronic systemic inflammation (Beavers et al., 2010). An
acute bout of skeletal muscle contraction is sufficient to induce glucose uptake, fatty acid
oxidation, mitochondrial biogenesis, and protein synthesis (Egan & Zierath, 2013).
Whereas repeated exercise bouts can induce functional adaptations in contractile proteins,
mitochondrial function, and metabolic regulation (Egan & Zierath, 2013). After an acute
bout of exercise PGC-1α is rapidly up-regulated leading to a subsequent increase in
mitochondrial associated gene transcription and mitochondrial biogenesis (Baar et al.,
2002; Pilegaard et al., 2003). Up-regulation of these genes persists for up to 4 hours
before returning to baseline levels. Exercise has been hypothesized to be a potential
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therapeutic option for cancer induced cachexia (Hardee et al., 2019). We have recently
shown that repeated eccentric contractions are sufficient to induce anabolic signaling in
the cachectic environment, coinciding with suppressed inflammatory signaling in
glycolytic muscle (Hardee et al., 2020). Additionally, we highlight that repeated
contractions improved muscle oxidative capacity further supporting that cachectic muscle
has the plasticity to respond to contraction stimulus. While high frequency eccentric
contractions show promising results in preclinical models, clinical populations hesitate to
employ such a potent stimulus therefore rehabilitation settings utilize a low-to-moderate
frequency of contraction/load (Hody et al., 2019). We have previously shown that an
acute bout of low-frequency electrical stimulation (LFES) induced downstream mTORC1
phosphorylation and oxidative capacity, however this response was suppressed in
cachectic muscle (Puppa, Murphy, et al., 2014). While we have made advances in our
understanding of cachectic muscle’s response to acute contraction, significant barriers
still exist in understanding if the suppressed contraction occurs early during cachexia
progression.
Skeletal muscle mitochondrial function plays a pivotal role in muscle glucose
uptake, and impairments in oxidative capacity have been associated with insulin
resistance (Lanza & Nair, 2009). AMPK is a critical regulator for the exercise response in
skeletal muscle. An acute exercise bout increases protein levels of AMPK, despite this
exercise training induced an increase in muscle protein synthesis even in the cachectic
environment. Exercise is also able to attenuate the chronic activation of AMPK that is
seen with severe muscle wasting (Lombardi et al., 2012). The improvements in the
regulation of AMPK activity may be due to the improvements in glucose uptake which
could alleviate the energy stress that is placed on the muscle due to the cancer
environment and metabolic inflexibility. More research needs to be done to examine the
effects of exercise on muscle after the initiation of cachexia and if exercise can rescue
mitochondrial dynamics and function. However, most exercise interventions are used as a
prevention. Additionally, several animal models use a volitional modality of exercise
which provides variability in treadmill and wheel exercise; electrical stimulation is
another exercise modality often used to elicit skeletal muscle contractions. Skeletal
muscle’s metabolic and growth response to contraction have been examined using
electrical muscle stimulation (Baar & Esser, 1999; Nader & Esser, 2001; Puppa, Murphy,
et al., 2014; Witkowski et al., 2010). In pre-clinical models, electrical stimulation is
performed in an unconscious animal, which electrodes are used to stimulate a nerve at a
specific frequency. Several studies have examined skeletal muscle anabolic signaling
following high-frequency electrical muscle stimulation (HFES) (Baar & Esser, 1999;
Hardee et al., 2016; Sato et al., 2019), which induced mTORC1 associated signaling and
protein synthesis. In contrast, low-frequency electrical muscle stimulation (LFES) has
been used to examine the acute and training adaptations to endurance like muscle
contractions (Nader & Esser, 2001; Puppa, Murphy, et al., 2014). An acute exercise bout
of low frequency stimulation can induce mTORC1 signaling (Tsutaki et al., 2013). In
human populations, a single bout of LFES improved glucose uptake (Hamada et al.,
2003) and 4wks of LFES induced markers of glucose metabolism and oxidative capacity
(Theriault et al., 1994). Furthermore, 4wks of LFES improved fatigue resistance
following spinal cord injury (Harridge et al., 2002). Taken together, LFES has therapeutic
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potential, however more work is needed in order to under the molecular mechanisms of
exercise in chronic disease.
The anabolic response of resistance exercise in combination with nutritional
stimulus has been highly sought after in all populations (Barclay et al., 2019; Breen &
Phillips, 2013; Moore, 2019; Symons et al., 2011; Trommelen et al., 2019); specifically,
in the elderly or during disease in hopes to offset anabolic resistance. Several studies
have investigated skeletal muscle’s response to contraction and/or mechanical signaling
(Hornberger, 2011), however very little work has been done to examine the combined
effects of contraction and feeding on skeletal anabolic signaling (Gordon et al., 2014;
Nakayama et al., 2019) specifically during disease (Hardee, Counts, et al., 2018; Puppa,
Murphy, et al., 2014; Sato et al., 2019) and disuse (Roberson et al., 2020; Shimkus et al.,
2018). Interestingly, there is promising work that the combined effects of exercise and
nutrient supplementation can increase muscle protein synthesis to a greater extent than
feeding alone in cancer patients (Hanson et al., 2017). Given that we know cachectic
muscle has a suppressed anabolic response to muscle contractions, gaps remain in our
understanding if tumor-bearing mice have to capacity to synergistically induce protein
synthesis in response to contraction and feeding. Therefore, the purpose of aim 3 was to
determine if an acute bout of muscle contraction could improve the muscle protein
synthesis response to feeding during the progression of cachexia. We hypothesized that
an acute bout of muscle contraction could improve muscle protein turnover response to
feeding, and the response would be greater during pre-cachexia compared to refractory
cachexia.
Methods
Animals
Male C57BL/6J (B6; N=36) mice were bred at the University of Tennessee
Health Science Center Animal Resource Facility. B6 mice were initially purchased from
Jackson Labs (Bar Harbor, ME, USA). Mice were kept on a 12:12h light/dark cycle
beginning at 6:00AM and were given rodent chow ad libitum (Harlan Teklad Rodent
Diet, #8604, Harlan, Indianapolis, IN, USA). All mice were fasted for 12hrs during the
dark cycle. At the start of the light cycle, mice were either given ad libitum access to a
food pellet (fed) or sacrificed at the end of fast (fast). Mice then underwent low frequency
electrical stimulation and sacrificed 3hrs post.
Lewis lung carcinoma cell inoculation
Between 11-12 weeks of age, B6 mice were injected with either phosphate
buffered saline (PBS) or 1 x 106 Lewis lung carcinoma (LLC) cells subcutaneously in the
right flank under anesthesia for less than 3 minutes (Puppa, Gao, et al., 2014). A total of
22 mice were injected with LLC cells and 19 mice were injected with PBS. Seventyseven percent of the LLC injected mice reached the studies endpoint. A mouse reached
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the studies endpoint if the following criteria were met (1) mouse reached 30 days post
tumor inoculation, (2) >20% body weight loss from day 10 after day 25, or (3) had a
tumor >3cm in width or length after day 25. Once an endpoint was achieved, the mouse
was prepared for tissue collection and euthanized within 24 hrs. At day 20, 2 mice had
ulcerated tumors and was not included in the analysis and 1 mouse died unexpectedly at
day 21. At day 24, 2 mice had ulcerated tumors and were not included in the analysis. To
be included in the study, mice needed to achieve at least 25 days post tumor inoculation.
Therefore, a total of 17 male LLC injected mice were used in these experiments. Tumor
volume and body weight were measured every 5 days to calculate tumor growth. Tumor
volume was calculated by the same investigator and caliper using the following equation:
½ (width2xlength) (Jensen et al., 2008).
Low frequency electrical stimulation
LFES was conducted as described by (Nader & Esser, 2001) with slight
modifications. Briefly, all animals were fasted during the dark cycle for 12hr before
stimulation. At the end of the 12hrs, mice were either given access to a food pellet for 1hr
or maintained in the fast condition, mice were then subjected to an acute bout of LFES.
Animals were anesthetized with isoflurane in a chamber at 3-4% and remained
anesthetized for the procedure via a nose cone that was connected to the isofluraneoxygen. Animals were placed on a heat pad, and the left hindlimb was shaved free of hair
and cleaned with alcohol. Electrodes were placed on both sides of the tibial nerve and
stimulated via subcutaneous needle. Proper electrode position was confirmed by
observing plantar flexion at the ankle joint. This protocol elicited an overall effect of
plantar flexion, resulting in tapping of the foot. The voltage was applied by Aurora
Scientific (Aurora Scientific, Ontario, Canada). Stimulation was delivered at a frequency
of 10 Hz, 5 V, 10-ms duration, 90-ms delay, for a total time of 30 min. Mice were then
sacrificed 3hrs after the stimulation.
Blood glucose and plasma insulin
Immediately prior to ad libitum access to a food pellet, mice had their tail
snipped. The initial blood was wiped with a Kim wipe and blood glucose was determined
using a standard and readily available glucometer (Contour Next, Parsippany, NJ). Blood
was collected with a heparinized capillary tube, placed on ice, and centrifuged (10,000 x
g for 10 min at 4°C). The supernatant was removed, and plasma insulin concentrations
were determined using a two-site enzyme immunoassay assay kit according to the
manufacturer’s instructions (Catalog #10-1247, Mercodia, Uppsala, Sweden). Blood
glucose and plasma insulin measurements were taken again 1-hr after access to the food
pellet and prior to anesthesia at sacrifice.
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Western blot
Western blot analysis was performed as previously described (Hardee et al., 2014)
and extensive methodology can be found in extended methods section. Briefly, frozen red
and white gastrocnemius muscle was homogenized in lysis buffer and protein
concentration was determined by the Bradford method. Crude gastrocnemius muscle
homogenates were fractionated on 8-12% SDS-polyacrylamide gels and transferred to
PVDF membranes. Membranes were stained with Ponceau red to verify equal loading
and transfer. Membranes were then blocked at room temperature for 1hr. in 5% non-fat
milk or 5% BSA-Tris-buffered saline with 0.1% Tween-20 (TBST). Commercially
available phosphorylated and total protein primary antibodies for rpS6, AKT, AMPK,
STAT3, and DRP1 were raised in rabbit. RpS6, AKT, AMPK, STAT3, and DRP1
phosphorylation antibodies were expressed relative to total protein on the same gel and
quantified as phosphorylation to total ratio. Commercially available total protein primary
antibodies for PGC1α, and FIS1 were raised in rabbit. Puromycin incorporation was
purchased from Millipore and raised in mouse. Briefly, primary antibodies were
incubated overnight in 5% TBST milk or 5% TBST BSA. Membranes were then
incubated in 5% milk-TBST containing anti-rabbit or anti-mouse IgG horseradishperoxidase conjugated secondary antibody purchased from cell signaling for 1h at room
temperature. Enhanced chemiluminescence (ECL) (GE Healthcare Life Sciences,
Piscataway, NJ) was used to visualize the antibody-antigen interactions. Immunoblot
images were collected using a digital imager (Invitrogen iBright, Waltham, MA) and
quantified by densitometry using imaging software (Image J; NIH). Please see end of
document for details of catalogue numbers, companies, dilutions, incubation durations,
and secondary substrate (Figure A-1).
Statistical analysis
Pre-planned unpaired T-Test were used to compare the feeding and contraction
response in PBS and LLC mice. Two-way (Tumor x LFES) (Feeding x LFES) ANOVAs
were used, and Tukey’s post-hoc analysis was used when appropriate. Pearson spearman
correlations were used to associate skeletal muscle signaling with indices of cachexia.
Prism 8 (GraphPad) was used for statistical analysis. All results are reported as means
± standard error of mean (SEM). Statistical analysis was performed using GraphPad
(Prism 8 for Mac OS X, La Jolla, Ca). Level of significance for all measures was set at p
≤ 0.05.
Results
Between 11-12 weeks of age C57BL/6J (B6) mice were injected with phosphate
buffered saline (PBS) or Lewis lung carcinoma (LLC) cells and were then sacrificed 2530 post injection. There were no differences in age or study duration between PBS
(N=19) and LLC (N=17) mice. The study was initiated at approximately 12 weeks of age
and completed at approximately 15 to 16 weeks of age. PBS and LLC mice bodyweights
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were similar before tumor inoculation and 10 days post tumor inoculation (Table 5-1).
While there were no differences in absolute body weight at the end of the study, after
accounting for tumor mass, LLC mice had decreased body weight compared to PBS
mice. LLC mice had a greater body weight change from day 10 when accounting for
tumor mass (-4.0%) compared to PBS mice (2.9%). Body weight change from day 10
was chosen because the tumor is initially palpable but prior to the rapid tumor growth
phase (days 15-25). LLC mice had decreased total hindlimb muscle mass (-18%) and
eWAT mass (-25%) compared to PBS mice. LLC mice had increased spleen mass and
plasma IL-6 compared to PBS mice. Tumor volume and tumor mass were used to
validate tumor development. Tumor volume was measured every 5 days throughout the
study and was measurable 10 days post tumor inoculation. Utilizing the LLC model's
rapid tumor growth phase, we calculated the slope of tumor growth from days 15-25.
Tumor growth rate ranged from 0.029 to 0.645 cm3/5days. Tumor mass ranged from
0.993 to 4.84 grams (Table 5-1).
To examine the effect of feeding on systemic metabolism and muscle signaling,
we first needed to examine if there were differences in animal characteristics between the
fast and fed condition in both PBS and LLC treated mice (Table 5-2). PBS and LLC
mice consumed similar amounts of food during the 1-hr ad libitum feeding (p=0.959).
There was an interaction for blood glucose post the 1-hr ad libitum feeding to be
increased compared to fast (p=0.027). There were no differences between PBS and LLC
fast mice. PBS fed mice increased blood glucose compared to PBS fast. Additionally,
LLC fed mice increased blood glucose compared to LLC fast, and was greater than PBS
fed. There was a main effect for fed mice to have increased plasma insulin post pellet
independent of PBS or LLC (p<0.001). At sacrifice, there was a main effect for fed
groups, independent of condition, to increase blood glucose (p<0.001). There was a main
effect for LLC to have increased blood glucose compared to PBS. At sacrifice, plasma
insulin was increased in fed compared to fast mice, independent of condition (p=0.004).
At sacrifice, there was a main effect of liver mass to be increased compared to PBS
independent of feeding status (p=0.003). Additionally, stomach mass was increased in fed
mice, independent of PBS or LLC (p<0.001). As anticipated, there were no differences in
empty stomach mass in PBS or LLC mice in either the fed of fast condition. There was a
main effect of stomach content to be greater in fed mice, compared to fast mice for either
PBS or LLC (p<0.001). Taken together, these results validate the whole-body response to
feeding in both PBS and LLC mice.
Next, we sought to first validate the acute contraction response by LFES in PBS
male mice (Figure 5-1). We report that LFES induced rpS6 9.5-fold, puromycin
incorporation 4.7-fold, and PGC1𝛼 0.7-fold in the stim leg compared to the non-stim leg.
In LLC mice, we report that LFES induced rpS6 1.7-fold, puromycin incorporation 0.9fold, but was not sufficient to increase PGC1𝛼 in the stim leg compared to the non-stim
leg (Figure 5-1). While LLC mice were able to induce mTORC1 signaling and protein
synthesis, the overall response was lower in the LLC mice compared to PBS (rpS6
decreased 2-fold and protein synthesis decreased 3-fold in LLC compared to PBS).
Furthermore, the induction of mTORC1 and protein synthesis was not associated with
indices of cachexia. Taken together, we highlight that LLC tumor-bearing mice can
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Table 5-1.
Animal characteristics of PBS and LLC mice in the fast and fed
condition 3hrs post LFES

Characteristics
BW Pre-treatment (g)
BW d10 (g)
BW End of Study (g)
BW End of Study
Tumor Mass (g)
BW∆ during treatment (%)
BW∆ d10 (%)
Tumor Volume d15 (cm3)
Tumor Volume d20 (cm3)
Tumor Volume d25 (cm3)
Tumor Slope Rate d15-25
HMM (mg)
eWAT (mg)
Testes (mg)
Spleen (mg)
Tibia Length (mm)

PBS
Fast
Fed
N=10
N=9
25.7 (0.4)
24.5 (0.8)
26.6 (0.5)a 25.8 (0.7)a
27.2 (0.6)
26.8 (0.6)
27.2 (0.6)a 26.8 (0.6)a,b
5.7 (1.0)
9.5 (1.1)
2.0 (0.8)
3.8 (0.8)
194 (4)
192 (5)
306 (26)
241 (14)
204 (6)
198 (4)
63 (3)
59 (2)
16.7 (0.1)
16.6 (0.2)

Fast
N=8

LLC

24.3 (0.8)
25.6 (0.6)
27.8 (1.0)
24.8 (0.8)a#
3.0 (0.5)
0.9 (1.8)#
-3.2 (1.5)#
0.332 (0.120)a,b
1.042 (0.365)a
3.103 (0.772)b
0.277 (0.071)
179 (5)#
208 (7)#
187 (7)
243 (32) #
16.8 (0.1)

Fed
N=9
24.3 (0.7)
25.4 (0.7)a
27.2 (0.7)
24.2 (0.8)b#
3.1 (0.4)
-0.7 (1.6)#
-4.8 (1.3)#
0.311 (0.100)a,b
1.339 (0.355)b
2.584 (0.529)a
0.231 (0.046)
176 (6)#
202 (23)#
194 (10)
246 (40)#
16.6 (0.1)

Notes: Data are presented as mean ± SEM. Abbreviations: BW: body weight, mg:
milligrams, eWAT: epididymal white adipose tissue, PBS: Phosphate buffered saline,
LLC: Lewis lung carcinoma, mm: millimeter, g: grams, ME: Main Effect, HMM:
Hindlimb muscle mass. One-way repeated measures ANOVA was used to compare
within LLC fast and fed mice body weight over the course of the study (BW End of study
is not included in analysis/ BW end of study accounting for tumor mass is included) a
Different from Pre within treatment group, b Different from BW d10 within treatment
group. One-way repeated measures ANOVA was used to compare tumor volume over the
course of the study. a Different from d15 within treatment group, b Different from d20
within treatment group. Statistically significant p<0.05. Two-way ANOVAs were used to
compare PBS and LLC in the Fast and Fed condition. # Main Effect of LLC. Unpaired Ttest were used to compare tumor growth and mass in the fed and fast condition of LLC
mice. * Different from LLC fast.
.
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Table 5-2.

Whole-body response to feeding in PBS and LLC male mice

Characteristics

Pellet Consumption (g)
Blood Glucose Post-Feeding (mg/dl)
Blood Glucose @ Sac. (mg/dl)
Plasma Insulin post-feeding (ng/mL)
Plasma Insulin @ Sac. (ng/mL)
Liver Mass (g)
Stomach Mass (mg)
Empty Stomach (mg)
Stomach Content (mg)

Fast
N=10

PBS

92 (3)a
12 (8)
0.241 (0.037)
0.207 (0.003)
1.2 (0.0)
381 (30)
159 (7)
222 (28)

Fed
N=9

0.78 (0.11)
190 (6)b
159 (6)#
2.604 (0.394)#
0.452 (0.090)#
1.2 (0.0)
763 (100)#
170 (10)
593 (101)#

Fast
N=8

LLC

97 (9)a
133 (15)$
0.243 (0.039)
0.295 (0.072)
1.4 (0.1)$
424 (41)
161 (8)
263 (37)

Fed
N=9

0.79 (0.06)
228 (7)a
182 (4)#$
1.961 (0.217)#
0.531 (0.113)#
1.3 (0.1)$
586 (48)#
143 (4)
443 (48)#

Notes: Data are presented as mean ± SEM. Abbreviations: mg: milligrams, PBS:
phosphate buffered saline, LLC: Lewis lung carcinoma, g: grams, mg/dl: milligrams per
deciliter, ng/mL: nanograms per milliliter, Sac.: At Sacrifice, and ME: Main Effect.
Unpaired T-test was used to compare PBS and LLC fed pellet consumption. Two-way
ANOVAs were used to compare PBS and LLC in the Fast and Fed condition. #ME of
Fed. $ME of Tumor. If an interaction was present; different letters were used to
differentiate differences between groups. Statistically significant p<0.05.
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Figure 5-1.
to LFES

LLC tumor-bearing mice exhibit a blunted protein synthesis response

Notes: Data are presented as mean ± SEM. A. Study Design. B. Phospho-rps6 to total
ratio in PBS and LLC fasted mice 3hrs after LFES. Non-Stim leg was used as control. C.Puromycin Incorporation in PBS and LLC fasted mice 3hrs after LFES. Non-Stim leg
was used as control. D. Phospho-AKT to total ratio in PBS and LLC fasted mice 3hrs
after LFES. E. PGC1α protein expression in PBS and LLC fasted mice 3hrs after LFES.
F. Phospho-AMPK to total ratio in PBS and LLC fasted mice 3hrs after LFES. G.Phospho-STAT3 to total ratio in PBS and LLC fasted mice 3hrs after LFES. Non-Stim
leg was used as control. Protein expression is completed in white gastrocnemius muscle.
Two-way repeated measures ANOVA were used to compare within animal of the nonstim to stim leg in PBS and LLC mice. Abbreviations: PBS: phosphate buffered saline,
LLC: Lewis lung carcinoma. # Main effect of Stim, & Main effect of LLC. * Groups are
different
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respond to LFES; however, the overall protein synthesis response is suppressed in LLC
mice. The added protein synthesis response to feeding and contraction is blunted in precachectic tumor-bearing mice. Furthermore, we show that LFES was not sufficient to
increase PGC1𝛼 in pre-cachectic tumor-bearing mice. Taken together, LLC tumorbearing mice exhibit suppressed anabolic signaling and do not synergistically respond to
feeding and contraction to examine regulators of muscle protein turnover, we examined
AMPK and STAT3 signaling, which are known to be regulated by contraction and cancer
cachexia progression. We report that LLC tumor-bearing mice have increased AMPK
(1.5-fold), and LFES did not alter this response (Figure 5-1). Interestingly, STAT3 was
induced by LFES in PBS mice, but was not induced in LLC mice (Figure 5-1). In the
non-stim leg STAT3 was elevated in LLC mice compared to PBS. Taken together, we
suggest that the suppressed mTORC1 signaling and protein synthesis in LLC mice, might
be attributed to disrupted AMPK and STAT3 signaling following acute contractions
Next, we sought to examine if this blunted anabolic response to contraction can be
improved with the combination of feeding, therefore answering the question if LLC
tumor-bearing mice exhibit a synergist anabolic response to feeding and contraction.
First, we established the synergistic effect of feeding and contraction in non-tumorbearing mice (Figure 5-2). To validate the feeding induction, we report that AKT was
induced in fed mice independent of contraction (Figure 5-2). Furthermore, we report a
main effect for LFES and a main effect for feeding to increase rpS6 and puromycin
incorporation (Figure 5-2). Our results validate the synergistic effect of feeding and
LFES in non-tumor-bearing mice. Next we determined if tumor-bearing mice exerted a
synergist effect of feeding and contraction. We report feeding increased AKT in LLC
mice, which was not altered by LFES (Figure 5-3) nor was it associated with indices of
cachexia. LLC tumor-bearing mice increased prpS6 and puromycin incorporation in the
stim leg, which was not further induced by feeding (Figure 5-3). Taken together, our
results suggest that LLC tumor-bearing mice do not have the capacity to elicit a
synergistic anabolic response to feeding and contraction. Lastly, we sought to examine if
feeding and contraction can regulate AMPK or STAT3 protein expression. LFES nor
feeding altered AMPK signaling in PBS mice (Figure 5-4). Interestingly, feeding
induced AMPK in LLC mice (Figure 5-5). Feeding suppressed the STAT3 induction of
LFES in PBS (Figure 5-5), and STAT3 was not altered in LLC tumor-bearing mice
(Figure 5-5). Taken together, these results suggest that feeding and contraction can both
regulate STAT3 protein expression, and LLC disrupts this response.
Discussion
Cancer cachexia exhibits reduced volitional activity, whole body weakness, and
fatigue in cancer patients and in pre-clinical models. Exercise has been hypothesized to
be a potential therapeutic option for cancer induced cachexia. We have previously shown
an acute bout of low-frequency electrical stimulation (LFES) induced downstream
mTORC1 phosphorylation and oxidative capacity, however this response was suppressed
in cachectic muscle. There is promising work that the combined effects of exercise and
nutrient supplementation can increase muscle protein synthesis to a greater disease
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Figure 5-2. LFES and feeding exert synergistic effect on skeletal muscle protein
synthesis in non-tumor-bearing mice
Notes: Data are presented as mean ± SEM. A. Study Design. B. Phospho-AKT to total
ratio in PBS fast and fed mice 3hrs after LFES. C. Phospho-rpS6 to total ratio in PBS fast
and fed mice 3hrs after LFES. D. Puromycin incorporation in PBS fast and fed mice 3hrs
after LFES. Non-Stim leg was used as control. Two-way repeated measures ANOVA
were used to compare within animal of the non-stim to stim leg in PBS fast and fed mice.
Abbreviations: PBS: phosphate buffered saline. # Main effect of Stim, & Main effect of
feeding.
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Figure 5-3. LLC inhibits the synergistic effect of LFES and feeding on skeletal
muscle protein synthesis in tumor-bearing mice
Notes: Data are presented as mean ± SEM. A. Study Design. B. Phospho-AKT to total
ratio in LLC fast and fed mice 3hrs after LFES. C. Phospho-rpS6 to total ratio in LLC
fast and fed mice 3hrs after LFES. D. Puromycin incorporation in PBS fast and fed mice
3hrs after LFES. Non-Stim leg was used as control. Two-way repeated measures
ANOVA were used to compare within animal of the non-stim to stim leg in LLC fast and
fed mice. Abbreviations: PBS: phosphate buffered saline. # Main effect of Stim, & Main
effect of feeding.
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Figure 5-4. LLC tumor-bearing mice have altered feeding and contraction
regulation of AMPK and STAT3
Notes: Data are presented as mean ± SEM. A. Study Design. B. Phospho-AMPK to total
ratio in PBS fast and fed mice 3hrs after LFES. C. Phopsho-STAT3 to total ratio in PBS
fast and fed mice 3hrs after LFES. D. Phospho-AMPK to total ratio in LLC fast and fed
mice 3hrs after LFES. E. Phospho-STAT3 to total ratio in LLC fast and fed mice 3hrs
after LFES. Non-Stim leg was used as control. Two-way repeated measures ANOVA
were used to compare within animal of the non-stim to stim leg in PBS or LLC fast and
fed mice. Abbreviations: PBS: phosphate buffered saline. & Main effect of feeding.
*Groups are different 3hrs post contraction.

101

population. We extend previous studies by highlighting that pre-cachectic tumor-bearing
mice can increase protein synthesis in response to LFES. However, protein synthesis was
overall suppressed in tumor-bearing mice. We report the novel finding that the added
protein synthesis response to feeding and contraction is blunted in pre-cachectic tumorbearing mice. Furthermore, we show that LFES was not sufficient to increase PGC1𝛼 in
pre-cachectic tumor-bearing mice. Taken together, LLC tumor-bearing mice exhibit
suppressed anabolic signaling and do not synergistically respond to feeding and
contraction.
Healthy skeletal muscle stimulates protein synthesis in response to anabolic
stimuli associated with daily living, which can include physical activity and feeding
(Egan & Zierath, 2013). While basal muscle protein synthesis and mTORC1 signaling is
suppressed in tumor-bearing mice the capacity for cachectic muscle to respond to an
anabolic stimulus is not well understood. The inability of severely cachectic mice to
perform voluntary exercise remains a consistent barrier and has limited our understanding
of the muscle’s response to exercise during refractory cachexia. To address this, we have
reported that cachexia disrupts the metabolic and anabolic signaling response to a single
bout of stimulated low-frequency concentric contractions which mimics low intensity,
endurance type exercise. We extend these findings highlighting that pre-cachectic tumorbearing mice exhibit blunted anabolic response to LFES. These findings have significant
implications because we report an altered response to contraction, prior to cachexia
development. It can be hypothesized, that increased physical activity might play a
beneficial role in improving the contraction response however this requires further
investigation. Additionally, it has been suggested that an exercise threshold is required to
improve skeletal muscle function during cachexia (Vanderveen et al., 2020). While we
show the reduction in anabolic signaling in response to LFES in pre-cachectic mice, it is
within reason to speculate that a more robust stimuli (high frequency electrical
stimulation) is necessary to provide an anabolic response similar to that of non-tumor
controls. Future studies are needed to determine if repeated bouts of low frequency
electrical stimulation are sufficient to improve the basal suppression of protein synthesis.
In addition, in aim 1 we show that feeding is sufficient to increase protein synthesis,
however herein we do not in LLC tumor-bearing mice. The difference between the two
studies is the time point post feeding (aim 1 was 1hr and aim 3 was 3.5hrs). It is
interesting to speculate that the anabolic window of feeding is shortened in pre-cachectic
mice. However, future studies should determine if cachexia progression alters the
anabolic window following feeding.
Contractile decrements have also been reported in cachectic muscle (Christensen
et al., 2014; Roberts, Frye, et al., 2013), and is highly important given that force
production and fatigue are directly related to life quality in disease (al-Majid &
McCarthy, 2001; Barreiro & Gea, 2015; Siegel, 1989). We and others have recently
shown that cachectic skeletal muscle develops a slow-fatigable contractile phenotype
during cancer cachexia progression (Murphy et al., 2012; Roberts, Frye, et al., 2013;
VanderVeen et al., 2018). Furthermore, the regulation of muscle’s contractile properties
are strongly related to the muscle’s inflammatory signaling highlighting the regulation of
muscle contraction by inflammation during disease (VanderVeen et al., 2019).
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Interestingly, cachectic muscle exhibits increased SERCA1 and calsequesterin mRNA in
cachectic skeletal muscle (VanderVeen et al., 2018), further supporting the transition to a
more faster muscle phenotype (Khodabukus & Baar, 2015). While fatigue and weakness
are the most commonly reported issues in cancer patients, we have only scratched the
surface on trying to understand how this may occur (Chang et al., 2000). It is very
possible that LLC tumor-bearing mice have impaired contractile properties which is
inhibiting the ability to return protein synthesis levels to healthy control levels. While
pre-cachectic tumor-bearing mice do exhibit slight fatiguability (VanderVeen et al.,
2018), herein pre-cachectic tumor-bearing mice have the capacity to responds to
contraction. Future studies should determine if the acute contraction response
(immediately post) is dysregulated in pre-cachectic tumor-bearing mice.
A delimitation of this study is that we are examining the muscle’s response after
an acute bout of muscle contraction. A limitation of this aim is that we did not complete
repeated contractions which can result in an exercise response. However, examining the
acute contraction response is a necessary step in understanding the muscle’s response to
contraction during cancer cachexia progression, and is classical methodology for
examining muscle’s capacity to respond. While we did report a blunted response to
contraction in tumor-bearing mice, it is possible that the stimulation protocol was not a
strong enough stimulus. Future studies should determine if the response to LFES and
HFES is similar in pre-cachectic tumor-bearing mice. These would provide interesting
finding within itself because it means there is likely a stimulus threshold required. An
alternative approach to stimulation is treadmill training or wheel access, however the
voluntary nature of treadmill training and wheel activity is a confounder in tumor-bearing
models because as cachexia progresses mice significantly reduce volitional activity.
Conclusion
In conclusion, we report that pre-cachectic tumor-bearing mice have the capacity
to increase mTORC1 signaling and protein synthesis following an acute bout of low
frequency electrical stimulation. However, pre-cachectic tumor-bearing mice do not have
the capacity to synergistically increase protein synthesis by feeding and contraction.
Future studies should determine if repeated low frequency contractions can improve the
basal suppression of protein synthesis, and if repeated contractions can improve the
synergistic effect of acute feeding and contraction. Additionally, future studies should
also determine if the there is a stimulus threshold required to synergistically induce
protein synthesis early during cachexia’s progression
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CHAPTER 6.

DISCUSSION AND FUTURE DIRECTIONS
Discussion

Cancer-induced cachexia disrupts skeletal muscle protein turnover in the basal
condition (decreasing protein synthesis and increasing protein degradation). In preclinical models, our laboratory has demonstrated altered protein turnover through the
suppression of anabolic signaling via mTORC1 which coincided with the chronic
activation of AMPK (White, Baynes, et al., 2011). Interestingly, mTORC1 signaling
exhibits diurnal fluctuations in response to changes throughout the day in feeding and
activity (Counts et al., 2020). Furthermore, the cachectic environment disrupts these
diurnal fluctuations, and suggest a link between disruptions in feeding and activity
behaviors to the progression of cachexia and altered mTORC1 signaling (Counts et al.,
2020). While progress has been made in understanding some of the mechanisms
underlying the suppressed anabolic signaling in cachectic muscle, gaps remain in our
understanding of muscle’s ability to respond to anabolic stimuli prior to cachexia
development. The purpose of this study was to determine if cachexia progression disrupts
the feeding regulation of AMPK signaling and if gp130 signaling and muscle contraction
can regulate this process. In Aim 1 we examined the feeding regulation of skeletal muscle
protein synthesis in pre-cachectic tumor-bearing mice. Our results are in partial
agreement with our hypothesis. In agreement with our hypothesis, pre-cachectic tumorbearing mice have overall suppressed Akt/mTORC1 signaling and protein synthesis. We
hypothesized that pre-cachexia would inhibit the feeding response, however this did not
happen. We reported the novel finding that pre-cachectic tumor-bearing mice have the
capacity to increase muscle Akt/mTORC1 signaling and protein synthesis, and lower
AMPK signaling in response to feeding. Lastly, in agreement with previous findings
reporting AMPK’s regulation of cachectic muscle signaling, muscle-specific AMPK loss
was sufficient to improve the fasting suppression of muscle mTORC1 and protein
synthesis in pre-cachectic tumor-bearing mice.
Inflammation has been implicated as a key mediator of cancer-induced cachexia
leading to chronic elevation of skeletal muscle STAT3 and MAPK activity and may be
critical for gp130 activation (Deans & Wigmore, 2005). Glycoprotein-130 (gp130) is a
regulatory point of interaction between systemic inflammation and JAK/STAT and
MAPK muscle signaling (White & Stephens, 2011). We have previously reported muscle
gp130 loss prevented muscle wasting and restored STAT3 and MAPK signaling (Puppa,
Gao, et al., 2014). In pre-clinical models, our laboratory has demonstrated altered protein
turnover through the suppression of anabolic signaling via mTORC1 which coincided
with the chronic activation of AMPK (White, Baynes, et al., 2011). In aim 2, we
examined if muscle gp130 signaling regulates the feeding regulation of AMPK during
cancer cachexia progression. We hypothesized that gp130 regulates AMPK’s regulation
of feeding. While we report muscle gp130 loss lowered the fasting induction of AMPK in
pre-cachectic tumor-bearing mice, gp130 loss was not sufficient to improve muscle
protein synthesis. Furthermore, muscle gp130 loss did not alter the feeding regulation of
muscle Akt/mTORC1 signaling and protein synthesis in pre-cachectic tumor-bearing
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mice. Taken together, gp130’s regulation in pre-cachectic tumor-bearing mice does not
exert regulation on skeletal muscle protein synthesis. Given the known regulation of
gp130 and associated signaling on muscle wasting, our findings suggest that gp130’s
regulation of skeletal muscle’s response to anabolic stimuli is likely more important in
cachectic muscle.
Cancer cachexia exhibits reduced volitional activity, whole body weakness, and
fatigue in cancer patients and in pre-clinical models (Baltgalvis et al., 2010; Murphy et
al., 2012; Toth et al., 2016). Exercise has been hypothesized to be a potential therapeutic
option for cancer induced cachexia (Hardee et al., 2019). We have previously shown that
an acute bout of low-frequency electrical stimulation (LFES) induced downstream
mTORC1 phosphorylation and oxidative capacity, however this response was suppressed
in cachectic muscle (Puppa, Murphy, et al., 2014). In aim 3, we examined if an acute bout
of muscle contraction could improve muscle protein synthesis response to feeding during
the progression of cachexia. We hypothesized that an acute bout of muscle contraction
could improve muscle protein synthesis response to feeding and would be greater during
pre-cachexia compared to refractory cachexia. Our results partially support our
hypothesis. We found that pre-cachectic tumor-bearing mice exhibit suppressed protein
synthesis in response to low frequency electrical stimulation. Furthermore, we
hypothesized a synergistic effect of feeding and contraction would be present in precachectic tumor-bearing mice, however pre-cachectic tumor-bearing mice were unable to
synergistically induce protein synthesis in response to feeding and contraction.
Unfortunately, we set out to examine the range of cachexia progression, but our mice
were pre-cachectic which does not allow us to examine the progression of cachexia,
however this does provide useful information highlighting that the blunted contraction
response occurs prior to wasting.
Overall, pre-cachectic tumor-bearing mice have suppressed Akt/mTORC1
signaling and protein synthesis in the fast and fed condition. Muscle-specific AMPK loss
was sufficient to improve muscle mTORC1 and protein synthesis in pre-cachectic tumorbearing mice. Gp130 can regulate the fasting induction of AMPK, without improving
downstream protein synthesis in pre-cachectic tumor-bearing mice. Tumor-bearing mice
do not have the capacity to synergistically increase mTORC1 signaling and protein
synthesis in response to feeding and contraction. In summary, feeding can induce
Akt/mTORC1 and protein synthesis, which is not regulated by gp130 in pre-cachectic
tumor-bearing mice. AMPK regulates the fasting suppression of protein synthesis in
tumor-bearing mice. The added protein synthesis response to feeding and contraction is
blunted in pre-cachectic tumor-bearing mice. These findings provide novel insight into
the regulation of Akt/mTORC1 signaling and protein synthesis in response to feeding.
Additionally, these studies provide novel understanding of gp130’s regulation of AMPK
prior to cachexia development, and the blunted anabolic muscle response to an acute bout
of muscle contractions. By understanding these intracellular signaling processes and
perturbations prior to cachexia development, we will be able to elucidate potential
therapeutic targets and treatment options to manipulate and prevent cancer cachexia
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Future Directions
While we have made several advances in understanding the basal regulation of
skeletal muscle during cancer cachexia progression and cachectic muscle’s capacity to
respond to anabolic stimuli several questions still arise. We report the novel finding that
feeding has the capacity to increase muscle Akt/mTORC1 signaling and protein
synthesis, and lower AMPK in pre-cachectic tumor-bearing mice. Importantly, precachectic tumor-bearing mice have overall suppressed Akt/mTORC1 signaling and
protein synthesis independent of the fast and fed condition. Future, studies should
examine if cachectic muscle has the capacity to increase muscle Akt/mTORC1 signaling
and protein synthesis. We also report the novel finding that muscle-specific AMPK loss
was sufficient to improve the fasting suppression of protein synthesis in pre-cachectic
tumor-bearing mice, however the addition of feeding was not sufficient to further
increase protein synthesis. Further work is required to determine why muscle AMPK loss
in combination with feeding did not restore impaired muscle protein synthesis in precachectic tumor-bearing mice. Additionally, we extend previous studies by highlighting
that muscle gp130 loss reduced elevated AMPK but was not sufficient to rescue
suppressed protein synthesis in pre-cachectic tumor-bearing mice. Future studies are
warranted to examine if gp130 loss is sufficient to suppress AMPK and rescue muscle
protein synthesis in cachectic muscle, specifically when the IL-6 family of cytokines are
elevated. Furthermore, given that we have previously found AMPK loss was sufficient to
rescue protein synthesis in tumor-bearing mice, future studies are warranted to determine
why gp130 loss can reduce AMPK, but is insufficient to improve protein synthesis in
tumor-bearing mice. Previous studies have shown that muscle gp130 loss can prevent
cachexia development, suggesting that targeting gp130 in cachectic muscle might provide
difficulty. Therefore, future studies could examine if STAT3 inhibition in cachectic
muscle can improve the fasting regulation of AMPK and protein synthesis. Lastly, we
extend previous studies by demonstrating that pre-cachectic tumor-bearing mice exhibit
suppressed mTORC1 signaling and protein synthesis in response to an acute bout lowfrequency electrical stimulation. We report the novel finding that the synergistic increase
of mTORC1 signaling and protein synthesis in response to feeding and contraction is
inhibited in pre-cachectic tumor-bearing mice. Future studies are warranted to examine if
repeated contractions can improve the acute response to feeding and contraction.
Furthermore, future studies are warranted to examine if repeated contractions can
improve the fasting suppression of protein synthesis during cancer cachexia progression.
Finally, researchers should examine if AMPK is inhibiting the protein synthesis response
to contraction during cancer cachexia progression
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APPENDIX A. ANTIBODY SPECIFICS
Table A-1.
Protein
pAKT

Antibody specifics
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pAMPK
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pFOXO3a
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-

pACC
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-

P62

-

LC3B

-

Beclin-1

-

pSTAT3
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STAT3
pP65
P65
pERK
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T202/Y204

ERK

-

pP38
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P38

-

gp130

-

pULK1
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Atrogin-1

-

MuRF-1

-

PGC1alpha

-
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Signaling
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Catalogue #

Protein (ug)

13038S

35
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25

5364S

30

2217S
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2535S

35

2603S

30
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35

2497S

35
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25

3662S
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30
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35

3738S

30
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35
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30
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30
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Blocking
(R.T. 1hr)

1° Dilution
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5% TBSTMilk
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TBST-Milk
1:2000, 5%
TBST-Milk
1:1000, 5%
TBST-Milk
1:1000, 5%
TBST-Milk
1:4000, 5%
TBST-Milk
1:4000, 5%
TBST-Milk
1:4000, 5%
TBST-Milk

1° Duration
O.N. 4°
R.T. 4hrs
O.N. 4°
R.T. 4hrs
O.N. 4°
R.T. 4hrs
O.N. 4°
O.N. 4°
R.T. 4hrs
O.N. 4°
R.T. 4hrs
O.N. 4°
R.T. 4hrs
O.N. 4°
R.T. 4hrs
O.N. 4°
R.T. 4hrs
R.T. 4hrs
R.T. 4hrs
R.T. 4hrs
R.T. 4hrs
O.N. 4°
O.N. 4°
O.N. 4°
O.N. 4°
O.N. 4°

pDRP1

S616

DRP1

-

5391S

30

FIS1

-

Sigma

HPA017430

35

OPA1

-

Cell
Signaling

80471S

35

OXPHOS

-

Abcam

ab110413

25

Puromycin
Incorporation

-

Millipore

MABE343

30

OXPHOS

-

Abcam

ab110413

25

Puromycin
Incorporation

-

Millipore

MABE343

30

5% TBSTMilk

1:4000, 5%
TBST-Milk

R.T. 4hrs

OXPHOS

-

Abcam

ab110413

25

5% TBSTMilk

1:4000, 5%
TBST-Milk

O.N. 4°
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O.N. 4°
R.T. 4hrs
R.T. 4hrs
R.T. 4hrs
O.N. 4°
O.N. 4°
O.N. 4°

2°
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Cell
Signaling
Anti-rabbit
1:4000
Anti-Mouse
1:4000
Cell
Signaling
Anti-rabbit
1:4000

2° Dilution
Solution
(R.T. 1hr)
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk
5% TBSTMilk

APPENDIX B. FEEDING AND FASTING SUPPLEMENTAL DATA

Figure B-1. The effect of LLC on skeletal muscle signaling in male mice following
an overnight 12hr fast
Notes: Data are presented as mean ± SEM. A) AMPK associated signaling B)
Autophagy associated signaling. C) E3 Ligase protein expression. D) Akt/mTORC1
signaling and protein synthesis protein expression E) Mitochondrial quality control
protein expression Phosphorylation proteins were normalized to total protein expression.
Protein expression was normalized to PBS mice. Protein expression was analyzed in
white gastrocnemius muscle. N=7-9 per group. Unpaired T-test were used to compare
PBS and LLC male mice. * Different from PBS.
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Figure B-2.
fast

The effect of feeding in PBS male mice following an overnight 12hr

Notes: Data are presented as mean ± SEM. A) AMPK associated signaling B)
Autophagy associated signaling C) E3 ligase protein expression D) Akt/mTORC1 and
protein synthesis protein expression. E) Mitochondrial quality control protein expression.
Phosphorylation proteins were normalized to total protein expression. Protein expression
was normalized to Fast mice. Protein expression was analyzed in white gastrocnemius
muscle. N=7-8 per group. Unpaired T-test were used to compare AMPK WT Fast and
Fed mice
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Figure B-3. Early onset whole body metabolism and physical activity in a subset
of LLC tumor baring mice
Notes: Data are presented as mean ± SEM. A) Study Design B) Glucose overtime during
glucose tolerance test. C) Area under the curve from glucose tolerance test. D) Average
cage activity during the light and dark in PBS and LLC male mice. E) Average lipid
oxidation during the light and dark in PBS and LLC male mice. F) Average carbohydrate
oxidation during the light and dark in PBS and LLC male mice. N=5-7 per group. Twoway repeated measures ANOVA were used. Unpaired t-test was used to compared GTT
AUC in PBS and LLC mice. * Groups are different. $ Main effect of Cycle.
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Table B-1.
Associations of early onset systemic metabolism and physical activity
to indices ot cachexia and tumor development
LLC
Factor 1 (early-onset)

Factor 2 (late stage)

GTT Glucose AUC (N=12)

Lipid Oxidation (N=14)

Carbohydrate Oxidation (N=14)

Physical Activity (N=14)

R

p

BW𝝙d10

-0.518

0.084

BW𝝙d0

-0.423

0.171

Gastrocnemius Mass

0.175

0.587

eWAT

-0.579

0.048 *

Tumor Mass

0.261

0.413

Tumor Growth Rate

-0.036

0.911

Plasma IL-6

0.093

0.773

BW𝝙d10

-0.131

0.654

BW𝝙d0

-0.064

0.827

Gastrocnemius Mass

-0.027

0.928

eWAT

-0.443

0.113

Tumor Mass

0.346

0.225

Tumor Growth Rate

0.155

0.600

Plasma IL-6

0.153

0.601

BW𝝙d10

-0.342

0.231

BW𝝙d0

-0.269

0.353

Gastrocnemius Mass

-0.369

0.195

eWAT

-0.117

0.689

Tumor Mass

0.330

0.249

Tumor Growth Rate

-0.106

0.718

Plasma IL-6

0.437

0.118

BW𝝙d10

0.029

0.922

BW𝝙d0

0.103

0.726

Gastrocnemius Mass

0.784

<0.001 *

eWAT

0.402

<0.001 *

Tumor Mass

-0.487

0.078

Tumor Growth Rate

0.187

0.522

Plasma IL-6

-0.656

0.011 *

2

Notes: Associations of early-onset systemic metabolism and physical activity to indices
of cachexia and tumor development. Data are presented as mean ± SEM. N=5-7 per
group. Pearson spearman correlation were used to association of systemic metabolism
and physical activity to indices of cachexia and tumor growth rate. Abbreviations: LLC:
Lewis lung carcinoma. * Statistically significant p<0.05.
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Table B-2.
Associations of early onset systemic metabolism and physical activity
to AMPK association signaling in fast and fed LLC mice
Fast
Factor 1

Factor 2

pAMPK T172

pULK

S555

pFOXO3a

S413

Fed

R

p

R

p

GTT Glucose AUC

-0.164

0.792

-0.672

0.328

Lipid Oxidation

0.823

0.087

0.032

0.946

Carbohydrate Oxidation

0.141

0.821

0.214

0.644

Physical Activity

-0.056

0.928

0.186

0.690

GTT Glucose AUC

-0.173

0.826

-0.760

0.241

Lipid Oxidation

-0.980

0.021*

-0.179

0.701

Carbohydrate Oxidation

-0.288

0.712

-0.623

0.135

Physical Activity

0.339

0.661

0.805

0.029 *

GTT Glucose AUC

0.453

0.444

-0.613

0.271

Lipid Oxidation

-0.256

0.677

-0.178

0.703

Carbohydrate Oxidation

-0.897

0.039*

-0.521

0.231

Physical Activity

0.538

0.349

0.355

0.435

2

2

Notes: Data are presented as mean ± SEM. Pearson spearman correlation were used to
association of systemic metabolism and physical activity to indices of cachexia and tumor
growth rate. Abbreviations: LLC: Lewis lung carcinoma. * Statistically significant
p<0.05.
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Figure B-4. The effect of muscle-specific AMPK loss in PBS male mice following
an overnight 12hr fast
Notes: Data are presented as mean ± SEM. A) AMPK associated signaling B)
Autophagy associated signaling C) E3 ligase protein expression D) Akt/mTORC1 and
protein synthesis protein expression. E) Mitochondrial quality control protein expression.
Phosphorylation proteins were normalized to total protein expression. Protein expression
was normalized to AMPK WT mice. N=7-10 per group. Unpaired T-test were used to
compare AMPK WT and AMPK KO mice.
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Figure B-5. The effect of muscle-specific AMPK loss on the feeding regulation of
muscle protein turnover in PBS male mice
Notes: Data are presented as mean ± SEM. A) AMPK associated signaling B) E3 Ligase
protein expression. C) Mitochondrial quality control protein expression. D) Autophagy
associated signaling. Phosphorylation proteins were normalized to total protein
expression. Protein expression was normalized to Fast mice. Protein expression was
analyzed in white gastrocnemius muscle. N=7-10 per group. Two-way ANOVA was used
to compared AMPK WT and AMPK KO mice in the fast and fed condition. * Different
from AMPK WT –Fast, $ Different from AMPK WT –Fed, &Different from all groups,
#Different from AMPK KO Fast, ^Main Effect of AMPK KO.
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Figure B-6. The effect of muscle-specific AMPK loss on the feeding
regulation of muscle protein turnover in LLC male mice
Notes: Data are presented as mean ± SEM. A) AMPK associated signaling B)
Autophagy associated signaling. C) E3 Ligase protein expression. D) Mitochondrial
quality control protein expression. Phosphorylation proteins were normalized to total
protein expression. Protein expression was normalized to PBS mice. Protein expression
was analyzed in white gastrocnemius muscle. N=8-11 per group. Two-way ANOVAs
were used to compare AMPK WT and AMPK KO LLC mice in the fast and fed
condition. Main effect of KO, #Main Effect of Feeding, *Different from AMPK WT
Fast, &Different from all groups.
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Figure B-7. The effect of muscle-specific gp130 loss on skeletal muscle protein
turnover in PBS male mice following an overnight 12hr fast
Notes: Data are presented as mean ± SEM. A) gp130 associated signaling B)
Mitochondrial complex protein expression C) PGC1α and FIS1 protein expression D)
Marker of skeletal muscle protein turnover. Protein expression was analyzed in white
gastrocnemius muscle. Phosphorylation proteins were normalized to total protein
expression. Protein expression was normalized to gp130 WT mice. N=7 per group.
Unpaired T-test were used to compare gp130 WT and gp130 KO mice.
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Figure B-8. The effect of muscle-specific gp130 loss on skeletal muscle
inflammatory signaling and mitochondrial quality control in PBS and LLC male
mice following 1hr ad libitum feeding
Notes: Data are presented as mean ± SEM. A) gp130 associated signaling B)
Mitochondrial complex protein expression C) PGC1α and FIS1 protein expression D)
Marker of skeletal muscle protein turnover. Protein expression was analyzed in white
gastrocnemius muscle. Phosphorylation proteins were normalized to total protein
expression. Protein expression was normalized to PBS gp130 WT- Fast mice. N=7-11 per
group. Two-Way ANOVA was used to compare within each treatment group (PBS or
LLC) gp130 loss in the fast and fed condition. # Main effect of gp130, $ Main effect of
feeding.
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APPENDIX C. EXTENDED METHODS
Tamoxifen Preparation and Administration
1. Dissolve 85mg of tamoxifen (Sigma T5648) in 1 ml ethanol (200 proof).
Note: The OpenWetWare site
(http://openwetware.org/wiki/Tamoxifen_administration_to_mice) indicates
tamoxifen is soluble at 100 mg/ml but I have never been able to get more than 85
mg/ml consistently into solution.
2. Add 150 ul tamoxifen suspension to 850 ul sunflower seed oil (Sigma S5007)
and vortex (highest setting) until mixture becomes clear. The tamoxifen is now at
12.75 mg/ml.
Note: A 15:85 ethanol: sunflower mixture was the best I could achieve before to
two phases would spontaneously separate after vortexing.
3. This mixture is stored for up to 1 week at 4°C.
4. Prior to use, each aliquot (I typically make 1 ml aliquots) is sonicated for 20
minutes using a Branson Ultra-sonicator.
Note: My understanding is that this step helps to emulsify the solution, possibility
improving tamoxifen “bioavailability”, but I have not read anything to directly
support this idea.
5. Following sonication, load each aliquot into a 1 ml tuberculin syringe (BD ref.#
309602) with a 27 g ½ inch needle (BD 305109).
6. Administer 2mg of tamoxifen by IP injection (approximately 160 ul) or
equivalent volume of vehicle (15%ethanol in sunflower seed oil).
7. We do 5 consecutive days of injections followed by a two-week washout
period.
Feeding Stimulus
When mice achieve criteria of study endpoint, mice were fasted during the
dark cycle for 12hrs. At the end of the dark cycle, mice were given access to a
standard rodent chow food pellet for 1hr. Food pellet weight, plasma insulin, and
blood glucose were measured pre and post feeding stimulus for feeding
validation. Ad libitum access to food pellet for 1hr has been consistently shown to
induce mTORC1 and protein synthesis (Gordon et al., 2015). In aim 1 and aim 2,
mice were sacrificed immediately after the 1hr ad libitum access to a food pellet.
In aim 3, mice were given access for a food pellet for 1hr ad libitum after the
overnight 12hr fast. Mice then underwent 30 minutes of low frequency electrical
stimulation and sacrificed 3hrs post stimulation. Therefore, aim 3 mice were
sacrificed 3hrs and 30minutes post feeding.
1. Place mouse in fresh cage single housed at the start of fasting.
2. Bring mouse to Rm. 336 and let acclimate for 30minutes.
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3. Make sure the cage has a water bottle (preferred to be placed in the night
before during the fast).
4. Complete pre pellet weight, blood glucose, and plasma insulin
measurements.
5. Place the food pellet at the bottom of the cage and confirm that the mouse
initiates eating the pellet.
6. Complete post pellet weight, blood glucose, and plasma insulin
measurements.
CLAMs Cages
1. Placing Mice in CLAMs Unit:
i. MRI Protocol:
1. Each mouse will be weighed prior to analysis by Echo
MRI.
2. The Echo MRI machine will be calibrated with corn oil in
the calibration tube.
3. Each mouse will be processed through the Echo MRI
individually by insertion into a 48cm x 5.4 cm cylindrical
MRI tube.
4. Once in the tube, the MRI process inside the machine lasts
up to 3.2 minutes.
5. Once the MRI is completed, each mouse will be returned to
its home cage.
b. General Protocol:
i. Animals will be housed individually for up to one week, in sight of
other animals.
ii. Animals will always have access to water and will not be fasted
longer than 12 consecutive hours.
iii. Each cage will be labeled with the appropriate mouse number a
second hard copy recorded will be kept, and a third recorded will
be noted on the CLAMs computer program.
iv. Four 5-ounce scoops of Harlan Teklad 7087C soft cob bedding
will be added to each cage. An additional 5-ounce scoop of dirty
bedding from the mouse’s home cage will be added to the clean
cage (26.6cm x 20.7 cm. 14.3 cm) in efforts to comfort the mouse
in its new environment.
v. Each cage part will be placed beside each other.
vi. A stationary metal cylinder will be attached to the plastic
connector on the lid.
vii. Feeding containers will be filled with the appropriate diet. When
full, each container holds approximately 80g of food. A full
container will last a mouse 10-14 days.
viii. Feeding containers will be hooked into the motorized feeding
monitor facing forward. The motorized feeding monitor/feeding
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container combination will be attached to the cage lid-again will
care taken to ensure the feeder is facing forward.
ix. A water bottle containing approximately 125 mL of water will be
screwed into the appropriate place on the lid.
x. Mice will be removed from their LACU cages and caged
singularly in a metabolic cage with new and old bedding as
outlined above (Step 3).
xi. A cage brace will be added to the center of the cage and clasped
into place. After a change of gloves, the cage will be placed into
the CLAMs incubator and all wires and tubes will be connected.
To prevent any direct contact between the contents of the cage and
the inside of the incubator, no cages will be opened prior to
removal from the incubator.
xii. The CLAMs will be calibrated for CO2 and O2 (per computer
program protocol).
c. Before run checklist.
i. Each cage has bedding.
ii. Each cage has a water bottle with liquid attached and screwed in
tightly. Tap the bottles to ensure that there are no clogs and water
is free flowing.
iii. Each cage has a cage brace, Wheels are set to free or locked.
Check all wires and cords: Air connection, Fan plug, Wheel plug,
Feeding monitor ethernet cord.
iv. All feeding containers are facing forward (are accessible to the
mice).
v. All feeding containers are facing forward (are accessible to the
mice). Check after first cycle (up to approximately 32 minutes).
vi. All airflow is within the acceptable range (approximately 0.50).
Check after the first cycle (up to approximately 32 minutes). If the
airflow tubing is properly connected. If the airflow is high
(highlighted red and above 0.85) make sure there are no blocks in
the airflow tubing.
d. Daily Checklist.
i. Check water bottles have liquid in them. If water bottles have
leaked, ref-fill with deionized water. If bedding is wet, change
bedding.
ii. Check that food containers are turned forward (accessible to mice)
and have sufficient food. Re-fill empty containers and turn feeders
forward, as needed.
iii. Check each mouse for any visible ailments and that it is not stuck
yin any compromising positions (i.e., inside the feeder).
iv. Airflow is within the proper range.
2. Starting Protocol
i. Oxymass Windows
ii. Yes
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iii.
iv.
v.
vi.
vii.
viii.
ix.
x.
xi.
xii.

Use default hardware configuration
File
Open experimental configuration
Recent Places (Han/Carson) Pick trusting protocol
Experimental Configuration
Set-up
Data File
Recent-2020 January then save
Put in mouse # and body weight
Done

b. Properties
i. Environment
ii. Change lighting to today’s date/Save to controller
iii. Temperature- 22degress start-end then save to controller
c. Calibrate
i. Put yellow tubing in O2 tank
ii. Turn on O2
iii. Experiment
iv. Calibrate
v. Start/yes
vi. OK
vii. Once completed Turn off O2- take our yellow cord
d. Changing Drie-rite
i. Goes purple when moist
ii. Take top part out and check if blue/purplish
iii. Change the two connected (1st and last)
e. Hit run then start experiment.
3. Saving Experiment Files
i. Stopping Experiments:
1. Experiment
2. Stop
3. Yes
4. Exporting Files
5. Export
6. All Subject CSV’s
7. Export
8. Experimental Parameters
9. Selected All-Metabolic, Feeding, Activity
10. Next
11. Finish
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4. Cleaning:

i.
ii.
iii.
iv.
v.
vi.

Metal dishes go into dish washer
put water bottles and water lids upside down
run on plastics
~52 minutes
Autoclave buckets and place foil on top
Gravity settings

b. Cage Cleaning
i. 10% alconox
ii. 10% Bleach
iii. 10% acetic acid
5. CLAMs Analysis for Carson Lab
a. Sorting Data
i. Open Raw file in excel
ii. Copy all raw data into a separate tab
iii. Sort for analysis: VO2, VCO2, RER, heat, Feeding, and Activity –
remove all unnecessary raw data
iv. In the column to the right of VO2 and VCO2 convert into ml/hr
v. In the column to the right of Activity; Analyze Total XY Activity
by summing XTOT and YTOT
vi. Remove the first day of analysis as this is when mice are
acclimated to the system. Start with the next day starting at
6:00am.
1. Analysis only needs to be completed on the average of the
first three days. *Please refer to other completed analysis if
confused.
a. In a separate tab copy and paste the VO2 in
ml/kg/hr and ml/hr.
i. In side-by-side columns copy and paste the
VO2 values for over the first 3 days, each
day in one column.
1. For example, all 6am data will be in
side-by-side columns. Resulting in
one days 24hrs of measurements in
one column, day 2 will be in the
second column, and day 3 in the
third column.
ii. Average the 3 days of VO2 for both
ml/kg/hr and ml/hr. This is done by
calculating averages for each measurement.
Start a new column then take the average of
time point output. Therefore, the last column
should be the average of each timepoint over
a 24hr time.
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2.

3.

4.
5.

iii. Copy and paste the average VO2 ml/hr into
the cumulative analysis file.
1. Note* if adding data for the first
cohort of mice in the CLAMs unit
during that time frame make sure the
average column is correctly
averaging each hour.
a. When mice were placed in
the CLAMs system can be
found the weekly tracking
sheet.
2. The average column should take the
average per hour. Please refer to
completed cumulative analysis if
confused.
3. Note* There should be no 0’s in the
analysis.
Next, normalize the VO2 to lean mass. Lean mass can be
found in the CLAMS weekly tracking file.
a. Take the average per hour of the normalized VO2 to
lean mass.
b. Note*please refer to completed averaging on the
cumulative sheet if confused.
Complete all steps in vi for VCO2 and heat.
a. Note* if VO2 averages per hour are correct. Copy
and paste the average columns to VCO2 and heat
tabs. Then input the VCO2 and heat data into the
spot where VO2 was. This will automatically
update the averages per hour for totals and
normalized values.
Complete steps in vi except normalizing to lean mass for
RER.
Complete steps in vi except normalizing to lean mass and
averaging each hour for XY activity.
a. The averaging per hour needs to be changed to sum
per hour in the cumulative file. Do not average each
hour.
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ECHO MRI
Get red tubes from TSRB shared lab - head to animal facilities
Calibrate machine w/ sunflower oil (tube is in the room) for ~20min
Put mouse in larger tube and use other tube to push mouse to the end, so it is
immobile
New file à start scan and enter weight
Label mouse #, weight “okay” wait for scan to complete
Record lean and fat mass
When finished click ok and turn machine off

Run to Fatigue
1. Acclimate mice to the treadmill by placing mice in the lanes 10-15 minutes
prior to the start of the warm-up
2. Run the warm-up protocol 5min at 5m/min, 5min at 10m/min, 5min at 15m/min
3. Start the fatigue test running mice at 20m/min
5. Use gentle hand prodding to keep mice running
6. Fatigue will be defined as the time at which mice are no longer able or willing
to keep up with the treadmill despite gentle hand prodding for a period of 1min.
7. Clean the treadmill and the area around it with a sponge or paper towels.
Sweep the floor around the treadmills. There should be no feces on the treadmill,
the treadmill cart, or the floor when you leave
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Cell Culture
General: Check and maintain cleanliness of cell culture room
• Each month add fresh ddH2O to water bath
• Add 1-2 drops conditioner every 2wks
• When vacuum container fills, empty down sink with bleach; add small amount of
bleach to container and reattach
• Always wear a lab coat and gloves when working with cells
• Spray hands and all equipment with 70% EtOH before working with cells to
avoid contamination
• Check on cells daily
Growth Media (GM) (store 4C):
1. Pre warm in water bath @36C:
a. DMEM (Gibco cat#11995-065, high glucose, 500ml) (new bottle)
b. Fetal Bovine Serum (FBS)
c. Penicillin/Streptomycin cocktail
2. Remove 55ml DMEM → 50ml tubes
3. Add 50ml FBS (10%)
4. Add 5ml Pen/Strep (1%)
Differentiation Media (DM) (store 4C):
1. Pre warm in water bath @36C:
a. DMEM (Gibco cat#11995-065, high glucose) (new bottle)
b. Horse Serum
c. Penicillin/Streptomycin cocktail
2. Remove 15ml DMEM → 50ml tube (place in 4C, can combine once you get
enough for complete media)
3. Add 10ml HS (2%)
4. Add 5ml Pen/Strep (1%)
5. To be added once myoblasts reach 85-90% confluency – Day 0 differentiation
once added.
a. ~day 3-4 tubes start to form, fully formed & contractile tubes ~ day 5-7
Media Change (every 2 days – if you wait too long, media becomes yellow and acidic
and can affect cell growth & environment)
1. Turn on water bath to 36C & take out required equipment (clean everything with
70% EtOH before placing into hood)
2. Warm media and invert or pipette up and down to mix
3. Aspirate old media from plate with glass Pasteur pipette tip
4. Add ~1ml/well of autoclaved sterile PBS to rinse (wash when switching from GM
to DM, or when adding a treatment)
5. Aspirate PBS
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6. Add fresh media
a. 6 well plates: 3ml/well
b. Flasks: 15 ml
c. Petri Dish: 10 ml
d. 150mm Dish: 25 ml
7. Place plate back in incubator
C2C12 Myotube formation
- C2C12 myoblasts are plated in Type-1 collagen (Advanced Biomatrix #5056)
coated 6-well plates at 1.0x105 in GM (3ml per well)
- After 48hrs (85% confluence), cells are washed with PBS and placed in
Differentiation Media (DM) (DMEM, 2% Horse serum, 1% Pen/Strep)
- NOTE: Never let C2C12 myoblasts get to 100% confluence – this will
alter the phenotype and reduce differentiation potential down the road
- DM is changed every 48hrs
- Myotubes begin to form around day 3 of differentiation, contractile properties are
visible by Day 5-6 of differentiation
CELL HARVEST
1. Harvest cells to either freeze back, add to new plate, or for mouse tumor cell
injection when confluent (85-95%)
a. NOTE: Never let C2C12 myoblasts get to 100% confluence – this will
alter the phenotype and reduce differentiation potential down the road
2. Spray everything going under hood with 70% EtOH
3. Pre warm in water bath @36C:
a. Trypsin
b. Freeze back media
c. Growth media
d. PBS (room temp)
4. Aspirate old media
5. Rinse with PBS, and then aspirate – Growth media inactivates trypsin, must
perform this step to detach cells
6. Add 1-3ml trypsin (larger volume for larger flasks, just enough to cover the
bottom, should never have to use >5ml)
7. Place in incubator (~3-5min)
8. Check under scope to ensure cells detach
9. Stop trypsin activity by adding GM ~3-5ml
10. Label 15 ml tubes
11. Remove trypsin + GM w/ serological pipette into 15ml tube
12. Spin down at 4000 rpm 5 min
13. Carefully aspirate media from cell pellet
14. Add 1ml fresh GM (if replating) or freezing media (if saving back), or PBS
(injection) and resuspend pellet by pipetting up and down
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15. Count Cells – NOTE: resuspend cells in GM for counting, then spin down the
appropriate # of cells and resuspend PBS/freeze media if using for injection or to
freeze back, if cells are kept in PBS or the DMSO freezing solution too long they
will die:
a. Add 10 ul Trypan Blue (TB) + 10 ul cell suspension to 1.5ml tube
b. Add 10 ul of TB+cells to cell counting slide (countess), insert into
machine & record total and # alive
16. Calculate dilution:
a. C1 V1 = C2 V2 to determine amt cell suspension to add to new flask/cryo
tube
C1 = # cells alive from countess readout
V1 = unknown; volume of cell suspension to add to each plate
C2 = final/desired concentration
1x10^6 cells/ml for large flasks
250,000 cells/ml/well for 6 well plates
V2 = 1 ml (volume of cell suspension in 15 ml tube)
17. For injection:
a. Determine ml necessary for 1,000,000 [cell] injection
b. Make 1ml PBS LLC cell solution
c. Ex: 1.0 x 1x107 cells in 1ml = 0.1ml injection for 10 mice
18. Add V1 to plate or cryo tube
19. Plate: add growth media and place in incubator
a. Follow steps for media change and check confluency of cells daily
20. Cryo tube: place in Mr. Freeze -20 overnight → Mr. Freeze -80 → LN2 tank
Collagen Coating: (protocol is adapted from collagen website – Advanced
Biomatrix)
Collagen coat 6-well plates for C2C12 myotubes
1. Take out materials:
a. Collagen Rat Tail Type 1 (4C) @ 3.9mg/ml
b. Acetic Acid
c. Sterile ddH2O
2. Each 6 well plate = 1ml/well
3. Stretcher = 3ml
4. Count total wells to coat
a. Ex: 18 plates x 6 wells = 108
b. → round up 110ml final desired volume
5. Determine amt collagen to add
a. 3.9mg/ml collagen
b. C1V1=C2V2
c. C1 = 3.9mg/ml
d. V1 = X
e. C2 = 0.1mg/ml
f. V2 = 110 ml
g. (3.9) (x) = (0.1) (110)
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h. x = 2.8 ml collagen
6. Determine ddH2O to add:
a. V2 – V1 = ddH2O ml
b. 110 – 2.8 = 107.2 ml
7. Determine amt acetic acid to add:
a. Want 0.1% of ddH2O (NOT TOTAL VOLUME)
b. ddH2O ml * 0.001 = ml acetic acid
c. 107.2 * 0.001 = 0.1072 ml * 1000 = 107.2 ul acetic acid
8. Optional: run collagen solution through a filter (Nalgene 20micron)
9. Add 1 ml of final solution to each well
10. Let sit for ~2hrs under UV
11. Can store plates in fridge up to ~2weeks
Harvest Experimental 6-well plates
Protocol: Keep everything ice cold
1. When experiment is complete aspirate media and rinse twice with ice cold PBS,
aspirate, and place plates on ice to harvest.
2. Add 100ul RIPA cocktail to each well, scrape cells with blue cell scraper, transfer
to 1.5ml conical tube [see example below]
a. 100ul used in the lab and results in ~1.0-3.5 ug/ul protein (acquired from
Bradford)
3. Aliquot 1ml RIPA (thermo cat # 89900) into 1.5ml conical tube – place on ice
4. Immediately before scraping plate add the following to RIPA buffer:
a. Add 10ul protease and phosphatase inhibitor cocktail (thermo cat # 78440)
b. Add 10ul EDTA
5. NOTE: ONE 6-well plate will require 600ul RIPA (+ 6ul protease + 6ul EDTA)
→ calculate total buffer needed before making cocktail and adjust ratios
accordingly
6. Centrifuge scraped cells in RIPA cocktail at 14,000 rpm for 15min at 4C to
remove cell debris (pellet gets thrown away, transfer supernatant to new tube, add
date and label sample).
7. Store supernatant at -80C
Conditioned Media Collection
1. 2.0x106 C26 or LLC cells are seeded in 100mm tissue culture treated plates in
12ml Growth Media (GM) (gibco DMEM cat#11995-065; 10% FBS; 1%
Pen/Strep cocktail)
2. Conditioned media is collected 48hrs (~90% confluence) post cell seeding and
spun down at 3000rpm for 5min to remove cell debris
3. Cells on the plate were pelleted and counted via trypan blue exclusion test to
ensure an equivalent number of cells on the plate, with a final density averaging
from 7.0 – 9.0 x 106 cells per culture dish
4. Conditioned media is stored in aliquots at -20C (Freeze thaw cycles may affect
media components, so only one freeze thaw cycle is ideal)
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5. At time of experiment, conditioned media aliquot is warmed in warm water bath
Conditioned Media Dosing:
- Conditioned media is diluted with 50% serum-free DMEM for a final serum
concentration of 5% FBS
- 50% CM was chosen as it has been shown to produce significant myotube atrophy
(Pin et al., 2018; Zhong et al., 2019).
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Tissue Homogenization for Protein
1. Cut and weigh a small portion of frozen tissue in liquid nitrogen (~20-35mg)
2. Add beads to locking homogenization tubes (label with EtOH proof marker on top
and side of tube)
3. Calculate total Mueller & Diluent Buffer based on tissue weights
a. Mueller = 10 X mg tissue
b. Diluent = ½ Mueller
c. Example: 20mg tissue = 200ul Mueller + 100ul Diluent

4.
5.
6.
7.
8.

Add Mueller Buffer to tubes with beads & place on ice
Add frozen tissue to Mueller buffer tube
Freeze at -20C overnight
Remove from -20C and thaw on ice for ~20min
Bring samples to bead homogenizer on the 4th floor of TSRB
a. Homogenize at 30 Hz for 3min à ice for ~5min’
b. If clumps remain, repeat in 2min intervals
9. Centrifuge homogenized samples at 15000rpm for 15min.
10. Add diluent buffer to a new 1.5ml conical tube and place on ice
11. Remove supernatant from centrifuged samples and add to tubes with diluent
buffer
12. Quantify protein via Bradford Protein Assay
13. Freeze samples at -80C for long term storage
STOCK Solutions with Importance
HEPES - Acros Organics (fisher) #172571000; soluble in H2O
EGTA (pH 8.0) – Sigma #E4378-25g; soluble in dH2O at basic pH
EDTA (pH 8.0) – Sigma #ED2SS-500g
Na4O7P2 (Sodium pyrophosphate tetrabasic) – Sigma #P8010-500g; H2O soluble
b-Glycerophosphate – Sigma #G9422-10g; H2O soluble
NaF (Sodium Fluoride) – Sigma #S7920-100g
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NaVO4 (Sodium Orthovanadate) – Sigma S6508-10g H2O soluble
Protease Inhibitor Cocktail (PIC) - Sigma #P8340-5ml; DMSO solution
Genotyping
Scruff & cut small piece from end of tail, place in pre-labeled 1.5ml tube
Add 200 ul tailing buffer (enough to cover tail completely) – use molecular grade H2O to
avoid DNA contamination
a. For master mix, make extra (add ~2)
b. i.e., 12 tails +2 = 14 à 14 * 200 = 2800 ml
c. Make 3 ml tailing buffer and add 75 ul proteinase K
Place in water bath overnight (~8 hrs minimum)
Remove & vortex then centrifuge to pull tail residue to the bottom of the tube
Put on heat block at 92°C for 10 min to stop proteinase K activity
Remove & vortex
Spin down for 30-60s in mini centrifuge
Use for PCR or store in 4°C (this is the DNA)
Genotyping PCR
Take out PCR tubes and label
Determine genotypes and make a master mix (formula sheet on excel doc)
a. Sample Sets: B6 = control; Min; AMPKa1; AMPKa2; HSA; GP130
i. Flox = single band, Flox + = double band
b. Master Mix = molecular grade dH2O or Rnase free dH20, GoTaq,
forward & reverse primers
Add 23 ul master mix to each tube
Add 3 ul DNA
Run PCR reaction
When reaction has ~30 min left, cast gel
2% Agarose Gel
c. 100 ml 1X TAE
d. 2 g agarose
e. 2 ul Midori Green
Mix and microwave in 30 second intervals until boiling and clear (at least 30 seconds
intervals) Swirl thoroughly.
Pour into mold (make sure clear casing is inserted) and place combs for lanes
Wait ~30 min for gel to cool
Remove gel and place in PCR electrophoresis, add ~300ml 1XTAE to cover/fill
Once reactions are complete pipette sample into each well
f. Min RXN: 10ul
g. HSA RXN: 9ul
h. gp130 RXN: 10ul
i. AMPK alpha 1 and alpha 2 RXN: 8 ul
Add 8 ul DNA ladder 4:1:1 ratio
j. 16 ul dH2O
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k. 4 ul DNA ladder
l. 4 ul 6X tracking dye
Run gel for 30 min at 100 volts (check 5 min in to make sure it is running)
Remove gel place on plastic divider
Image on nucleic acids.
Tailing for Genotyping
Scruff & cut small piece from end of tail, place in pre-labeled 1.5ml tube
Add 200ul of master mix tailing buffer to each 1.5ml tube w/ tail (make sure tail is in
solution at the bottom)
d. Master mix tailing buffer – 200ul tailing buffer + 5ul Proteinase K
e. Example: i.e., 12 tails → 12 * 200 = 2400 ml
Place in water bath overnight @56degree (~8 hrs minimum)
Next Morning - Remove & vortex then centrifuge to pull tail residue to the bottom of the
tube
Put on heat block at 95C for 10 min to stop proteinase K activity
Remove & vortex
Spin down for 30-60s in mini centrifuge
Use for PCR or store in 4C

Final Concentration
Volume
Stock Solution
10nM Trish-HCL, pH 8.3
5 mL
1.0 M
50nM KCL
25 mL
1.0 M
2.5nM MgCl2, 6H20
1.25 mL
1.0 M
0.45% NP-40
2.25 mL
0.35% Tween 20
2.25 mL
Molecular Biology Grade
Volume to 500 mL
dH20
Tailing Buffer – Sterilize all stock solution prior to making tailing buffer.
Store stock solutions at room temp and tailing buffer at 4 degrees.
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Genotyping PCR
Take out PCR tubes out and label
Make a master mix
m. Master Mix = molecular grade dH2O or Rnase free dH20, GoTaq, forward
& reverse primers (see master mix volumes below and an example far
right column)
HSAcre/+

dH2O
2x buffer dye (GoTaq)
F Primer
R Primer

ul/sample
9.5
12.5
0.5
0.5
23
23 Mix + 2 ul DNA

gp130 Flox

10

total samples

ul total
95
125
5
5
230

total samples

dH2O
2x buffer dye (GoTaq)
F Primer
R Primer

ul/sample
9.5
12.5
1
1
24
23 Mix + 2 ul DNA

5
ul total
47.5
62.5
5
5
120

Add 23 ul master mix to each tube
Add 2 ul DNA
Run PCR reaction (see below)
Thermocycler Protocol
Gp130
Stage 1 (1x): 95oC 5min
Stage 2 (4x): 95oC 30 sec
65oC 1min
72oC 30 sec
Stage 3 (34x): 95oC 30 sec
60oC 1min
72oC 30 sec
Stage 4 (1x): 72oC 10 sec
Stage 5 (infinity): 4oC
Thermocycler Protocol
Gp130
Stage 1 (1x): 95oC 5min
Stage 2 (4x): 95oC 30 sec
65oC 1min
72oC 30 sec
Stage 3 (34x): 95oC 30 sec
60oC 1min
72oC 30 sec
Stage 4 (1x): 72oC 10 sec
Stage 5 (infinity): 4oC

Thermocycler Protocol
HSA-MCM
Stage 1 (1x): 95oC 3min
Stage 2 (34x) : 95oC 20sec
58oC 20sec
72oC 30sec
Stage 3 (1x): 72oC 10min
Stage 4 (infinity): 4oC
Thermocycler Protocol
HSA-MCM
Stage 1 (1x): 95oC 3min
Stage 2 (34x) : 95oC 20sec
58oC 20sec
72oC 30sec
Stage 3 (1x): 72oC 10min
Stage 4 (infinity): 4oC

When reaction has ~30 min left, cast
gel
2% Agarose Gel
n. 100 ml 1X TAE
o. 2 g agarose
p. 2 ul Midori Green
Mix and microwave in 30 second intervals until boiling and clear (at least 15-30 second
intervals) Swirl thoroughly.
Pour into mold (make sure clear casing is inserted) and place combs for lanes
Wait ~20 min for gel to cool
Remove gel and place in PCR electrophoresis, add ~300ml 1XTAE to cover/fill
Once reactions are complete pipette sample into each well
q. HSA-MCM RXN: 7ul
r. gp130 RXN: 8ul
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Add 8 ul DNA ladder 4:1:1 ratio
s. 16 ul dH2O
t. 4 ul DNA ladder
u. 4 ul 6X tracking dye
Run gel for 30 min at 100 volts (check 5 min in to make sure it is running)
Image (example below)

Gp130

HSA c/+

~550bp

Mouse Samples

700bp
500bp

1500bp
1000bp
700bp
500bp

300bp

300bp

75bp

75bp

1500bp

FF F+

-

#1 #2 #3

~749bp

Mouse Samples

+

-

#1 #2

#3

Primers: Purchased through Integrated DNA Technologies - 25nmole DNA
Oligo
HSAc/+ MCM Forward – See image below
HSAc/+ MCM Reverse – See image below
gp130 Forward – See image below
gp130 Reverse – See image below
Primers: Purchased through Integrated DNA Technologies - 25nmole DNA
Oligo
HSAc/+ MCM Forward – See image below
HSAc/+ MCM Reverse – See image below
gp130 Forward – See image below
gp130 Reverse – See image below
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Blood Glucose
1. Immediately prior to ad libitum access to a food pellet, post food pellet, and at
sacrifice mice had their tail snipped.
2. ~1cm of tail was snipped and blood was wiped with a kim wipe.
3. Milk the tail and analyze blood using the readily available glucometer
(Contour Next, Parsippany, NJ).

Plasma Insulin
1. Immediately prior to ad libitum access to a food pellet, post food pellet, and at
sacrifice mice had their tail snipped.
2. Snip ~1cm of tail was snipped and wipe blood with a kim wipe.
3. Milk the tail to get ~50ul in a heparinized capillary tube.
4. Place on ice till centrifuged.
5. Centrifuged (10,000 x g for 10 min at 4°C).
6. The supernatant was removed, and plasma insulin concentrations were determined
using a two-site enzyme immunoassay assay kit according to the manufacturer’s
instructions (Catalog #10-1247, Mercodia, Uppsala, Sweden).
7. Store in -20 till analysis.

Western Blot
Determine which size gel and the appropriate % for protein of interest
o - MW, ¯ % gel
When making SDS wear mask and goggles (cancerous)
o Mini gels need 8 mL per 1 gel
o Midi (large) gels need 10mL per 1 gel
o Stacking 3mL per 1 gel
Set up casting station and take out materials
o ddH20 – autoclaved water
o 30% acrylamide – 4degree
o 1.5M Tris ph. 8.8 - RT
o 10% SDS – RT
o 10% APS - -20degree
o TMED - RT
Mix ingredients together (swirl after adding each ingredient), add TMED last
Pipette thoroughly mixed materials into casting station.
Wait ~2 minutes; add methanol to top of gel while it sets ~60 min
Remove methanol w/ vacuum attachment
Make stacking portion of the gel (always make 6% stacking)
Mix, add TMED last, and pipette into gel
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Add comb for wells immediately after pipetting mixed ingredients into the casting station
(check the number of wells needed)
Let set ~60 minutes
Running Gels
Determine amount of sample to add based on Bradford assay, protein, & marker of
interest (15-50 ug) – check antibody sheet for reference
Prepare samples (turn on heat block)
a. Label tubes
b. Add half of loading volume sample 2XSDS (2%), 1/3 for 4XSDS stored
20°C
i. Use 4x if sample volume is too large for wells.
c. Add sample to 1.5mL tube then vortex
d. Samples can be prepped the day before and stored in -80°C
Place samples on heat block for 5 min at 92-95°C
Vortex and spin down – NO BUBBLES
Place on ice till use
Running Gels:
e. Set up casting stations for a run. Place gel in tank (align the charges in
toward middle)
f. Add 1X SDS running buffer
i. Dilute 10X stock SDS running buffer to 1X needs to mix for ~10
minutes if not the running current will be off, and gel will not run
straight.
1. Determining Volume needed calculation
a. C1V2=C2V2
b. (10X) (unknown volume) =(1x) (1000mL)
c. (10X) (unknown volume) =(1000mL)
d. (Unknown volume) =(1000mL*1X)/(10X)
e. Unknown volume = 100ml of 10X stock SDS
f. Need 1 L therefore your volume up to 1L
g. 100mL of 10X SDS and 900mL of dH20
g. Pipette samples and ladder (5 ul) into wells
h. Note* if samples are over 20 ul–pipette 20ul of sample into well, run for 2
minutes and then pipetting the rest of the sample into the well
i. Be careful when pipetting samples & avoid bubbles
i. Bubble will pushout samples from wells.
j. Fill tank with 1X SDS running buffer so that gels are covered & place lid
on
k. Run at 120 volts until protein is through stacking, then up it to 140
volts (~90min)
Run is finished when ladder has a nice spread and protein is near bottom of gel – or
protein of interest are in the middle of the gel.
Transferring Gels:
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Make transfer buffer (only need 50ml methanol for 1 or 2L) and stir with magnetic
stir bar.
Cut PVDF membrane – do not touch with fingers as oil will destroy the membrane. Only
use forceps and tweezers to touch membrane.
l. Let membrane sit in methanol for 5 min on shaker
Wet Transfer Midi Gels (large gels):
m. Make sandwich: Black cassette side; sponge; filter paper; gel; membrane;
filter paper; sponge; red side cassette (close) roll after each step to remove
bubbles
i. * Membrane paper should not be larger than the gel. This allows
for air bubbles to go underneath the gel.
n. Place in transfer tank (2L transfer buffer) red to red, black to black –
Transfer runs black to red.
o. Add ice pack in back and stir bar to keep TB moving
p. Run at 1.8Amps for 90min (add ice to bucket so it does not overheat)
q. Take out cassette and follow steps 23 on
Probing:
r. After transfer is complete remove lid, filter paper, and gel (save filter
paper, clean and dry flat in clean space)
s. Carefully remove membrane and cut triangle at ladder depending on
protein of interest, cut in corner of first well for easy reading
t. Add membrane to antibody box
u. Ponceau stain to check transfer à add 10% of 0.1% ponceau with dH2O
and let rock for ~15 min
v. Scan ponceau membrane and save – make sure equal loading. If not, then
trash and start over.
w. Place membrane back in the box and wash with TBST 3x until pink is
gone
x. For blocking/primary and secondary steps – Reference antibody
sheet.
y. Between blocking and primary – wash once for 5-10minutes with 1X
TBST
z. Between primary and secondary – wash 3 times for 5-10 minutes with 1X
TBST
aa. Between secondary and ECL – wash 3 times for 5-10 minutes with 1X
TBST
Imaging:

bb. Place membrane on plastic cover & pipette ECL reagent (Prometheus
usually) for imaging
cc. ratio is 1:1 of A: B, 1mL per membrane – make sure entire membrane is
covered.
Leave reagent on membrane 1-2 min for total proteins and 3-5 minutes for
phosphorylation proteins, then aspirate off
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Cover membrane with the plastic then remove excess ECL reagent with KIM wipes and
bring down to image
Open CARSON 3356 à Chemi blots à Smart exposure to determine exposure time
More options à routines à signal accumulation à ~10 exposures and set start/end time
according to smart exposure to get a good image à options à membrane overlay
Save image & membrane overlay to flash drive
ash membrane in TBST and either Ponceau stain and save back, or add stripping
buffer for next antibody (i.e., total AMPK)
Start text, 1st-Level Head, or table/figure on this line.
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